var title_f25_16_25856="Brow presentation";
var content_f25_16_25856=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F77290&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F77290&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 550px\">",
"   <div class=\"ttl\">",
"    Brow presentation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 530px; height: 441px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The fetus in the brow presentation occupies a longitudinal axis with the fetal neck extended, but not to the degree in face presentation. The area presenting in the birth canal typically extends from the anterior fontanelle to the brow (orbital ridge).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_16_25856=[""].join("\n");
var outline_f25_16_25856=null;
var title_f25_16_25857="Skin warts";
var content_f25_16_25857=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Skin warts (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?25/16/25857/contributors\">",
"       Authors",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/16/25857/contributors\" id=\"au5343\">",
"       Beth G Goldstein, MD",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/16/25857/contributors\" id=\"au5345\">",
"       Adam O Goldstein, MD, MPH",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?25/16/25857/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/16/25857/contributors\" id=\"se7157\">",
"       Robert P Dellavalle, MD, PhD, MSPH",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?25/16/25857/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/16/25857/contributors\" id=\"de2840\">",
"       Abena O Ofori, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?25/16/25857?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      SKIN WARTS OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Common skin warts (also called cutaneous warts) are raised round or oval growths. A wart may be lighter or darker than the skin around it. Some warts may have tiny black dots in them, often called seeds. The dots are small, clotted blood vessels. Warts may occur alone or in larger groups that merge and form patches.",
"    </p>",
"    <p>",
"     You can become infected with the virus that causes warts (human papillomavirus) by touching another person's wart. The virus is more likely to infect skin that is injured or softened by water, but it can infect healthy skin as well. It can take up to six months after exposure to the virus for a wart to appear.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H2\">",
"     <span class=\"h2\">",
"      Who gets skin warts?",
"     </span>",
"     &nbsp;&mdash;&nbsp;Skin warts are most common in children and young adults. They are also more common among people with certain jobs, such as handling meat, fish, and poultry. People who have chronic skin conditions, such as eczema, and people with a weakened immune system (eg, from AIDS or after an organ transplant) may have more extensive warts or warts that are difficult to control.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3\">",
"     <span class=\"h2\">",
"      Where do warts occur?",
"     </span>",
"     &nbsp;&mdash;&nbsp;Skin warts can occur in the following locations:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Common skin warts, also called verruca vulgaris, can occur on any area of skin, but are often seen on the fingers, hands, knees, and elbows (",
"       <a class=\"graphic graphic_picture graphicRef78884 \" href=\"UTD.htm?9/17/9488\">",
"        picture 1",
"       </a>",
"       ).",
"      </li>",
"      <li>",
"       When common warts are located around the fingernails, they are called periungual warts (",
"       <a class=\"graphic graphic_picture graphicRef62677 \" href=\"UTD.htm?25/54/26478\">",
"        picture 2",
"       </a>",
"       ).",
"      </li>",
"      <li>",
"       Plantar warts are found on the soles of the feet (",
"       <a class=\"graphic graphic_picture graphicRef67490 \" href=\"UTD.htm?13/36/13891\">",
"        picture 3",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       Flat warts are most commonly found on the back of the hands, face, and lower legs (",
"       <a class=\"graphic graphic_picture graphicRef78653 \" href=\"UTD.htm?19/47/20211\">",
"        picture 4",
"       </a>",
"       )",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H4\">",
"     <span class=\"h1\">",
"      SKIN WART DIAGNOSIS",
"     </span>",
"    </p>",
"    <p>",
"     Skin warts can usually be diagnosed based upon how they look. Skin biopsy or other testing is not usually necessary.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H5\">",
"     <span class=\"h1\">",
"      SKIN WART TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     Treatment of warts depends upon where the wart is located and how much it bothers you. Treatment is not necessary in all cases because about two-thirds of skin warts will resolve on their own within two years, without treatment. However, during this time, the wart may enlarge or new warts may appear. In addition, a few small warts are usually easier to treat than multiple larger warts. For these reasons, most people choose to treat skin warts.",
"    </p>",
"    <p>",
"     There are many ways to treat warts, and the \"best\" treatment depends upon your and your healthcare provider's preferences and any underlying medical problems. Most treatments take several weeks or even months to work, and warts can come back after treatment.",
"    </p>",
"    <p>",
"     Treatment of skin warts is also discussed in more detail in a separate article. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/40/26249?source=see_link\">",
"      \"Cutaneous warts\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Treatments you can use at home",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h3\">",
"      Salicylic acid",
"     </span>",
"     &nbsp;&mdash;&nbsp;Salicylic acid is a type of acid that is applied directly to the wart. It comes in different forms, such as a liquid or patch. Some forms of salicylic acid can be applied at home, while others must be applied by a healthcare provider.",
"    </p>",
"    <p>",
"     Salicylic acid is useful for most types of skin warts and can be used in children. You may choose to combine salicylic acid treatment with duct tape. (See",
"     <a class=\"local\" href=\"#H8\">",
"      'Duct tape'",
"     </a>",
"     below.)",
"    </p>",
"    <p>",
"     If you decide to try salicylic acid treatment at home, you should first soak the area in warm water for 10 to 20 minutes (to soften the skin) and dry the skin completely. Apply the liquid or patch to the wart at bedtime and leave it in place overnight. Between treatments, you should use a nail file or pumice stone to gently slough off dead skin from the surface of the wart. It is normal to have some skin irritation or light bleeding during treatment; this is a sign that the treatment is working.",
"    </p>",
"    <p>",
"     You should continue treatment for one to two weeks after the wart is gone to be sure that the virus is gone.",
"    </p>",
"    <p>",
"     If you have neuropathy (nerve damage that causes numbness), you should not use salicylic acid. In people with neuropathy, salicylic acid could potentially injure the skin without the person being aware of the injury.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h3\">",
"      Duct tape",
"     </span>",
"     &nbsp;&mdash;&nbsp;Duct tape, a sticky tape available at most home improvement stores, has been used to treat skin warts. It is not clear how duct tape works or if it is an effective treatment. Some studies have shown success while others have not.",
"    </p>",
"    <p>",
"     If you choose to try duct tape, silver duct tape is preferred over clear tape because it sticks to the skin better. You should cover the skin wart with tape and leave it in place for six days. You then remove the tape, soak the skin in warm water for 10 to 20 minutes, and use and emery board or pumice stone to gently slough off dead skin. Leave the skin uncovered for one night, then reapply the tape for another six nights.",
"    </p>",
"    <p>",
"     Most people who find duct tape an effective treatment have resolution of their skin warts within four weeks. Warts are unlikely to respond if you do not see any improvement within two weeks.",
"    </p>",
"    <p>",
"     Duct tape treatment is not recommended if you have diabetes, nerve damage (neuropathy), peripheral artery disease, or any condition that causes the skin to be irritated. In these people, duct tape may cause complications, such as skin sores or infection.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h2\">",
"      Prescription treatments",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h3\">",
"      Liquid nitrogen",
"     </span>",
"     &nbsp;&mdash;&nbsp;Liquid nitrogen is a very cold liquid that destroys warts by freezing the skin (also called cryotherapy). Liquid nitrogen must be applied by a healthcare provider, and multiple treatments are often needed to eliminate the wart.",
"    </p>",
"    <p>",
"     Liquid nitrogen may be recommended for skin wart treatment in older children and adults, but it is not usually recommended for younger children because it can be painful. You may be given local anesthesia before treatment with liquid nitrogen to decrease pain.",
"    </p>",
"    <p>",
"     After treatment, most people heal within four to seven days. Home treatment with salicylic acid is usually recommended for at least one week after the skin heals to reduce the chances of the wart coming back.",
"    </p>",
"    <p>",
"     People with dark skin can develop permanent loss of skin color in areas treated with liquid nitrogen. If you have concerns about how your skin will appear after treatment with liquid nitrogen, talk to your healthcare provider.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h3\">",
"      Cantharidin",
"     </span>",
"     &nbsp;&mdash;&nbsp;Cantharidin is a liquid that is applied by a healthcare provider to treat skin warts. It may be particularly useful for young children because it causes no pain initially. However, some people (although not all) develop pain, blisters, and swelling 2 to 24 hours after the treatment.",
"    </p>",
"    <p>",
"     The skin usually heals within 5 to 10 days after treatment. Most providers recommend treatment with salicylic acid for at least one week after the skin heals to reduce the chances of the wart coming back.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h3\">",
"      Shave excision",
"     </span>",
"     &nbsp;&mdash;&nbsp;Shave excision is a procedure that involves removing a skin wart with a blade. A healthcare provider performs the procedure, usually after injecting local anesthesia to numb the skin.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h3\">",
"      5-Fluorouracil",
"     </span>",
"     &nbsp;&mdash;&nbsp;5-Fluorouracil is a prescription cream that can be used to treat flat warts. You apply the cream to the affected area twice a day for three to five weeks. During treatment, it is important to protect the treated area from the sun because sun exposure can worsen skin irritation. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?32/60/33729?source=see_link\">",
"      \"Patient information: Sunburn prevention (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h3\">",
"      Imiquimod",
"     </span>",
"     &nbsp;&mdash;&nbsp;Imiquimod cream (Aldara&reg;) is a prescription cream that works by stimulating the immune system to eliminate the wart. You apply the cream at bedtime several times per week. It is normal to develop some skin irritation during treatment.",
"    </p>",
"    <p>",
"     Imiquimod is more expensive than other wart treatments, but may be recommended in certain situations (for children, if other treatments are not effective, or if scarring is a concern).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h3\">",
"      Immunotherapy",
"     </span>",
"     &nbsp;&mdash;&nbsp;Immunotherapy involves injecting a substance directly into the wart to trigger an immune response. Your clinician may repeat the injection every three weeks (up to five injections) until the wart completely clears up. Salicylic acid",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     duct tape may be used in addition to immunotherapy.",
"    </p>",
"    <p>",
"     The advantage of this type of treatment is that it does not leave scars and is less expensive than imiquimod.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H16\">",
"     <span class=\"h3\">",
"      Other treatments",
"     </span>",
"     &nbsp;&mdash;&nbsp;Other wart treatments are available, and may be recommended if you do not respond to one of the treatments discussed above. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/40/26249?source=see_link\">",
"      \"Cutaneous warts\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H17\">",
"     <span class=\"h1\">",
"      WHEN TO SEEK HELP",
"     </span>",
"    </p>",
"    <p>",
"     Consult a healthcare provider if:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       You are not sure if you skin growth is a wart",
"      </li>",
"      <li>",
"       Your skin wart does not improve with home treatment",
"      </li>",
"      <li>",
"       You would like to use home treatment, but are not sure which treatment is right for you",
"      </li>",
"      <li>",
"       You have been treated for warts and have developed signs of a skin infection, such as redness, pain, or pus-like drainage from the treated area. In some cases, redness and pain are normal reactions after wart treatment, so discuss possible side effects with your healthcare provider in advance.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H18\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11284302\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11284309\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/5/11346?source=see_link\">",
"      Patient information: Skin warts (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?0/51/818?source=see_link\">",
"      Patient information: Seborrheic keratosis (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11284325\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     This topic currently has no corresponding Beyond the Basics content",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11284350\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/40/26249?source=see_link\">",
"      Cutaneous warts",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/6/21610?source=see_link\">",
"      Epidemiology of human papillomavirus infections",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       KidsHealth",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://kidshealth.org/parent/infections/skin/wart.html\">",
"      file://kidshealth.org/parent/infections/skin/wart.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Medline Plus",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/ency/article/000885.htm\">",
"      www.nlm.nih.gov/medlineplus/ency/article/000885.htm",
"     </a>",
"     , available in Spanish)",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Academy of Dermatology",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.aad.org/public/publications/pamphlets/common_warts.html\">",
"      www.aad.org/public/publications/pamphlets/common_warts.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?25/16/25857/abstract/1-4\">",
"      1-4",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 3, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?25/16/25857?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25857/abstract/1\">",
"      Gibbs S, Harvey I. Topical treatments for cutaneous warts. Cochrane Database Syst Rev 2006; :CD001781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25857/abstract/2\">",
"      Wenner R, Askari SK, Cham PM, et al. Duct tape for the treatment of common warts in adults: a double-blind randomized controlled trial. Arch Dermatol 2007; 143:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25857/abstract/3\">",
"      Moed L, Shwayder TA, Chang MW. Cantharidin revisited: a blistering defense of an ancient medicine. Arch Dermatol 2001; 137:1357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25857/abstract/4\">",
"      Muzio G, Massone C, Rebora A. Treatment of non-genital warts with topical imiquimod 5% cream. Eur J Dermatol 2002; 12:347.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f25_16_25857=[""].join("\n");
var outline_f25_16_25857=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           SKIN WARTS OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H4\">",
"           SKIN WART DIAGNOSIS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H5\">",
"           SKIN WART TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H17\">",
"           WHEN TO SEEK HELP",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H18\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          PICTURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_picture\" href=\"UTD.htm?9/17/9488\" title=\"picture 1\">",
"           Common warts PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_picture\" href=\"UTD.htm?25/54/26478\" title=\"picture 2\">",
"           Periungual warts PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/36/13891\" title=\"picture 3\">",
"           Plantar warts PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_picture\" href=\"UTD.htm?19/47/20211\" title=\"picture 4\">",
"           Flat warts PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f25_16_25858="Patient information: Anorexia nervosa (The Basics)";
var content_f25_16_25858=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/16565\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/63/7154\">",
"         Person having an ECG",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?25/37/26194\">",
"         Patient information: Bulimia nervosa (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?11/57/12179\">",
"         Patient information: Depression (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?31/32/32257\">",
"         Patient information: Generalized anxiety disorder (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?24/6/24675\">",
"         Patient information: Medicines for depression (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?13/6/13413\">",
"         Patient information: Depression in adolescents (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?19/41/20116\">",
"         Patient information: Depression in adults (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Anorexia nervosa (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/anorexia-nervosa-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H12782676\">",
"      <span class=\"h1\">",
"       What is anorexia nervosa?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Anorexia nervosa is an eating disorder that makes people lose more weight than is healthy.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H12782691\">",
"      <span class=\"h1\">",
"       What are the symptoms of anorexia nervosa?",
"      </span>",
"      &nbsp;&mdash;&nbsp;People with anorexia nervosa:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Weigh much less than they should for their age and height &ndash; To lose weight, people eat too little, exercise too much, or do other things. For example, they might make themselves vomit.",
"       </li>",
"       <li>",
"        Are very worried about gaining weight &ndash; To avoid gaining weight, they will not eat, even when they are hungry.",
"       </li>",
"       <li>",
"        See their body and shape in an abnormal way &ndash; They think they are fat, even when they are underweight.",
"       </li>",
"       <li>",
"        Have stopped having their menstrual periods (in women)",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      It is also common for people with anorexia nervosa to:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Spend almost all their time thinking about food, meals, and calories",
"       </li>",
"       <li>",
"        Create rules around food and eating",
"       </li>",
"       <li>",
"        Skip meals and avoid eating in public",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Anorexia nervosa is more common in women than men. It usually begins in the teenage or early adult years.",
"     </p>",
"     <p>",
"      People with anorexia nervosa often hide how thin they are or deny that they have a problem. They often don&rsquo;t want treatment, because they don&rsquo;t want to gain weight. But it&rsquo;s important for people to get treatment, because people can die from anorexia nervosa.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H12782706\">",
"      <span class=\"h1\">",
"       Is there a test for anorexia nervosa?",
"      </span>",
"      &nbsp;&mdash;&nbsp;No. There is no test. But your doctor or nurse should be able to tell if you have it by talking with you, measuring your height and weight, and doing an exam.",
"     </p>",
"     <p>",
"      Your doctor or nurse will do tests to check your health, because anorexia nervosa can lead to many health problems. You will probably have:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Blood tests",
"       </li>",
"       <li>",
"        Urine tests",
"       </li>",
"       <li>",
"        An ECG &ndash; An ECG measures the electrical activity in your heart and records your heart rate and rhythm (",
"        <a class=\"graphic graphic_figure graphicRef53145 \" href=\"UTD.htm?6/63/7154\">",
"         figure 1",
"        </a>",
"        ).",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H12782721\">",
"      <span class=\"h1\">",
"       What problems can anorexia nervosa cause?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Anorexia nervosa can cause many problems. That&rsquo;s because the body and brain don&rsquo;t get the nutrition they need. Anorexia nervosa can cause:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Heart, liver, and kidney problems",
"       </li>",
"       <li>",
"        Bone loss and muscle weakness",
"       </li>",
"       <li>",
"        Bloating and trouble having bowel movements",
"       </li>",
"       <li>",
"        Thinning hair and nails that break easily",
"       </li>",
"       <li>",
"        Feeling cold all the time or tired a lot",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      People with anorexia nervosa can also have:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Depression &ndash; This is when people feel very sad most of the time. Some depressed people think about hurting themselves.",
"        <strong>",
"         If you are thinking of hurting yourself, call your doctor or nurse right away",
"        </strong>",
"        or go to the hospital.",
"       </li>",
"       <li>",
"        Anxiety &ndash; This is when people worry a lot or think about certain things over and over.",
"       </li>",
"       <li>",
"        Problems with memory, thinking, or paying attention",
"       </li>",
"       <li>",
"        Trouble sleeping",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H12782736\">",
"      <span class=\"h1\">",
"       How is anorexia nervosa treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Treatment for anorexia nervosa involves:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Gaining weight &ndash; You will work with your doctor and a dietitian (food expert) to gain weight. The dietitian will make meal plans that can help you gain weight safely and slowly. The doctor will follow your weight and health closely.",
"       </li>",
"       <li>",
"        Talk therapy &ndash; Talk therapy involves meeting with a therapist to talk about your feelings, thoughts, and life. Different kinds of talk therapy can be helpful, including:",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"hyphen-block\">",
"       <li>",
"        Working one-on-one with a therapist",
"       </li>",
"       <li>",
"        Family therapy &ndash; Your family can work with a therapist.",
"       </li>",
"       <li>",
"        Group therapy &ndash; You can join a group for people with eating disorders.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Medicines are not usually used to treat anorexia nervosa.",
"     </p>",
"     <p>",
"      Some people can be treated at home, but others need to be treated in the hospital. It depends on the person&rsquo;s weight, symptoms, and health problems. Treatment for anorexia nervosa can be hard work, and it can take a long time. A complete recovery can take years.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H12782751\">",
"      <span class=\"h1\">",
"       What happens after treatment?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Many people get better with treatment. But people with anorexia nervosa often &ldquo;relapse.&rdquo; This is when their symptoms return and they lose weight again.",
"     </p>",
"     <p>",
"      To help prevent a relapse, you can follow your treatment plan and keep seeing your therapist. If you start to have symptoms again, let your family or doctor know as soon as possible so that you can get help.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H12782766\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?25/37/26194?source=see_link\">",
"       Patient information: Bulimia nervosa (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?11/57/12179?source=see_link\">",
"       Patient information: Depression (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?31/32/32257?source=see_link\">",
"       Patient information: Generalized anxiety disorder (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?24/6/24675?source=see_link\">",
"       Patient information: Medicines for depression (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?13/6/13413?source=see_link\">",
"       Patient information: Depression in adolescents (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?19/41/20116?source=see_link\">",
"       Patient information: Depression in adults (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?25/16/25858?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16565 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-200.131.240.2-B6001DE224-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_16_25858=[""].join("\n");
var outline_f25_16_25858=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12782676\">",
"      What is anorexia nervosa?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12782691\">",
"      What are the symptoms of anorexia nervosa?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12782706\">",
"      Is there a test for anorexia nervosa?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12782721\">",
"      What problems can anorexia nervosa cause?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12782736\">",
"      How is anorexia nervosa treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12782751\">",
"      What happens after treatment?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12782766\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/16565\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/63/7154\">",
"      Person having an ECG",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?25/37/26194?source=related_link\">",
"      Patient information: Bulimia nervosa (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/57/12179?source=related_link\">",
"      Patient information: Depression (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?13/6/13413?source=related_link\">",
"      Patient information: Depression in adolescents (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?19/41/20116?source=related_link\">",
"      Patient information: Depression in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?31/32/32257?source=related_link\">",
"      Patient information: Generalized anxiety disorder (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/6/24675?source=related_link\">",
"      Patient information: Medicines for depression (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_16_25859="Primary biliary cirrhosis x-rays";
var content_f25_16_25859=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F74002&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F74002&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 534px\">",
"   <div class=\"ttl\">",
"    Primary biliary cirrhosis x-rays",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 514px; height: 361px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFpAgIDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5XjQuSAQOM80/yG/vLTYfvH6VIBzQA37O2R8y8+9BgYZwyn6U7PFCZ3jbwc9c4xQAgtmIzuX9aRrdlONyn6GpHbHy5zTCCMbhjIzz6UAIICf4l/GjyGzjcv50o6YpQPSgBBbt/eQfjThaOejJ+Zp8YGcHHtk4qxGM9On0oGVhYyn+JPzP+FTR6TO4yrxfmf8ACrYXC5B74q3CTgA/XimIoR6BdP0lg/76P+FdR4a+FWt+IdB8QavZXemJbaJbG6uVlkcOy7XbCAIQTiNupHaoIWIGVGOMZPQCvavg63/FrPi3jtox/wDRFzQB8wrEWx8y8+tSrZuxwHjz9ahRsevSnKSGBBwaQGlbeH7q4UGOSD8WP+FWD4VvA2DPa5/3m/8AiauaZeLGUKyFiF5z2Na39qRSk7gNw+8Qev0pgYS+Dr9hkXFn/wB9t/8AE1KvgfUWxi4suf8Abb/4muosrpHUlenTHpWjbS78ADBHJyeaQzj4vh5qsmMXWnj6yP8A/E1aj+F2tPn/AEvTQOvMj/8AxFd/p0Ty5YsETj5mOK2oIyoDiWJ2C7dwPP0pjseXp8ItebGLzS+fWWT/AOIqRPg7r74xe6T/AN/ZP/iK9hs7hW/jAPTB7VtWSLKQEkRvxpCPCh8FfEZBP23SOP8AprJ/8boX4K+ImHF9o+emPNk/+N19BxssCfvmCnuM5JHtVaOcEEqCN3TI6fWgR4UvwO8SEZ+36MPrNL/8bqQfAnxNtJ+36Lj/AK7S/wDxuve4ZuCw6CpkuwMY6enegD5+/wCFE+JsZ+36L/3+l/8AjdH/AAonxNjP2/Rf+/0v/wAbr6MWUsuBg57+tRTuQPl6+nQUAfO4+BXiU9L/AEU+/nS//G6kj+AnieQZXUNEx/12l/8Ajde+CVt4I/HmtCCXkFWHHX2oA+VPib8Ltb+HcOjSa1dadcDVVkaAWcjuV2bM7tyLj/WLjGehrhhESSMjI4xX03+2c2/SPh2w7wXR/wDHbevmVCcDHY9qAJbqyktbp7eUr5qnaQM9fyrpNO8BarfoGims0yAcO7ZH5Kapa5FI/iPdGCxn2SpjnOQP617L4QWT9yk0SodvQHvQOx5/B8ItfnAKXWmY95ZP/iKuL8EfErLlbvST/wBtZP8A43XuukwyqT8hHHaujtCuQHb8MUAfNyfAjxQ/S80f/v8AS/8AxupV+AXilv8Al+0UfWaX/wCN19MuUAUxFsd6kS4Iyvy47UBY+aU/Z48WOMrqOhf9/pv/AI1Uo/Zy8XEZ/tHQcf8AXeb/AONV9P28kbex9uhrQDrt680hHygP2cfF3/QR0H/v/N/8apf+GcPF/wD0EdB/7/zf/Gq+sojn2p5DFSFIDdjjOKAPko/s4eLx/wAxDQc+nnTf/GqT/hnHxd/0EdB/7/zf/Gq+tXJIPB9KjAIAGM89fSgD5N/4Zz8Xf9BHQf8Av/N/8apD+zp4tA/5COg/9/5v/jVfWbDjmkU7cnbu9gOTTA+Tf+GdPF3/AEENC/7/AM3/AMapH/Z28WIQG1HQRk4GZ5R/7Sr6zIAHB5681DKFwCwGenNAHyfqP7PXiyw0DVtXmv8AQzbaZayXcyrNLvZERmIUeVgnCnqRXjgGT1xX6E+LTn4VeO+mf7Fuun/XCSvz3Xr9KAHeUcZyKPLP94VKGwB3x6mgEjO3jIxx6UDIvLP95aPL4PzD/GpAOR3PA4pSMEbv0oEReUR1I56UeWfUVKAAh5HPUYoxx3oGReUfUUCFj6VOF/Ptip0hPpwf85oEVVtXYZUqfXrxTvsUh6Mn6/4VoxQnI459quLAAFPb1xTAwzYyjun6/wCFLf2Etkls0rIRcRCZNpP3SSOePY1uzW2EOcZ9Kzdfv5L0WaShQbOBbVQO6qSQf1pAZFFFFAEkXU/SpO1Mg+8eM4HSngjuPw9aAADPQj2ozgkA/XFKPunnn0ppNAAcYHHOeTmj6YwaQEjkUpAx3NAC5496UcjrzR1yeM+n9acqbv4gPrQAqZ3c9cVbgBYkDlsZxntUCjA5P0qaHB5APamBbiBIz0B4I9auRKFI5ycVVhwSFyKuwkMwoAnjyF55zzXtPwcx/wAKs+L2P+gKf/RFzXjSLkYAr2b4OqF+FXxcx/0BW/8ARFzQB8wrzTmHHPGenHWgJgA5BBGeDnH1pCcmpAvWEm1j6Bat2Em45YDk1mwkhWKnnb0xU9jIQwzTA66ykCkBVBJHrWxZXDoSdoz0rD00RSFfvA9iK1fsyjJ3Zx3pjRrwXDMQWYE+56Vo29z8w28fSsG3KZ4U4Fadq43ZAA/xpIZ0lrccAIMnHU1r208jqipv3AnLbuMemP61zlm5Pp7Yrcs5ETbuOW/rQBtW6NJgkgf3uafcYiJ2qy4OcE5qg906IGXgUNd7o1JJOepPUUCL8crK/qPSrJbIwrcmspp/3WTnjrimC6bzTtyVHBHpQB0NtPgASenGKkmkO5cHOe3rWVBM5lJVfwqyH3k4I5/T3oAlMoUscc9R7CrFtPgbR+PfFZjsQMnp2qSF+dwHPXOKBHJ/tj86D8N/+va5/wDQbavnXRYEutQghkYhGJB/Kvoj9sM58O/DUnqbW4/9Atq+efDjqms2pfpuxkdelAHplzo8RWzmihBlt1wrDsMVveFmla4tzINspwGwOD60mlfvbcA4KLzx39q09PP2acGP+LnPpTKO+tk80j7NcOCB8yueh9q0rdpY2Ab5gK5qwn2rmT73r610mn3IKDdjkdTSEakEgYZIIxSP97dyB6UsLpgZwc9MVN9oiIGxQeccigBLeTJwCwYdq0ocqGO4n2rKLk/OgH0UVNaHbCY0G0DoKANqJwQD3NW42J4FZNvJk/1q/GcgetAiyeWqKUhVOBTlbpnj2NIx6kYP1oAj3ccUbsU1znoarySUAT7u5phcFsfhUO/KdfpimK4yOeRxQA3xUMfCvx5xgf2Ndfj+4k5r8+Y8bhniv0F8UnPws8e85/4kt1/6Ilr8+k+8AO/FAE6HBBZQwyDg9DQBk9ce5o7f1oA45yRnkCgBA207hkEc0pIPft2o9cClwScAc+3egBMGnKCQB+ZzSxjnmrNsm3lRhv60DEgjyeRx2rUt7fcnr2pLW3A2cfga27G1yQoI45yemaYilHZndx09MVZjtjgDHQ9K1UhIYgqAR0HrTnt02B0JLnO5SMY9Oe+f0oHYy5UG0g4bI5zXM69aLFEsw4JcKfyP+FdlLCpjwAa5zxUu3TkPczDn8GoEcrRRRSAlgGWbnGBTsjNMi6n6U7qx6CgBck/nSHqaUckUN196AAckADmik7dacOB1oAO1OVSelJipFPpkGgCSOFzxwB9asqgQ8D2qsmPep85I55PTNMC1AoBPb61ehAZRnG4HAFZ8Dc81fhPzDGfrQBowj5d2c44969k+EIx8K/i51/5Azf8Aoi5rxmA456Y717P8Ijn4V/Fz/sCsf/IFzQB8vKpZgoH60uMn5QScZpoOOD+VOT6E5qRksa7lbHZc1NbOiKc/Mx6e1RQHL46AgikRe+elMR0mlTHzAOQfSuht/vEEkjvXLaVcLHhQMn1NdBbTEjj2pga0RA6HntirkDAncOlZqNzxnpxirUB4wOnWgZt2koRRz75rYt588Dk4xkVzMJOMdefWtGCbawB/HnrQM6KOQFQrcn+VNdgr5B6jmqEc27JwQak8zcST6UAa8LHYGUlgONtTpGMhwc4OetZ9tMVAUEc1ehcgZ3D1oEWwcNlT8uORUquM7yMY4wKrJIjKMDApyswY42kehpAXciUDB56c0qIyuck1VgIjbkArWkrLIF568YoEcV+2H/yLvw1z1+y3P/oFtXzppJKajA6ggq2a+jP2w/8AkAfDUE8fZbjn/gFtXzppR/06NiMjp0oA9j0y4XCckBgCeOlbsWCwGOcZGO9chohlJAkGQvIPtXVWE44ORweKYzpLSXMS5BB6VtWUvyAZ5PHXpWAsh2r5akliDx2PrWpZtheB05we9IDo7RyBw3NW1PzAgduvasaCRi/I6j860oHIFMRpwMc4xjvUxB25HTqRVSBwCCf1q7AAQQTzSGh0Eu5SqjleMelXoZCABniqiLtJ29DU8ZAByMn1pCLiuG6GlB9aroxJx2qYnbjvTARxkdfyqF+OeMVMByc1GydxQBTJ67Rx703o2ei9asyR9wKqsCD7mgA8RNu+Fnj89/7Fuf8A0RLXwAhFffuvqV+Ffj/PP/Elucf9+Ja+AU6igCfOQueuKMZXJ3YPHA7+lJwcZxSp8wwGPrj1NAAMevFWY41flePUZ6VWUHv0NW7dckHB46460AWY7JmBMI3HHTNWUtJBuVkZWHXI6UWgxIGAOD056VrL50ykF2K45I7imBXsY+e+c9a6C0hPXGRVCCDy+cGte2O0YYEH6UDRKq8ZPOelOKDI4GPep4xlTjr6UgBOPl470hkLwKw+UiuQ8art0yL/AK7D/wBBau5dM428fWuT+IUOzR4W5wbhev8AutQJnn1FFFAiSL7x+lO7+9Mj6n6U/t7+tAAOooYcnmgnkEYH0pwLMccHnPI/U0AJQDzx1pPzpQflI7E56c/nQAo+lPUjtTOacuQQR165oAnRuOppyn3pm4u7O5JZiSSe5pU6g+9MC5Fzz61chbGOv0qlEcMB+PNXo8BuDnPqKANCBiefSvaPg9n/AIVX8XdwIP8AYzdf+uFzXisOdgbJI9RXtPwcJPwq+LmQP+QK3T/rhc0AfMWcgk8lu5pykjBBIPqKjGenangcVIDozg5I6dKmDBXYkHB9DUFSHoM5z05pgW7NyJAeK6KxuP4R9a5WEkNkCtqxkwowcE0wOngkztAwR7VoQfdJJ+o9awbKXucE9+9a8B3gAAn60DRopIpAC9e9TxPzx1qiPkJxgjOOKsx4yCOaVxmpFJ5ZAJ5NTO7ZDZ+XpmqAY5ABOanV+NvOM560xGxAGKjk59fSrkTjuMEY5NUbB96gkc4xg1ajIyAQT3zQBegkUALzzx7VIHYkgjHUdOtV/vYxkH1o3EHBJIxigC5u2jJ6fWtC0mKgYxg8YIrLl4hzgYxjA7VLaysEGVJ9MUCMf9sJd3h/4a8gD7Lc/wDoFtXzVBK0Lbo2w3rX0n+2Dz4c+Gn/AF6XH/oFtXzUjFTkYzgjkZpAei+ENRuSl1LMyGMIPmYcit/SdSNwemATwVriNALDTL3BA3W+ePatnQ22LHhiAcHG3tTGen2E7F1XO4DqenFblmsjSoApGeACOa5fRZYzcoWWQkHrXYnUVRdsEeMj7wHWgDas4Jl4ZODxnNaCxEMODu9KwLa/k+XLEHqc9K0lv2IyZRtzxjk0CNVEPXBH17VbtTgnkk+1Uba8+4MZrRtrpJW/1QDE460gJ48gEE4NOAPfpTZXHmYYKp449KfGwx3x70APU/LnOKcsuByD7fSmDpyADQvI64HSgC0HzjtQT2qKP0JyQOanIJB56dKAInXJBzn2x3qtImGyfyqywOSwJ4qJ13D1PT60AVPEOf8AhVnj8dhotzz/ANsJa+AE61+gHiJcfCvx/j/oDXX/AKIlr8/06igCYdsAknpgZzUka5JByCOnFRqeh6Y6kVbgzxuHHrQBLFb/ACjHIznp1q/aw5ADY6ce1MtF2MuMDvg9DVs7lk7D6UwLtrHAgUyscjjYBzWhBOFOEiRSTjJ5rKtkJcBgDnt04rUhgUsGwckbeDQBYBUsQSdw61ZiDuw9PWiG3hEmW6AY5q9AqjgAgUFDokIxUwTcMbiSO9OVABUqkY3Yx6j0oAjVMqeAa5P4kKRoUBIPNyv0+61dxGm87h93GQSMfpXH/E//AJF224IH2pfp9x6AZ5dRRRSJJIcb+c9O1OHA5602I4Jx1xT227jszt7butAAnXrg5496Dgk5JwOOBmkHWg9aAFbHakHtSjnrSCgBwqQd8VGOO2akUZz/AJzQA8e1KnA9qF4BGOppxXB6nmgC1CeR0q6rAEYJYYGeMc+n0qjFxj2q5DknnO2mBoQE4617V8HTn4V/F05yf7FOf+/FzXiqLtOAdwIyK9p+DRz8Kvi4B/0BT/6IuaAPmJfbpT6bGBkZzjpx1pScdaQxSMlcEkntipEkCq3ckYqLIpBjOOPrQInWYr90AVs6c6shyRuFYHfjpngVf01gsy7uh4xQB0tocMuMEeua3LXGBnj361zdoZAwAARQMHI/rW3aXeAAJMEcetMDYijZsngAevAq1EgHLsB6Y5xWZHcbsc57dKtxyFhjHHt2oGaEMcW8kMx+gq2Ps6p0LHrjpWYhznnB9M1YhQ7hkgDHTFAF61uHR8jAGa14Jg+DnG3jPSsRoBFHu3EH0IxU1nKVkHoecf40DN8spCgvtYnAPQ59BUz/AHAQFbHXJ5xWeJM/dJBPep4CdwIYE+poEXt6unuRTkbauAccVEF/eAqDg9frT0RgDuK5Hp6UCMj9sAn/AIRv4ac9bS4z/wB8W1fNRUg4r6V/bCGPDnw0HpaXH/oFtXzWhwvTIpAdx4JjBtXZiCWhdVXvxV7Q3W5vYwxYRMAC3THqay/BOwNE7OcK5BHTqKv3Mq6bLLBD8m2X0zwaYzv7ZGDgRTm4Re8bHI+orYs93QiQc9yf8ivP9Lu3EgYPtYHgjrXb6TqkvBDE7ePm5oA6aG2KgAckcg7utaFrARj5cjOeaz7S/ZxndyOtWvOdzyxOelIR0drsC5dl49BWjbXEMZyi5yep7/hXM2knyccg1qW5G0YyTTA1bqfzHIAwB3AqWGQcDv6VmPJsc/hU8MoJGCOaQGmQc5AyMflU0S5KgEjHbsaqRSA8Aj61bVwExQA/GHqUEDOPyquWzT4jhuuaAHyAgfL+VRHg0+Z8EHPHpUO48EZx15oAh8UKP+FXePm5ydFuRz7QS1+fiDJ49K/QTxQ274WePT/1Brrt/wBMJa/P2NSeQBx696AJlxng9e3Y1ctwzSZ5z1Jxnj+lVUJXOOR796v2QOVOcD0NMDTjGzkgGp+XAJXA9qS1gldR8uAenFXfsbquduV9qAK1sSJFODkD0rcif5htwcDkjpWfFay+ZgxEKB1znJrUittgUMgBFAydRjGOARn1q7bHnkc/SoFT5QCMVPHjgfhQM0sArjAHenxx+oHFV7eQ4AGD25q3GwGD3x3oEAYCTA5z171x3xTA/wCEfgZckG6Xk/7j11ZPzjJzmuS+KIH/AAj9sR0+0qP/AB16AZ5dRRRSEPj6n6U9wQARjB7ZzTIup6/h9aeWw2V+XHvzQAg4PPUUhJzSquTx2o4zQAq54oH1FHGMg85xj0HrQAM+lADgQM5NSpIucbCfxqDPPNPQEngUAWxKvaNR7k0ocyNkgcdgKjjjOPmbHrxVhYkC8O2fpTAdF7Vdt+uD09KqRLg1dhGRkdRQBdj/AIQCAO3pXtHwYP8Axan4u+o0Zv8A0Rc14tGRsBx04zXtPwaIPwq+LuP+gM3/AKIuaAPmWLJIC5LHgAdTScbqFOB7/wAqEYowZThgc5pABA54I+tA60rk9ckn60rYzx0xz2oGA5qa2Pz53FT61EgzxUqhUI7+tAjdQTuiyOzOvTJHAq3bfIByR35rOtJ2Xa2SFx0z0rbtbhCF3qpPuKYGhZOc544681qQsGHAPFZttPGCP3Y/OtGC4QsMDBx+dAy2u5mAFW4pBFjgZPr2qiZiTxxmlVixzwT/ACoAvtMWVicn36062mHBAIOefSoInBGMckYqKLIYjJz2oA3Yp+ADwT6VoxS4AGMDpXPpJgZ9ulaNrIDkFWUcEd6ANqF8D5sqD71YU/KMH39c1mQ9lY5GO1aUBMidsgcGmBk/thc+HPhof+nS4/8AQLavmtfu19KftgD/AIpz4Zg8f6Jcf+gW1fNY6cVIjofCcwS4ZOpYZGfauo1yIzRRzIOSADt/z+FcFp0728wePAAIJr0qyK3VoV65AINMCvo27yvmXLDiun09ypGDkH3rD09BGSPQ45Fb1mCWHOaBnSWExBALD04Fbdo/mAc//XFYuj2zyKM9PY1vWtuFOC4HsDzSBly3OCewHbFads+VGM5qrBEuMKwyBWjY24IBMqZHJBNAh0o3MD1yPyohYqynH5VYnVFiJZ1DdgOpqCJSfvc44pgXkkEYLyZwOyjNX0bPP8ulZfJGRVyB1K4OOKQF4dTmjdg9aijkD+9K5B6ZNADmYZye9N3YzjHNMOc4xx703fyVxkigB3iT/klXj7/sDXX/AKIkr4Ai3YOCMDnmvvzXzn4U+P8Apn+x7r/0RJXwJb9XBGcrj6UAWY2ZlGAoIIFbOmwwoqtLJnHZRnNY6W8yxiUR7ozyGq5E0xVfuoOvyjp9aYHUW9xhv3alR1yeSKvxSEj96+SOxPWsC2d1hIZzlecg9au2LsZPmBOf0oA1op0jfgNntzV1LsRsNy788YI9arRwM4+6eRjpUq2znG7n60DLckqNGAke0+oPH4UsQ3HJxn/Z4FMiglEZJX5e3NWLcr27UDJ1UqgwOcdM1LF7HvzTC/qvtT4idxzwPccCgRMV3de3Ncd8Uv8AkX7f0F0oB/4A9djuG7CnnrwK4/4phl0C3DZJ+1Lz/wAAegGeWUUUUhEkX8XOOP605sY5znNMiGSeccVIOMEHk9RjpQAJxjpnNN/jpQfmzTlQMFG5QDwdxxQAxelO6HpmkwSDxj2oA647UALjHPB9qkBxjtTAPXqKUUAWEORwfarEY9etVY+tW4z0x6daYEiHIPtViDIPXOfSq0ZIYjFW4iegoAvR/Mo6jFe0/Bgj/hVHxd9f7Hb/ANEXNeKRtxwRXtXwYOfhX8Xcdf7GP/oi5oA+Zc5wAPx9aD14poB/GlqQF6mnY+lMHWnk+34UwHKfzqzHEGwW5Hpmq2SAAQPqKnjJAwe/pQBoQyDaygY7CrsLkAEnmsxDuYY5GOMVoQbtqg/ypgalo5YjABJ98VpwsVxuI47ZrJtlIYfX9K0ouTjGSTgYoA0UbDA54PNXI8beOW+vWs+A5bGOT0yM1dhQ42n14oGWkYLjPUelSHhwx6e1NiXCEkE5qyFLAYHHYUARRnJwvOOtXoW2sGBx7VSdCjAN8oxxxVm3dRgsMgUAbNs5YdST7mr0DkMFzgZ4+tY0EhOMDjtmtO3VWVeeTjpQBU/a8bf4Y+GLetncH/xy2r5vQkEFTgjnNfRn7WfPhD4WHPH2Cb/0XbV85lCMDIbIB+U5pCHxS+VIrBVcf3T0+ldZ4c115ZBFIiIV6bRgYrjwODU1lM1vdxyLk4PT1ouB6/B+8BkIDHGcjvWxYKo5bnAH4VgeHL2K4hR1+YHgjsP8a2Z3jQKE3Z6nnimM2hqDIoSPKgdMHAq/aXLblJO1emB0Nc5bzFgTt3Hr83ar0TEkKTuoA66CcFhtPXn61r2ryNypwK5aykIJx26CujsJGyqkYGMnNAjVSLcBliM/nTpFMRXcx57UecsOFRvnPc9BUcp8yPJ7HueTQBcibIHoOlS5wQRniqNvIAMlj71OJRuwSQB+tAF6CQnPQE84zVgPjr3rMjkK8gd/yq1HJkcfjQBaLcfyqvI2JPlb6471KThcjnFVWc56daAJ9ZJPwo+IGf8AoD3X/oiSvgiAAMSTyvIXGdxz0r7z1Q5+FHxA9tHuf/RElfBUXXrSYFkyukmVY59v8K0bC8i4MsIZu5U4JrMZSVBx0qa2XD4x70AdRbT2nygCRSeg4IrUt5LcnKs6kc9K5ixRi2MfKePxFbNmWDqMZzTA6S3aO4QK4crnpnFaIZyvykLjoR1rMtUwQwJrVt4yedvNAyGUyCHLA7i3emwkg4z9a1poSLdT3zyayzHtcfXt2oAtfLgkggdqVTtA9P1qKMb+CcnNWCuwDBG7FAEifPJjNcl8Vcf8I9AM8i7X/wBAeuoVth9G+lcn8UCT4fgyP+XpTn/gD0Azy6iiikIki6t9KXj1zTYup+lOGOwoAUHAwAM56/0pwb5QBjPqBz+NNoFAC98n15oHrkZHrRRQA5VLEAdT60owDjNNODyTQKAJkOCMjIq0hJxVRTViNwBjHNMCc8GpY2IPU9c5quXyOecU+KTBbgcjHIz+IoA1IWARSP1r2v4KHPws+Lxz/wAwU/8Aoi6rwy3k4x2PUntXuXwROfhX8Xuf+YKf/RF1QB81cYznnvQFypJIFHakI54zikADrTgM03jdwMe2aersD2oAXGOtPSQggZGKj+8c8U9XRW3BSeO9AGvbhZVLOeSevvWoID5akMOO/pXNW85DkHo1dLYzE2xQnJHK+1MCWJvmGc8jFaFuxfPHfjiqscDEAnCgcc1cgkVMgjJ6cc5oA0oFWNeSc9fercN4gO0Lu9D6VlRsXI7+lWVG3qRkdupoGbK3ZbH7tcH1q7bXBCk4VV9cfyrEWfAG36VNBKSRknr60AXL6USOCBhB3B6UQuuz5fzJqE7mU4/MVGCQQpB20AaiTjaCVIPtWlaT4kRW4yw5rEt34wRgHqKvWrZkjGBkMP50wJf2qm3eB/hO3rp0p/8AIVrXz1C4jcM0aSrggq2R1GO3p1r6B/agO/4f/CI5HOlyH/yFa18+IAeOMjuT1qRCYIOD1oJHGOBj5jS7cEgEHHcd6nihBYYBJHOPWgDsPCFwy2SQvkHORnjiu7gvM28abVKHvjvXm2iW0puPMkfCjk54/Cu9tZ0ktwqDC9vUmmM37ZreQD+HI9K0beOHhhIMH/ZrnLdm25zgkdMc5rTtXycAkg80AdDG0EbKQfnIxkfyrTgvC4UKCpPX1rm4Pm9Qe4PT8K07N9vy5xjr6UCN1ZTnqOPXrmr9vIDx19zWNbuzoMj5u/NX7MkOM/dx2FAFhGw5HHXkVZLnaBgDHcd6ZHbtI/mRAnIyV7Coy21M5yKALkTfKMZNWlfbg5xnpWbbyDIye/OKuZDcqf8A61AF3eGTvn0qEHecZGPeoxwMsTxSK4ZhkAd6ALurDHwp+IIA/wCYRdf+iJK+CIxk195aoT/wrD4hg4/5AlwRj/rjN/hXwfCcA8nnr9PrSAvWKCQEEZBFPMTQyAdiP60yz3bgEyWyMY711FzYBfKnnAOVHy4pgVrCzlkbecKvXmt62hiTaHlY4OeKyTM7kKoKrjH4VoQKx64A9WoA3rQwjG0MQOeta9o8Z6Rkj/exXPWzYXCjPPetW3Yn6DgUDNqR0MJULjPOB61lSw/vAB171biGB8wonifbuGSCMD3+lAFaBPmOMD1xU5+TPPP51HGhHX+L9KVhjhmBI6UAMZMsTkk1yXxOBHh634/5el/9AeuxCfIGyBnpmuQ+KAx4ft+B/wAfS/8AoD0Azy6iiikIfF1P0py+2aSLqfpTsY+lACDGaeoJ4FG31p5kUIFjQZxyzdSf6CgBpUAcE5puOPem5JxmlycAduuKAFpV+oH1oxyD19s0cUAPU+v5VIOp6VEGUfeGasJPGvDRAke9AD1+70/Ghiy9uPelF5jhY1Vfpmo3kZjuZiTn9KYFuByPm7e9e7fAp9/ws+MHHTRf/aF1XgcbA4wea93+ATA/C34xd8aL/wC0bqgD51GaUn5QMDI74pCe4GBQCRyKQCgj05oPSkHrS5FAC9uKOwo4xx160DrnNAD14ANb+mzoojO4K3fJxXPr1HNXLd/mAPX2oA6zawXdNJgfw89fpSi5UoCiD0+b+oqlZRLIBl2J64FaSQAKCisSfWmA+GWRh8rYHHA4q3bsWOH+UVGkXHP5VOsKqNzHjrigZbjjUEFtxx2q5b7VZdqjHqarIflBHNK8ucZ6H06UAbEbx7DmJDnuODVe4VcBlGB0xmqkE2V64549KkmkJUBe/wClAEsD/N/9ar8JwUbocj8ax0kORtOT3NaELn5eM8ZGe9AFr9pc7/hr8HW650hz/wCQbWvAFHBzkDscd699/aROfhj8GT66O3X/AK4WteAknAGTgdKQieMgucAMQc8jg1YyqRowG1vY4pNJtWuLpVBABHBPSpr+2aG58tP4f85pgbmkysYRI4OPauhsLpQ68kK3ByK5bTZvJjRP7y457HPSug04CRlJGMdS3TNAHWRncFOASa0rQY57Vm6aA0JBYccEHtWjacsRngetAzRiIJ5/HFaEFs8p+X5frUGmxnfu4wBWikwRsBgGxyT1FAGhaQLEo8yQk+lasdzbQpghWb61yz6hg/IP+BE85pyzt8pJoEdG+os8exCRH6DgUyKXcu09AeMVm2waUfIOe1altYuE8yWRUU8E9c0ASInzg8g+/GauQyYPJ4z61SDDeVDZ96fkZznPvQBeMm4EAfjTUbnJPAHNVXKuEyOhDD5iOR0//VTWJbG0kH+dAGrqEok+HHxFUEnGgTH84rn/AAr4UiAz8zYXuQM4r7dZs+AfiWMk48Ov/wCi7uviKNcrkCkBt+H5MSKAEDjkM3IX3xXoWnfZLqFmMJmlAwATjJHWvMLSTyT8uQep9q6vSLibyJCrjyzyuG53f4UwLd/BIjnyYgDk4J7e1RW8cjNmTeWB5J6VYivJJCC+GA4Iq3DcQsclShHOAaBlmzjbAO046n6Vp2wXd8o4zVSCeJo92Sc9sYxVuGfGQoA9zQBqM4jiVsDcePY1JblZ1O4jNUGlV8AnnFT2p2ldpHqRQBMyMCQBgA8CoZ0ZCSDuzV91YkMBlSM/SmOAx6DP86AM5N2cnOK5T4pj/inrckY/0pf/AEB67Yx7e+FPOMd64z4rKB4dtiD/AMvS/wDoD0AeU0UUUhEkIyT9Kk4B61HCcFvpS0AOZs854HakXjkdRzSHHFJn0oAXjpQT0pDjNL1+goAPfNLjjOfwoPtRjmgBR0PGaADjtSrTuMUAO2fOVjbco6MRjP4U/a653KcetNDgcAYpVfrgnPtQA4Hjrg17z+z7k/Cz4yf9gUf+iLqvAlLKTjnPGMV73+zwc/Cz4y+v9jD/ANEXVAHz6vIAHJNB9B1oIAOM9PSk6fTFACDp1opW6nkGk7dKAHDPU96ci5IH4UwfrTwefQ0AOaIqxHX39at2MBZ9zcBeabHL5ZXnK/571ZWRndfLcr0zTA0LZirckBjnite0cugwT3yO9UdMSONw8zZKnPPrV8PtkfkbeoxQBbjcZ2hsEdzUjS/KPlGfcdarJIFXOe3rTkl3rz69DQBo2spKAHsMU2YhhgHIFVEn8sHJwTxmkacZ5JBoGWo5fLBYsAOmasm4zGCWzg/nWatwrNg464yOeasK25WGeR0A9aALVvIN3DL9BWgCVVmViDtJyPpWNbuQ3ygbs55rR3nyJSRn5Gz/AN8mgDY/aNP/ABa74Lnr/wASY9f+uFpXgR+6K99/aM/5Jb8F/wDsDH/0RaV4HSEb2hXcFreWq7W3HKlscDI44q34pnSSaKO1GGkGJAp+9XMRtsdHOTtYGtSAFdS3thlA3A+xpgadkNOsrNPt0pecNvCL/KpTrMtzeK4AihJxsXpj3rl3kMkrseeatwOVVSOo7UAep6KxRVLEHjH1FdNYJvUu+FAHJ7GuI8P30Qtow7EOuMZHX6/4V1cV35q7pNyuB8obp+VAzca7VEKRELnAL+n0FVEmLnvj9T71UhiaViSR1xknGPwrQFr5aZB5HagBytlxtBK/StG3j+UED5sZ6cVnRZx8q5PvV+CTYR5jDP8Adz0oA2LPagEkjYA7U+fUDJIBk7egrN80yJxx64PFV5HYTIQO+CKBG75zbN5IyRzT47jJGDj19qzxITD0OafFJ5Y+boegFAGoJD74zwaVZNvc8+nas4TYRupJ6YoSdhnHIPT60Aa0Uobwj8VIgeE8MhsdhlL3/Cvi+3GVYCvsDS5PM0D4wc52+F4R/wCQr0/1r5AtwfLdsdKQFy1QMQMjNbdtJlFQk4zkhTg1i2ONxL8KemK1rVeMKTjOaYG0sfyb0HBBz7U+JCccj14FS2OQAG5z8pxT41yQhydvoeKBlm1Q5XPKjoQK040LYAGe9VLdDJtUcZwK0zJ5SBEA44PrmgBVt3BG/Cg+p5rQt1hWI9enQcVnq+OvJHapEmI5z14oA14JsDBBUdOe/tQHBHAwR/Ks5ZSRkjJ9anN07RrFlfKD7sY74x16/hQBKSSQeD169a4z4sjHhy2wc/6UvXqPkeu1jjyoYgnOc8da4z4tqV8N23obte/+w9AHklFFFIQ+LqfpT9x2gEkgdPamRdT9Kd2P+PWgBCfTpSUoHc8D1oGD1/OgAAzSjrzRjFOXjBHWgA+lKRTaefWgAHr3zTwM496aB6/rUsY5AxyaABVFOChiAScjgCgfKTnjtTuRgjpTAYUIOGUgjqD2r3n9n3/klvxk5/5gg/8ARF3XhGPmOTjmveP2f8f8Ku+Mn/YEH/om7pAfPB7YOfWiijtQAueAPSlUAjkd/XtSCj6YoAcRjA6Z5H0pVGSMHqD+FM5ODU0OCWPGe2aAEHQVNbth/p3pDBIbYSbMKDgkmoUONwxnPagDSS5YHKucDkGtCK8VoS4+YjkY9DWAjsPm9Onua2rGBp+Y2wGGcE96YF2O5LYdycnjpUwuGYHCkZHrVCHargEnPp/WpSd4yo+U0AWWuXEYJJ46ioxKZGyT6Hk9agVXZsBTjpkipIYWViHRhG3UjnHuB3oAsxuw245981o20u1wd31rJhilJ5A47VftoHUli2efwxQBq+YsaqQBtY56YxViS4/0GdwePKfHH+yaqR27NHtJYg9D70SKq2N1lTnyXOQePumgZ137ReD8LfguW/6Ax7df3FpxXgbYye3PTrXvf7Rn/JK/gwP+oMf/AERa14GozgZAHvSEAGR9a24Y4VvLKR5QI3jCtgdxxWMOADznrmpvOYwop5VTnigC5b6W880qRvjD45/StZ/DrwRKZpRyMnFZ0Fz5dwCMlsdT3rs9MmN/ZI0qqwU4II/zxTAo6TaXAMbZJQnO/wBK6+3m/eqzDOD0U8GqC3KQwEGMKgAzxgYrT04xBQ6KSe24frQM3IJNvMqgE84PapzqCK+Aq+mTWRNO07jZndjoKjVjkEkcnrQBrPdyFhggKewFNR8SZPJ9ahVd6KQR7kdacOHP1xmgDds2Aj6jnmpDsJJHzEdT3rNScCPaMjBz9aljkz9D2oA0onw3PAFOY4yp7VFEcruHAx3p5UMB35GDQIcjE9OtSKQSc5wRiqry7TyPm9+KUTdT6HHWgC7oEvmaL8ah/c8OQqP/AAHuz/Wvk63AFnJJ6OBj8K+pfB7btI+OoH8OhQj/AMlLmvlSMnYQScE9u9ICzYq0km1QxJP8NbNu32SOOSZsOScx/wARxWY0n2GLy4siZwGLY6A1BHLJLJyS7E9KYHdaXP0OAUJDfh/jW0lqXmJiGcnOe1cp4fnRoo0dh8pxj2rs4llljTySFhIxgHk0DHQ7IgyqQz+vYCo2k4LZ4PUmm3JSMrEDk9TjuaiG7jduJoAkEmScnFWImwck4/DrVdY24IGMHnNSK3l4x1+tAGmjKQpKhT/M+9aEKJGgLDOTwMY/Gs21PG+TKr79T9KnacSSErkKOme1AGmJUYD5FGBjgYrhvi4QfDNt1z9sX/0B661nTyUKEsc5IHY1x3xYYN4atSQN4u1/D5HoA8mooopCJIhkt9KCdwpI/vU9OGGSdvfHpQAm0dmyKTj1zUrlW6Z9Mnv6fpSPGFIPrzQAzp3zTgKTFSQLmTHrQAi98HrwaeAQQfSnogzgfnU4jzQBCqE+lTLBxg9KkjiwcdzVlIj1xmmBUlixHk9ffr9aZGo2jByevStNod6c9McVCI9pwRk0AU5hhs88jNe6/AEEfDL4y5GB/Yi4H/bC7rxiWDcowOa9p+Ai7fhp8ZQoP/IEX/0Td0AfO3G0jHzetJT8c8kfhzSfKDwCfrSAQeo7UnWl7UADFACnA4U5/CkyMYpcccUYz25oAneVzAqEnae1NgZIyS67geOuKknhaOKLOeRUMgw5xwPSgBzMASU5B45FS2s0gKAORg8YquOlWbMK0wXgA8ZPr60AbNkks6kBckd624bDb95lUDGaq2KGNFIKtkdEHAq9EYlIDuZWznC9BTAtJaQrnL8eh70NFZBhtV2z6d6UXEa7QsC57FjUizylcoqqc9AuKBiRxReYQLdgpPUtjFXQbSNdpGBnOM7iKy7h5WIOSecdelLFG5TcB044ODQBrPfAwlbeFVyPvHrWfdEjTr1iDjyH69/lNWY4iACce1N1KNl0q+JyP9HkP/jpoA6T9oz/AJJZ8F/+wKf/AERaV4H0/CvfP2jP+SW/Bf8A7Ap/9EWleCYHpzSEOJODkZ+lKRhuGDKc4x/nimDggjtU2Y9oZAVbJ4IBHrx3/OgCxZy7p4QThgQOR1HvXomlQPGViAKqQdwP+ea81t1eedVgX5yeMjvXqMFvdaZ9leXMsJQbzno2O1MBlyfJAWVTuBwB71ciucwxhT8mT0FReIrRpvLmRgIwu4ue1Fi2/TfMth5rRttL9evegZpWzSZ6VZCkN8wBJHHoKoW939nAN2yYY7cHgg1pR6pFKBEsa7Qcg96AJ7YlVHPPb3q2i+aV5xjtjNR2sZnn2w/M3etIzxWZIt1EsvQt1VaAEt7OWVMooKcgMTgVcSyAxvnhTHqaypriaUFpXZjjhQePyquZC24EHd6UAdPELNBhr0EN2CE4p7T2Mf8AFJL3wOK5hWJYhsj6VKrlGAxyOmBQBo3kxeTzAoUdkFNil+XIP1AqrI+SD0A9etJG+OfT0oA0vAzbtJ+PnTA0eIf+SlxXy7DnyywA4YV9NfDg7tD+PnP/ADCUH/krc18yW7DypFOfmx+lIRavvnvPn6FRg1ZtbGMKWLZB6AdRVefc0UY744HrWlpkLNAMEB/1xTAtQ6bKQJIiQM8g9QK6KxkZVSNZmQKMZB+9WdZSsifMMr7ntWlYiLCnaTIG4JJ4B7UAa0RCxjYSeOpHNP3jIBZsHoSaaW8wIqlfRVHaqMgO7BPIP1oGXy0JB3SE+gxn8KbJMiHMKZOerf4VTkxuAbhT0NSLE3Abt3HSgC1FK0hJbnIx16VagwsijOCckDuR61VhQo33sHoeK0UjztwMMBQBYRC8PmLtHTjsK4/4q5/4R63zj/j6Xkf7j12Vk+0EEDaRgiuQ+Kwx4ZtTknN2vJ6/cegDyeiiikIfF1P0pw5psX3j9KcB2oAcvtSsx4B6dqBxTO5zk4oAXuM8CnRsVYY4po5pehHFAFu3z5hzWjBEzjODmqtskalXZhgjOfStFLxAQsbt7YFMB8dm/oPxqwtm4XHH4GovOVsZMhP1qVXULyG68c0AOW0f+HaQPelNnL/zzPrxUZuNuSqjPvQt3LgBZGUEdF4oAtrYSYJYBFHJLGvVfgkoX4d/GYL0/sNf/RN3XkZkMjAMxPfBORXr/wAFSP8AhXvxlxkD+wU/9EXdAHzaBjIOQw7UhBzxQSSSxOSTnPrQCe9IBfagYzjpRx1pR0JoAQ57dqeowevampgNzUqgFiR+VAFtoWlt1IbOMdaintnCBlUnA5x/OtSwQGA7xyx4OOtbdtaq1spAG7p9aYHFJG5GdpI9RUlumJBXS3liYoy6AkFv4emapNp5k+dEYdNwH9KALulwuwG0MynqAK2obKQYIjcD0xRp0AtkjBzvA+bn9K3IJmKD5T68nrQMz1tXUFdvBPcdMf8A66lW2YAA/KR6GtUNC3EkR6dc05o4TjbF74LHigDKlgdwFwg989Kt21gSycrlu1WhHHu+4oPqeeKmgJUEr0PTAxQAv9ltuy0kYx2J6VS8RW7Q6BqRcAD7NJgj/dPetWE5JBHB4x0ql4oz/wAIxqnp9mk4z7UwLX7Rg/4tZ8F/+wMf/RFrXgnGK97/AGi/+SWfBf1/sY/+iLWvBKkQc44oAzwO/pSZpeoPIHt60ALFLJBOkqEiRCCCa7aLxxM1xYrLGklvgCVGHJPTiuHbk5JyfU0j4B+QEZ6AnJoA9J8ea090LXS4wI0Ybm28ZHYVlzeJ59EWOzs1UhUG7PI57VW1PT724TSLqUFV8hVZieeKpeIdJlW7DxsJCyA7QOfwpgOm1m5v5/OuJt20ZAXgL9K6/Q76K6SNsjJ4cD1rhdKtE+aS4JQKeMjv9K6Czl+wSB41Kow4deBmgD02O/S2tvIgQ7nHzydM+1Qi7CfKhyo4yO9YdjKXT98zYbt/WtKJE4AD89z0NAy9HcNICG2quORUqnJyCf8AGqyRFSDhcN2znFTqrsBxwe+aALEYJyARjvVuK38wjLYJ54qpErdVUknoT0q1DdC3BeP95L3yOFoAuSWcECDz5ZCx6L61nSoqz4RiVxkZ/lUU907MSTlupNRXE7ALkjDL1oA1vhid2gfH08j/AIlY/wDSe6r5mi+VtxGR9a+lPhQS/hn49k8k6WP/AEnuq+akYo2OmOuT3pCL1jiUiJiRzkH0robO1eKdGXBR8bcfxVz2hW6XV9HFJKUBI5Wu5kD2mq24t2Wa2A2HHJU0wMm4zaSKkhyQcgDv9a0rSbdajYPmJyAetUvFlutrdGaRwWc/LGDzio7eWZreB1xHA2duB3+tAHT2WcL7/wA6kmj+bOeTg1S0uRjvV2AXG5T/ADrYURSRKEPzAnPoaBlUpuTJPTjp1qe0RlGSQfarVnZtM/C5GM5PatCNYIRmEByOSx6CgCC3spZjwp28Y7Vfh06ZQRIyqceuTVVr1yQIs8UxriVv4jk80AaBtRGAGlj3Y6Zrivi2pHhm3PBH2tOn+49dPkkDnBxgkDIrjfilIzeH4ASMfalxj/cegDy2iiikIfH1P0qQUyH7xx6U8UAKvXFLt4OD+FLGMt0qcR8kelAFdgc560h6jHWraIGUq3Q/zpot2zwaAFgUtgdhWlbWznkMv4mo4YBGigjJIzWjAiMASMcdu9MAjt8Bcsv0qwsPPLgrjGOuKmSCP+/U0cK9cDrzQBSaxyx+cbfpSNats+VlPoK0nQICXIxnjHcds+9CpHwMZ96AM5bWWM/dJ78V698FR/xb/wCM4P8A0Ak6/wDXC7rzYEoxDHnsRXp/wgGPA3xo4/5gMf8A6T3dAHzR2xSCl5oA4pAGRQMYowMe9GDkHsfegBR1p3IIIpo680ucUAdJo0heFcYG3OQe5rfso3eIBcEMe1cjo1xhihBK5ydvWu+06FZIEfAXPQY60wEig2xk8En8qmt0VAfl+bHQ9DVxIflwV5zmq82BJgc88UDJ7OyilcnGGJ5z2q3JGn3Vwqjp7U21UrCSM5Y546CrM0OZOMDuPegCttwfpU20ZyVOR+GalSIqRnbkcnFPC8HIO7P50AMEQ4HUHn1wasLEwOQfc+lTIhHbBxjkVMI+MAfdHJ7mgCKBMtz+dU/GMYTwhqrHqbd/6VsQw/MG4AHbNZnjkf8AFGaw2RxBj/x4UAR/tFf8ku+C+f8AoDH/ANEWleCHIOK97/aL/wCSWfBj/sDH/wBEWteCE9ieB+lIQYIVeOMcZHb1pVxg5B4Hr1pXdn272Ztq7Rk9B2poUnpjNADc56citeHRLtWtWkhK+d8yhuw96i8PQifVIAR8obJNej680TNAYcSFcZKDIFMCFrJ59JjhbLNFjaOy1N/YxuLOB2Y7ozy3etLRD5qyb+m3BA/StawjAzGwPA6ehoGcvP4ZM7maJ9jsu1h6+9W9J8JokbLcOzgnJB7H2rqFtiCpTjtk+tLErq8ign159KAMwaTIZAygBM/wjgfhW9Fp8dpb5lyrP+OBRZMC5xuGe2auXUcs8fmZz2IHbFAFKK3jj52Fv5UOkSnKx9OME1NBCx+WTd/vVO1uSACKAKUscr7SHCg/dUColt2X+LqfStVYQUyV6cfjTPLIwGAGAT9KAMnyMsQQcD8/xoltlkiBXPHHNaAUA5PXvSrFmNth56daAI/hYnl+Hfj2ueBpY5/7d7qvmQAY7+1fTXwuYP4f+P5HA/s49f8ArhdV8yqSOhwO1IQ+J2ikV1JDA5BrV8PX8sWpj5mYzHHJ79qycHB2klepwP50sB2So4OCpBHagDpJIrnWvEDmb5Qp24PYDtVmbxAlmslmsCPHGxC59R3rn7G7mt77zVkZH5wQehNU5XaVt0hy2cZpgdJp2pSnUbeSU4iztPPABr0my8raCWGMdu4/rXisczgY3MfTB6V03hy+vI1xJNIIR0HXP/1qAPT3ut6eXEuyH+7/AHvqah85QpHRSfpWNaahdTr5SRrGmMg4+99KWRJF/wBfI4cjpjOKBmmZV3ZQ8DnGelO8xeecDrWOrkZ8t9w6Hjmpj5p5B2/WgDVSXacAnHpXJ/FBt2h25AwPtK/+gvW9ArtgZc57jiua+JDQDQ4I4zmUXCluc4+VuKAPN6KKKQh8f3j9Kcp7mmxfeP0pxBzx0oAni+9jNWYF3HGdv1qnCMtW3ZWpC5PU8imBXjiy2B065NTLEM9wen1qdrZwGYjg01onGNowRxxQBZgtwLcOQT2qWEYOB25OaW1DeQ+cHABb0p6xE4dG5HbtigCxGeeg6ZzircfQcc46Cq8a5wcbsjr61agBA54HvQBGwJ4PTOAaXaQcenNXIog2SRnHYVIsWWAGSR17YoGQRRFwSRlq9J+EilPBPxrU9RoUf/pPdVwqQkAEFuePpXefCnjwf8bwOg0OL/0muqAPmRev60H1FCqWIxzngdqXPrSEA6UuMHmk7+1O60APi2qxLpvGDgZxzjg/ge1IU45pU61ZSEunT5vegDS8JWxluyAOPrXo0cCKywIw9jnpXB+E1eOSdmyNo4x613VkG81WxjAzz2pjNu4t0trZEJBkYdaz1s0K7nYk59OajWd57gu3Y8ZNLNdBQW6EHA9aANKxjjl3Qr9/bkZ71fNqDGp3KzrgH6dq5aCSQzb2kOdp59K1rORyFYN83X60AaSW67uFHqTTWjA5Gc/WnRuWXHOakx2AIPYmgBEj+Ukcc8g1OkbDAABFPjjBVVJUe+KcZhErBQvHNAC4IUhRjHXIrF8e5/4QXWWI/wCWS8Y/21rSN6VTIXB/zzXOeP7x38FasN2QyoPw8xaALn7Rv/JLfgx/2Bj/AOiLSvBDyeg/CvfP2jM/8Ku+DHY/2Me3T9xa14FxSELS44yc4NJR2znAoAmhuJIhtiYoD1K9TW3b6lKLDCsAycc9GB7VgKCTkVahUlME4TuaYHoPgvVlmfypD8xGAPevRfD1rJJdt56ERgZOO9eK+FbpbbUoxDGS24BmPpX0JoN3BBY7pcNK/Qd8UDJILOO7vFSJcKpOFrE8RRmK+EcIO/uQOBXa213bWsUk67Bwcelcq5N7eTXLv8mc7RxmgQaNZu7L5ilRnoe5rYhtAitE2Rk/gDWPd30VvCZfLLOvTHXNWP7YluWATChgPmxQBakttj4bgd6cEUKQxyR0qON5pEAdtw9xV+KEyL0yT39KQFADIwPu9KgeJtnYfXrW3FYljyMk8YxzVhdPUA7hjHrTA5R45No2j/8AXSAEbSR1PGOtdLLa2nJ+YNjg5FUri1QBTHcxBvQ8Ypgc/wDCwFfD/wC0CD1Gnt1/643dfNEeApB6fTNfS/wu/wCQD+0GMg4sXGQeD+6u6+Z1ycYFSA4AtkrxgZOTj/P0pOgxtxkA56nFGcE+tHbr/SgBRwSRnj0pMnsD6ninxlQ6g5I74ren077PZiaQN+9XKqOo9j60AYSgqysy8Hmt/Tfn+SQnawIwpwQfao7yyaLToppEC5GcHqfpVGwudsoGOAeKYHaaczWVszLOSykKA46Zq6l9KzZaSJyDjkdqyrZxI4jkXHmr98Dnp0qB5WgnQjGRwcigZ0ceo7XIMEBYDriifUpfLIRIkJPYZx9KzY7lJFBROO/PFPF0pGGUdMcelAEc95MSC0rMc8jNc74rlMmnpk5/fA/o1dMssW7DRg8Y4rn/ABlFEunRyRcEzAEf8BagRxtFFFIB8X3vwqQd6ZD9459Kd3oAtWIUzDNdHaMuSAcKOg7CsXTLYsxcggDvW1DEEh3HOfSmA2WRy5AJA/lVK5EokADdf5055dhZwe/WqjXcjtgYK0AaWkiVnYMSUZSCDWwkZVT8vHuOlYNk8mNwc5z+VbVvKzjnknqc0AWEzu5HIq5Eo4BHfnFReXvUEHnHHFXbaHkENnAoGSpgEcYPQ4FTqnzA4HNNWPb05H61bVBlSOCB1xQALF8pwBkDpXW/Cv8A5FT45jnjRYh/5K3Nc3BygDgBsc966X4Wjb4Z+O4znGjR/wDpLc0AfMYxindetIOlL1HFIQYpQaQZ9akjGSMZz70ASwIWYcZFbNjZPINuCfwqtpoXcRIAV9f6112jGABcEsc8HtTAuaFpQtLTzJAPMc8An8q27dP3TMBgnvVaZ/MkCjPHHWrsICR45zjFAyGC3OWIB2g4J6UyeBpJeFwcdh1rbtowkONv3hwDzVa0wskkjgYU7f8AGgDMtk3gDIGeBnj863NN06ZtpYRlT/tDiqV5bBMyJ/q371Fb8E4ba3qKAOzg0NnGfNjx9elSw6NLuIU7mx065rnbSSQIvzt+dX4PNJyHPHOAeaANq602SCIB1PA3A7elZEtnPKCFU7fQDmrN9fXsEakSsMjtWS2rXJBLSKPw5oAkewnj5kjYAdM9BXM/Ee1ePwRqEuxgoaIE46fOO9ba6zfAFVnKr7VzvxH1K7n8FXcU08jxtJFlSeCd2aANj9ov/klvwX/7Ax/9EWleCV75+0V/yS34Mf8AYFP/AKItK8DpCDFOB+U49c/Wm0vbPpQBYjIB9cHg4xmr2BIoUDB7CqEI3MK2bBEZM5LE8cdaYFfS0uFvgsOAzHIz7V7bo8c8lxAoJCCIFj+FcD4c0Frm9iZgWIOQSOn1r2KOC0g226MQ6qN2O9Axbqzka0ggLFTwzZP6U4WvkxFFzgjPArRV4zIjsCQMYJ71Ky+asqAjBPXHT6UCOTl0+a9aTYOE5+lXrGxeSKP5drA4IHStqyIhs5n25I4+tNk083kDzJmMnkhT1oAtWdhHEoM8iq3cZ5q8z28a/KM44yT/AErn7fTrlQfLJcDtnmr6W0mCMMTj8qALcl3tX5TwemKryTlgc9+tC23HTB75FOMGADzn0oAzZ97cfoDVJ4zuC44z37mtqaEY91PFVJYN5A5+lAHM/CTH/CN/tAccfYX/APRV3XzYOegxmvpX4Tjb4d/aCHpZSf8Aoq7r5qj2jrnpxj1/wpALg9aQ059m8+XuKdtwwaTHNAG74a0k6lN86skQG4sema3LjT7691gC2b/R4yF3NWfod7LbaOBGCfMcpgeg6mu109hFZO4U7Y0zgjvimM5rx88Vt9ms1bOFydorn7XSrtIRdLaStF054/Su90/T31C6F3dBXOcgMM4rU1ABYDjng4UetAHG7nkS2u1VlJXaytwRjgmm3UkU0YlSaN5F+8qnB+tbtvonn2AZ8hiSWBqW18OQSpIBDyxBGBigDnUm2x5BDD3HSnmY71GACe9dhF4SR4wojK4H3iaefBqYXc2wdh1zQBzMXzKQAOec1h+MFxpUWR1mGPyavS18MwQoFDsT6jtXHfE6yjtdEt9g5Fwq5/4C9AHmdFFFIRJCMsfpVq3jy3zVVh+8cHHB/GrVs37wduelAG/Zx/Kij7tadxCm0BQeetUrRcMGxyBV1m3phs5PFMDNv4MQEKoyTkZrGjUb+DXTyJ5k5TnYBz3rF1C1+z3jKAQp5X0oAuackbMEkO3uDW5axwoRlGbB5xWFYo74I4TucVtWiTlv3LE4/velAGzAYQpPlMR15NXLc25JXLL6+lZ0LSj/AFqkDuT/ACqxHMrY4GBzzxQM0/KRhlJARnPrU62jMOADxxg1mxvH5fPAP92r1vcRRAfO/A7dRQBahtXDEMuQepx3rd+Fy7PDfx5XOcaSg65/5drmsqK/QoCIywPXJ5Navwwk83w98fXwBnSxwP8Ar3uqGB8yDpS/SkWlpCF6t0wPQVPAhJ4HHvUJOSDV+yXKncOtAFiFQqqMcng4rpNFQgBiPukY96x4IUJ4Jrdsj5UeBk7j+VMDYLfvsuSc89a1reRZEB5+XgisaOB5Ap2tkc9OlaljFJ9ojC8oeoA60DNyNlZCd2Rjg+ntUWqQG2SPCnn5j261LDbMJ40PIZhkCuj1S2R2hV+VUfdHc+lAHMWCm8gaGQER5+8fuj2qxBpsaSqbmEIOgZeFxW0lsZbYBEQBGyV6VeE8U1v9lMa5HTb/ACoAqWWmRYAVlZG6Ff6ityy01UGTGhHTkYNYMamGdVj3Ln73rXWaZdthepwMZPTNAhg02ORMSQ7ge2KzL/wtbOMrlQegxXZ2twSASEyecYzV0NG5GYkbnnjHFAHjWoeF5oXcwtuGeOMZ/CuG+KFhPZ+FJmlUopnjGP8AvqvqH+z7K4BBiCNjqpryP9pbR0sPh0s0LFla+hTpj+Fzz+VMDmf2i/8AklnwY/7Ax/8ARFrXgde+ftFf8ks+DBIyP7FI+n7i1rwQnPpxxUgKo3MAMDJxyaAaBzjHX1pV6896ALVptPLc11egx2ybTOVGeBXL2ik4HYnmtK7by1+9gr29aYHquhXcEEsbRqXUDIPqa0odS8y5UuAHLc88GvPPD+oTN5StjAAIPpXX6cJDLmNC+enGfyoGd3bTeZdLGmMgetbFkv74FWIZTk59MVjeF7WeZtzRsvOTn/69bscTxzO7ZKkYFAjRgsIJLGSTaOSeKrzKINpQ4AA6c4q1BciPRsAAsT+tUVhklgLsMKT1zmgC9ZeTMS2394T1FLJBKXztyCcBqSztgihW3DPTPc1oEO8YUjAX2oArx2299rEZx2qwNNQqCHBGM5xTA/A2fiKd5jsMnGP50AQyaYhPzFTjpjrTf7Pt1wX+Y56Yyae7HGCeKRGaN0OD8xHSgDyz4VEHQf2h9oIH2WYAH/cvK+aVr6U+Epz4e/aFOc5tJj/45eV82KCV9s0gFHHTvVqytmuJBGiks3SooUDOAT19q6fwpFGLhfNIILYAFAG/pehR/YrNpIxhFLbT3JNdTHbRGzjQcbiS2B2qhNdRSsI4ztVPlHvWhYZeMIx+8e1MZcsrJYHUksYzw2Owqv8AZlN0zN9xCTz3963beA7IwQAf4h/WrFxppaOSWMDJTkf7VAGVZCAwgFWYKCcAc1JbXtnFJ8sLqcY/eDj8qlsY0ttjsoLMcHjqK10soLgNIyKV7+ooAzTfeZggjj7qgUn2jOeDn61onT1RwEVSp9RyKkWwQ4xtGPxoAyHYOAGIH9a4H4vIF8N2xA/5e1/9AevWm05doG1W56+9ea/G+0WDwtauAQTeoPb/AFb0AeI0UUUhEkH3/wAKsR7g+RUNoN0wB9DV6JCCP5UAbelqWADHryK24oV3BsEgCsTTY51kUBRtPQk11FpFiM7sEnvTAZFap5RcgDnrjrSvZwXEO2RBuxxVm4TbblR1PX2qO1JDAHH9aBkaacgUeWOig4HFWItPU5wSrDqa1mt0MSsoGcA1AuM4z7/WgBI7RwgwMr608WRY8oCD2xVqBCy/Kx9hVqOGQuGU529OeDQBQ+wgyA9BjHy81IbNgAY1DHuDwa2oImGCQPpU6Wm+Q8A9uv60AYcAcEh02nOPpW98JmDeGfj6R0/s0j/yBd1fgtFdcOoJ/UVR+FI2+Hf2ggMYFi44/wCuV3QxHzQtOApqDpzUijJpACKWPH8q29KgMi8jjPFZsAyRgcd/eum0mP5Qf0pgWrS1B5Y49fWtqCCPZlMAmqsabXChckc1o2ULylUVehxkdxQM2NFjVtyFOThRiur0+0gtIGkk4GMD1Oe9R6LpL21rFcSRDe3TPb3rprPSkvVWS4yFA7dDQIwLCFHnLR8lTwB/nrWm1sxl3zH25FdNDp9hAMIFBUZyB1rN1OJpoWMGGjDZbBHNAFSKGEwExuquzdG9cd/SohatsKpjKn73t9aoSpIsMccjHbvOcHHWtDTL6WJSFUSxjqrDqKAIjbOzCTaATkHvmp7D5XCqSSeoBzWgxilVHUFcdVPb/wCtT4rRmIeMcDpxQBctiwG4Ecd60YZWDLuHJ/SqNrBJ5gDjI+taF4REgx1xzzigCwl3syFCt6GvLf2np2b4a2i87TqcfH/bOSvRbSVXc5yCB3HNeY/tTuB4B0lAeupAn/v09AHP/tFj/i1vwX/7Ap/9EWleCjpxXvf7RRx8LvguQcf8SY/+iLSvByckNxk5z+HekA1eDzUyDcw569ajU4I5zVqwtnuLlUTuc/h3NAGpo9hLOcw4AH3mPQV01l4ft2nV5X8+THJ/h/CotMhj8mNYywiGcj1Pqa6K2YIwCgemaYzS0PR7K3OXQdcgKOR7V6J4fs9PaeMLEowRz3/+tXCWq7lVl6A54NegeDdJuQ0V06n5iPLB7+9AHT3tg9rua1QM+MAA1Ba2F3PEzXC7Dn061sx2couDNcScZ6Velm2KoC5B/SgRz9vpqyAggiNT39a0JIo7axZlQYXkcVYZQAWRjuPIpskLLbFR+8zywJ60AZEF6DJhlB/2mrXSS2aLIbDMef8A61Y9zYusuYxkfSpY1KBVYH/GgCw/lh2C49vpSKFxtHFVyp3kbSSMdququ9V4GTQBWkXdjHUcU6FMyRZBIDD+dWURQDwcDP40+JMPGBnlhjJ96APE/g6c+F/2gW65s5T/AOOXlfOMYJwB1r6L+DP/ACKXx/8A+vGX/wBF3lfPUK5jJxgdc+lIByxMWUFgmSB710Xh3TJfNUxy7fnznHXB/rWHbKHlAY5I6ZHFdt4fWRAMtznOKYHQ6bo12QRxIuc5ArpNNtWKeWbcl94O8DnjtU/hq5bzYwE3gEde1egzC0GHaIK45yO/4UDOTS2dJgCvyjqT3rTcodOkIIGTxkUl/HdSTny4sIT1Hf2p1vpzNE0ZJz1P1oEZUFu0sO0AA4/IVeghFvE2AS3Gc9q2IdOSO3k8xuAAcjtUcdvHJueMh+OnrQBlyAuAyjBHYGnQysrjcgYd89a12sCkPzLxj05qq8HKg4HHFIC1CYyA2xge1eX/ALQuz/hDrIoP+X9P/RclemKCqLxnJxjNeZ/tCKR4Nsiev29P/RclAHz5RRRQBYsjif8A4Ca07VDJIq55J7VmWKlpwFGSQa7jQdJEAW4m2liM4J6UwJbREt2DsDux8qita1nMhHygIOpI6VCbVJWLMTgVLFgPkHCDoB3oGW5Qk/Qkf0pYrMZOGBY471UuLsRsF+XBq7Zzl2Vl7D0oA0RbuygYH9Kk+ySfxLznOcVYs5OgPT37VpRqFYE5xjp60AZsaYB4C561ctjwoxjPHPc1pLDG6gmMH2pyaakjAqWU/oKACCIFVBAwTgYP6irkNth+QM9jViKxaLaNx55HvVuCBw5yuWHPNAiGKFsqqglia5r4SHd4b/aDJ/585f8A0XeV2IjaMg45J6Dtk1xfwdIbwt+0CR0NnKf/ABy8oA+cVHy9Dn17YqRBnPH40xRwBViNQB3pAWbKLLgZ611dhbMygKpP0rI0a1WRg0pwo6D1rtbTKjAVUTHTrzTASz06Z5eFJJ6DvXofh7RrXTYDdalHvlIwkYORWBoaqrpu5HZfSu1g/wBJmHmcY4xQMie+lvJ0ynlpgBRjCgVa/tMxvti3KF4x61oW0dvvKMgJc5PH4VDd+H18uWS2feNuVQ9jQIz31OSdwik5bjArUsgZWWKPOAMnBrG06xmhlkknjYHGFBGK6Dw7EwvUd8BM7aAKFzabLlhIv3uCw6j/ABqslrJaSYZvl6gjvXfajpIdvMhjOfun0qhcaWrW6mRGXaevtSA5OBpfPBB4PXPpXQaVLk4foT9KnttB89T9nZWK87e5rQtNBnhKFuinv3FMBq7UTd5ilgcYxzTZNzt8w545PNaMmlHbuGCc9KrJZSKw2nkcc9PyoAw5J3huNmDlvTuK8o/aSvXufCelq+f+P8n8oz/jXuGqaYWQygfvAMZ+vtXhX7SED2/hTQ1cYJvJfrwg/wAafQBf2if+SW/BjP8A0Bj/AOiLWvBAK97/AGif+SW/Bj/sDH/0Ra14KvynjrUgOTJIFdBo0TIrBD8z43e3tWRZwEjzOMAgbT3rZ0vMcpA+XPfNMDctG8s7ADjgnnFbFmWkYA9QeMVkWw3Y243Z2/1ro9KhK7VALOe9AzvvA+lx3UgMi5ROWB6GvUbe7gtY1AVRJjG1fuqK4DwodtqqwkBMc9vrXT2atLIuBkMMg+lAjSkvXJLHIH0qeOTfEWfPBHWiHT5JE6A5OADVi4sZRARGCe+D60AJb/vZ96g7RzVyIZYbcHBwRTdGt3MEjSqV5xkitWCOME7YwO2adgIWs/lyAPWqMtjBveXy8SsACR3x0rf+6mBzVZ0Vs9s0WAxltYHIK547UNarGvy9auy2xQ52/jTcELmhIDNniOznp396dD/roNzDBdRyOpzWkUDLgpk9jTI4h5y4zjrnHFAHz38F3EnhD4+uvRrGQgf9s7yvn+3ChAoGSRya92+ALb/h78cW/vaWT/5Bu68Jtsnbkc9jSAtWsTSOFQd+cdc12ui2zBfVup9a57TbZSQOQTzXqXg7TYpNjSKpjAyS3GcUDRueG7FkhhZw/mMflXHX/wCtXZ2Vvc3Mo80KqdDkVa0v7JHb7oQHmIxvxgAeg9Kl86WJ12DCjrQI1MW9pAi4G5+uRyaqXM0caECMKT0wOaLWdppDLKdzLwMio1g+1XclwFHlLjj3oAijiZ7eUEjkcjp+FU3t3RgETAIrftLUvgj7ua0bnTFOCAAAP1oA5ZLkqEWQgleBmq83zSHbjg1rXWnsXPllc9z61k3VtNE+4L1oAXO1F3DJJrzD9of/AJEyy/7CCf8AouSvUkUbAGHIrzH9opAngmyGSSdRQ8/9cpaQHzrRRRQBp+Hig1SMyDK4PFdzazPcOMfcBwAK4DSCFvVJ/un+Vdro0wEwVsY96YHRImQFHTHpSyQhELDr2FTWah1UnrnketWJ4tyg46elAzHns2ZQ5JVuuas2UJVAV61dig8zC8k49OlRQxyRycBgO9AF+3VtoDDB9K2LXeUAYHjoD2qnZXAVtjru/wBrFb1lHC6DYuM+/FAElnjIB579MVrWsKk5JNV4rQqwwARnJ21rWSEAgjFIRatYFKjv3Gatx25QDPIHcjk0tuCoXHJ+uKuwKT3waYCQ26PNCpxncDyOeteQ/BRt/g74+MO9hIf/ACHeV7TaL+/jbuHH5ZrxD4CuJPAPxzcdG0xj/wCQruhgeAxJuA4H51pWltvYZ+4OTgVDaRFuMDFdBZQ7tqgYCjJ460AW7KMBkAGFxnFbto+SAxPr0qhbIOMdenFalrB93JOKBnSeHmQ3KlgdhPFdxAh4whJ7EcVynh62LqpReh4b0rtdOglmcB8gDGcUCEgsriWUOOB6+lasayiDaA28cDAwD/jXSadp0eF8wYOOlakenxbSUUFscUAYiRwXSRW8yAvjBwOlX7Pw3bxuJVd/k6AHgVetdKjtgZXZjIexqym/aFGBnk460AMUshKKuRjBqdIY5V2soBPBBFSxRiQqSOasrbg/eOO1CQGZHpCwyF4htb1FaUaK4CSD5u1WUUgYPOKcyA9Rg+1MCpJZJu6cVGbJAc7RWgpA4Palx6AUAZVxZKQvy96+e/2w7ZIPC/hraoBN5N9fuLX0lINpHc96+cf20HH9g+FVyMm5uD+Sp/jQwOX/AGiP+SXfBfv/AMSY/wDoi0rwmNd30r3j9oUZ+F3wY/7Ap/8ARFrXiJAAAUDnrUjH2hwjDnnn6VtaYpK/MdpPQmqFlbK+PvAHsa6E24jhQLj3xTETaUGeXjG48AZ4rq7AGMAblzjJOP0rA0qMoGJAGOAD2rqNDsmuriOFDtJ5JPOBQM7rwdbtKrjkIeSfr716Lo9mI93H7sjqe9ZHhnSVW0jjT5QvL9+P/r108UJWPYMqg4GKQhZLjy/kjAO3irFtOxcb1O01AY1cA9x6VJFwQS3vimkBptIirgDbSRkY4ORVDcSxI71YQk4yeh6+tMC8uMdKY6d6b82fY1LyQeaAIUTt1qKaPg4Un2HFWkXnJ70sqce/tQBmFCp70BSu4t0wT+lWpYgwAYZX61DdjyrK6c8bYJGH4IaAPmP9nY7/AIZ/GtvXSM/+QbuvFtJj3y42k45Nezfs3Y/4Vd8Zs9P7GH/oi6rx7ScqxIyFPXnnFIDr9LtmJQ+URx1HSvQ/D9pKyKGBVc7R25rk/D9r9tePyd23ue2a9W0WyW0RIQBLM2CfQH0oGb2hwBohGuCyjvW/a2CyIocDe3QDpUOn2CwQmaQ4bOQucVoCcjY+wLz0BoEV7vTZYYWEa8kY471BYxM7CFPk5y3HFdHaXy3AGVJHQe1SzxxBWEIRZG68UgK1hZoAcMTzzn+dTzOhUqR7e9QKJo8A5BHJqYIs3JzuXr2oAzby1SQYBIPXIPNZ7xOFwyZ7c9a2pYWDEg84qtdQZCyH05AoAwniBX5Rgg9DXkX7SKbfBlmf+ojH/wCipa9lu4tuGKkg968e/aTx/wAIRYYOT/aMf/oqWgD5tooooAtab/x9r34P8q67Sd7MoFcvoaB78Kwz8p/lXf6XbiEF5AMdR9aYHS6f8oQOQpxyK1ooUMRQ4JY5+lbfhv4SeMtc0LTNZtX8Prb6hbRXcay30yuEkQMA2ICAcEZwTW9B8HfHMUqsT4bYL2/tGf8A+R6BnNabpUUeCRkkdDVmfSYW+ZAQxGSMcV1o+GHjlT8sfhwen/Ezn4/8lqkX4beOsDMXhsn1/tOcZ/8AJakI89OmMrkbMfWrVpDJC4wSBnNd7/wrnxuVAa18NEjv/ak//wAjU9fh540AwbHwyf8AuKz/APyLQBg6fISwww/3SO1btuiv90AMeKP+FdeNQcpaeHB/3FZ//kWrsHgvx3CAFtPDZA9dVn/+RaAEhQsBvTac96tIu0kdcVKvhrxzjDad4bYdv+JvPx/5K08+G/GxA/4lfhv/AMHM/wD8iUwHQR8l2yMKT+QzXgn7OR8z4Z/Gk/3tIB/OG7r27TLu/Mmu2erWlrbXemyG3k+zXLTo2bZJgwZkQ9JQOR1BrxD9mkZ+GfxkH/UIX/0TdUAeTWcK8DGe59/at2yQe2KzLaPtg+1bUaKsYO7IxnHvQBdsVyxJHTjgV02jaeL2dE3AZ4LHtWLpsHm7VQZyeFHU13tpo99p0Nu9rAjz3Fxb2qCWQxpvmlSJcsFYgAuDwD06UDOr0LRwBHFagFVOckctXbWVtDYRiRkUvjHrmqun+GfGtjFtj0rw2TjGTrM//wAiUsvhzx075OneGwPT+2J//kWkIuzXDqQVAw3p2q5Y3JLAZ6Vkjw/448kxnTPDePUazOMf+SlSwaH42hzjSfDZz/1Gp/8A5EoA6F7jzc9SfanQnIBIxWLHpvjdCMaN4b65/wCQ3P8A/IlTra+Nx/zBPDf/AIO5/wD5Ep3A6SBMKCO/Wpgtc9GfHCLj+wvDZ/7js/8A8h0/f43/AOgD4b/8Hs//AMh0XA6FBUhAzXOCXxuB/wAi/wCG/wDwez//ACHS+f43/wCgB4a/8Hs//wAh0XA32TvioWDA9eKq+FtVOv8AhbR9Y8n7P/aFnDd+Tv3+X5iBtu7AzjOM4FXmHY0wK7H0PNfNP7aEh+weEU7GS6b9IhX055SsemDXzF+2yNn/AAhye13/ADhoAyP2gTj4WfBo/wDUG/8AaFrXiCAMcEc+1e4ftAAH4W/BrP8A0Bv/AGha14tZw73OO3NIDR0yMLIuc8dq3JMt5aKp+Y9Afx5qrp1svmCZuQuPwrajjSSUFVBYHPtQMksFZp1jUfeOB7mvUPC2ht9mV94Mjn53A4X2Fcv4S0WbUb9BGh5bbn0Hc161dQXFg+jaVotpaXF5qNy1soubhoEXbDJKSWVHPSIjG3qRQBuaUGhgWOMYXHfqfrWiJFkiIHEgHY8Vjt4b8dshQ6f4bwfTV5//AJFp8Hh3x1D93TvDf/g4n/8AkWkIniuikhLZBBxg1bJZ03Lkg9qojQfG7KBLpXhtznJP9szj/wBtKtRaX42jUr/Y3hsj/sNz/wDyJQBbtzkhTzjvVuMAE/yrJXTPG4Of7H8N/wDg6n/+RKkFh44BB/sbw3kf9Ruf/wCRKaYGzEMYABxU468VirbeOAMf2L4b/wDB3P8A/IlKIPHA/wCYJ4b/APB5P/8AIlFwN3ZuFLIrbaxY08bpnOheGzn/AKjk/wD8h1Q8Sap4w0Tw/qer3fh/w+1rp9rLdyrFrcxdkjQsQoNoATgcZIouB0LDOaoa0Quh6m44AtJ2P18tq0Mc1meLJBbeE9dnc4WPTrlyfYRNQwPmf9mwZ+GHxlH/AFB1/wDRF1XlWi2b3EiQxDczkdO1esfszqX+GvxiVRktpCgD/tjdVmeBfDMkFmLp0CknIJ4zQBp+GrR7HEcKZYcFvevUNFngsYdxjV3A5Y+vpWB4P8JeIPEJ1CbRIdKe3sLr7IzXl9JC7P5UchIVYXGMSgdexrqf+Fe+OMk/ZvDXJzj+1J//AJGoAsyX/wBpiZSqkNjA6/hitOwGYAs7rubkc9DWbB4G8bxqAbLw2ecnGrTj/wBtauR+FPHCMSNO8Ne3/E3n4/8AJWgDYgkZVdlORjANNQSEhh1J59RVdtD8cFUH9l+Gxt6/8Tmfn/yUp8OjeN4xj+yvDjfXWp//AJEpAbUBEqFXIz2NQn91IQR2qnHp3jdGyNH8N/8Ag7n/APkSnS2HjeQ5/sbw2D/2G5//AJEoAuDDAnPHpTJIwy47elU107xuBg6P4bI/7DU//wAiUo0/xwMf8Sfw3/4Op/8A5EoAq3EQYFTwM9K8T/aai2eBrE/9RKP/ANFS17FcTa5Z+IrPS9e07TbcXlrPcxSWV+9x/qniVgwaGPGfOGCCehryf9qRQPAlge51OPn/ALZS0AfLtFFFAGz4VUNquSM7Y2IrtrZy0mOw6e9cV4T/AOQow7mJv6V2UDhAcnPcCmB9sfDKV4PhD4TligluZI9CtGWGIqHkIt0IVSxC5PQZIHqR1qz4T8UT+IPCs2r/ANjXMNzFPcwf2es0byloZnj27iypuJT+9tGfvEc1W+GTTr8IfCbWccUtyNCtDFHLIY0Z/s6YDMFYqCcZIU49D0qDwDpfiTQfD+p2uoWWjtdNdXN5aiDUJWSRpppJSjsYAUC7wNwD55OB0KA2fA3iBvFPhi21eSyaweaSaNrZ5BIYzHK8fLDgn5M8cc9T1rK8V+ML/Tddl0nQ9Gj1S8t9OOp3IluzbhItzKqoRG+52KPgHA+XkjNVvBHhbU7fwg2heKEhgVLiWeOXSNVuEd/MmklILqkTLjeBgEhsZOOlV9d8I61Z67JqXhJ7KY3Okf2TKuq3kxaPa7tHKJNsjSEeYwIYjOB8woAfrXj7ULbwtH4o0nQoLzw7/Z0epPcT6gIJSrDJjjjEbbnAxwzKCSACTXe20ont4pgjoJED7XGGXIzgjsa8t1vwDrEnguw8KWNl4dvrKzsIrW01G9kkjubKZU2tPGqxtlv4lwyEHjJrurLw3bwXtpfz3mqT30ESxs7ajcCGQhNpZoBJ5RJ6/d689eaAMq08cLv8XPq2lXWmW/h6ITyGWSOR5Y/LaQuFQkDhTgbiT3Cniqmi+NtVvNQs9P1LQbewvdU06TUNLH9oGWObZtzHKwiBjYb0J2hxgnBJGKfomi68PFfiS61rTtFbSdYSOMpHfSTPtRCgDI0Cghgefm46fNWd4I+H02leKINavYIbJLGzezsbCDVLm/SIOVLNvnC7BhFUIigAE9eMAF0eMfENvrOoabeeGrOeez043zJpepvcvuLbYoiHgjwzkOQcnAQk9s6HhTxVfan4i1LQtb0mHTtTsraC7YW159qiKSlgAXKIQwKHIx7gkVFo+ha3pHh7W7m3fTpvF2qSyXTyTO5tlkI2xJkDd5aIFUcZOCeM1J4G0rVdMlu21bSdKt57oLJc31tqUl1PdSgBcuGgjAGM4AOF6BQKAOL1Asuv/EZ0AJS6JwTgf8gy2714p+zGM/Dn4wA8g6Sn/om6r2nW5lt7z4pTPgBJWYn/ALhdtXjH7LwH/Cvvi7np/Zcf/oq6oA84tIfmyQxA6VsJGCuABjPPvUNtFuB44JxnNdN4X0o6lqMcAztPLnsFpsZ0fw80FpWFzIvye44xXeay0QfRo4zjGs6YOvX/AE2CqjXENhF9ktFUEAAgd6zbmRzqegrnIOtaaSf+3yHikI908YeI59FuNHsdNsEv9V1W5a3t4ZJzBGAsbSO7yBW2gKvZSSSOK5+9+JM9r4C1DxB/wjtzPd6bcTWl9ZxXMe23kiYqxMjbSydCCqkkMPl642fG2hajqGpeHtY0M2jajo91JKsF3I0cU0ckTRupdVYqfmBB2npyPTlr/wAEeIm+G+u6NbjSJtY167uLu8d7mSKC3MrZxGREzPtAVeQueTx0oA9UrhtQ8a6pputWcWoeHfs+j3mqjSYLprz9+7nIWTyNmPLJU8784+bbjmtubRTrUFlca6t1Z30OSYdM1i6SIHPcoYvM6D7yeo+uD/ZfiifxadR1TSPD9/Bb3Tf2fM2pzI1rAfl3CL7OymUqTk7u+0EDmgBNG+IttrfjK50XTTo/k21xJbO1xqqx3UrJkOYbYIxZQwK5ZlzgkZFdrfzyWtlLPBaT3kiLlbeAoHkPopdlXP1YCvMLf4eaxDJa6Sr6WugWuv8A9uRXiyP9rA80y+T5ezbncSu/f9zjbXd2uijQ7e+m0QXd3eTAFYtS1e5ljLDOAGkMnljk/dX044FAHPD4gu3gLSNeXSGOoarcpZWunG4AHnvIyBWlxgAbSSQD04BqxpfirW9TbVtPttE06PxBpV0kN1az6m6wGN496SxzLAxbOQMFF6N6c5mjeEdU/wCFbf8ACPeINJ0a9uLeQSW6RapPGjt5pkD+aIQ8TKTwVDHjqM8LoHgnWND8PeJH0+8hi8R626kyyXU9wlooURrtlkzJIyruYFsZY4wo6AF7RPFfiLWNHu7mx8OafLcw6i1imzVj9nkROJJvNMIbarhkwEJJU445rY8DeI38T6PNdzWYs57e7ms5Y0l86MvE5RjHJgb1yODgdxjiq97oVxpnhKx0Pw3p2k3tjBGLWaz1R2WOaDYVILKj/MTgnKMDznrmm/Dbw9eeGtAms7+S2VpbuW4jtLQs1vZRucrBEWAJRevReWOABigCt8Kv+SXeD/8AsDWf/ohK6Ugc1zXwpH/FrvB//YGs/wD0QldO3SmgGxjmvlv9t4/6T4OX0S7P6w19SxjrXyr+243/ABMvCS+kNyf/AB6OhgZ/x/APwu+DX/YF/wDaFrXjWnwyGUNkBB15617R8el3fC/4Nj/qDf8AtC1ry3S7fzXjVQfl5JAoA0rKREjdAM4PQ9q39ItjLIQpGTgVi21qVcE4HNejfD/TUe4a6nUG2t/mJHQt2FAz0Hw7aw6DoiPgfaGAHvUuk3Jn+IXgzcQWOozH6D7DdcVR1a682VVJGEIwP51J4bYN4/8ABZXp/aE2P/AG6oEeoeJvFOoWPiGLRNA0ePVNRNk+oSia7NsiRKwUAMEfc7NkBcAcHJFYUfxPl1eGCTwlog1P/iUR6xci4u/sxijcsFiXCPvkyj8fKvy/e5rW8TaFryeMI/EXhf8As2W5fTX02aG/leJVG/fHIrKjkkEtlSBkHqK5m7+F89r4Z0TSdHhs2vrTTBp0urvqV1aSKucn91CAJk3FmCO4H60gPS/D2r22v6Dp2r2BY2l9bpcxbhg7XUEAjseeayvD3ieXVvE2v6RcaTcacdKWBhJPNGxnWTzMMAhYKv7vjJyc8haTQvBemaNBpEdtNqn/ABLLaK1iUajcJEyxptBaFXETE9TleTWNZ+HNauvFviebXdP0k6FrlrHZSrBqUxmEcayr08leXEvOHG3HBagC54b8eQeIfGV5o1hZSGwis/tUOos+EucSGNvLXHKAggPnBwcDGCdzxbq82g+Hr3U7bTbjU5LaJpPs8EkaEgAkks7AADHOMn0B6VymlfDa10vxwNTs579dLXSfsCRPq95JIrb26bnOECHgZ+VuQAQDWxq/h64tPCGp6X4bV7q4vUeP/ibarcyBd6bSfMcSsMDnaAAeemc0AVtR8ZXKx+GLfSdLiutW16BrmG3nujDFFGkavIzSBGPG9AAEOc9qbpXi3V9d0CLUdE0fTxLDNPbahb6lqTW/2WaF9jKGSGQOMhufl4x6nFC98K6nfeENBtb7R9Km1rSwsUUkOt3VqIVEewyJPFEsmWwMpgDH8RwKba/D+7sfh1H4Wtb2PF9dNJq1yXcM8cshedY85JLA+WCxztJJJPUAs6d4v8San4V0/WbDwzYFbmKa4cz6uYoUiU/u2V/JLN5i/MMooA6kUzxZrSeI/gNr2sw281tHfeHbm4WGYYdA1u5wf8e9aXjXR9R1Gwj02w0Tw3q2kmEo9nqzvGqOMbGXbHICB6YB9GFY/iLSLrQP2f8AXdK1C+fULu08PXcUly2cyEQP6knA6DJzgUAdDgljxgZ6VyfxhnNp8KPFkmeumyx/99YX/wBmrsDktknk8mvPf2iJvI+C3iduheOGMf8AApkFNgeRfskIsnhL4opJ/q3sYA308u5zV+41RPKWK1AjiTIB/wAKpfsslT4M+KiIMKunRDPf/V3XNZ0JHlqq9D39aBnun7ODM/h/xMznJOtHn/t0tq2NF+Is1/e6NNcaMttoOtXk1jp999q3yNIgcqZItgCK4ifbh2PTIGaxv2blCeHfEir0Gsn/ANJLarOg+AtctH8NaVfTab/wj/h7UJb+2mhkc3FxkSiJHjKBU2iY5Ids7RwM0hG1pXjXVJPEejabrnh3+y49ZWdrJvtnmzL5Q3Hzotg8vKkHhmwSAcGui8TajqOnWludG0o6peTzrCsRm8mOMEEmSR9rbVAHZSckAAk1y/h3R/Ex1oX/AIn0nQZb2VJIJdQtNWnMkMLHIjhjMC7RwucOCSNxOcCr+r6DqumaJ9l8FytJPPcIbg6vq91IRDg7xFK/msjHgDAwMk9QKAK+mfEGCXw9f32pWL2+oWeoSaUbG3k883F0pGEhbC7856kLjDZxtNbXgTxA3irwlp2tPafYnu0LG383zPLIYrjdgZ6elYWm+BbK9s7Fda0WDSZtNeY2f9ja1dAqJcGRmkRYWLMRznd655NR+C/h3DpPgjTNF1W71I3Fq0ju9lrN5EpZm7MsinbgD5egOSBkkkA29Q8SzWfjXSdBbSbjyNQSZl1BpYxGCiBtqqCXJ9chQOxPbn7r4jzQXN3djRlbw1aasNHn1D7XiZZvMERfydmDGJGC5357hcVoeJdL8RXPjTQNR0yz0mXT9M80MbnUJY5ZPNQK3yiFh8uMj5ufbrWJ4h+G51rxQZFs7bT9Ikv4tQupINTuWa8eMq/zWuFhRiygF8sxAzwTwAbWveJvEWj6vp9tJoWkT2+oX62dt5eryee6EkmQxm22jbGrOw3kDBAJ4yv/AAntvN4/svDdjZSXMM3npLqAfbFHNEoZolGPnIBG4ggKSBycgaEOhXM/jqbXdSkheC2tRaabCjEmMOQ00jAgAOxCKMZ+VOvzEVzcXwt0/TfFPhe90N72203SfPL28mrXb4LBdgjVnKhdwO4cBgeQ3SgB/j7/AJKD4a9tK1L/ANG2VeJ/tU+Y3gbTWV18n+0UBQr827ypcEH068Yr27x3/wAlB8N8A/8AEq1Lr2/fWNeKftUDHgKwGP8AmJx/+ipqAPlmiiigC9pF+dNvBcLGJCFIwTitWbxKJJfM+x7WzniT/wCtXOUUAfSvhP8Aai/4R/wro2jf8Ih9o/s6yhs/O/tPZ5nloE3bfJOM4zjJx61q/wDDXP8A1JP/AJVv/tNfKtFAH1V/w1z/ANST/wCVb/7TR/w1z/1JP/lW/wDtNfKtFAH1V/w1z/1JP/lW/wDtNH/DXP8A1JP/AJVv/tNfKtFAH1V/w1z/ANST/wCVb/7TR/w1z/1JP/lW/wDtNfKtFAH1V/w1z/1JP/lW/wDtNH/DXP8A1JP/AJVv/tNfKtFAHtviH47tq9v4wjTw8bc+Ic/ML7d9nzbRQf8APMbv9Vnt97HbJ5v4VfEmHwL4c8Y6ZLpkl62v2i2yyLMIxCQkq5Iwc/6326V5tRQB10HjARE4sM5/6bY/9lrpdD+LC6RA6w6HulfrIbvH6bK8sooA9Yi+MDIxZtFLMTkn7Xj/ANkqx/wuZfNsXHh8g215bXf/AB+/e8mdJdv+r4zsxntnPPSvH6KAPqr/AIa5/wCpJ/8AKt/9po/4a5/6kn/yrf8A2mvlWigD6q/4a5/6kn/yrf8A2mj/AIa5/wCpJ/8AKt/9pr5VooA+qv8Ahrn/AKkn/wAq3/2mj/hrn/qSf/Kt/wDaa+VaKAPqr/hrn/qSf/Kt/wDaaP8Ahrn/AKkn/wAq3/2mvlWigD6q/wCGuf8AqSf/ACrf/aaP+Guf+pJ/8q3/ANpr5VooA+kPCn7Tv9geF9H0f/hEftH9n2cNp539pbPM8tAm7b5RxnGcZOPWtQ/tY5/5kv8A8qv/ANpr5booA+pF/axx/wAyX/5Vf/tNeT/G34p/8LPvdKnOj/2WLGORNv2rz9+4g5zsXH3fevM6KAPTPiH8TIvFnhTwVo8WmSWreHrL7I0rThvO/dxJuA2jb/qs4561y+leJv7PkLfZPNyMEGTH9K5uigDtR44UOT/Zv4ef/wDY102k/GFNNskt49A3BeSftmMn1/1deSUUAevyfGfeSToPU5P+mf8A2urml/HMWGvaLqQ8Ob/7NuHn8v7djzN0EsWM+Xx/rc5wfu475HilFAH1V/w1z/1JP/lW/wDtNH/DXP8A1JP/AJVv/tNfKtFAH1V/w1z/ANST/wCVb/7TR/w1z/1JP/lW/wDtNfKtFAH1V/w1z/1JP/lW/wDtNH/DXP8A1JP/AJVv/tNfKtFAH1V/w1z/ANST/wCVb/7TR/w1z/1JP/lW/wDtNfKtFAH1V/w1z/1JP/lW/wDtNZXiz9qL/hIPCus6N/wiH2f+0bKaz87+09/l+YhTdt8kZxnOMjPrXzVRQB9M/wDDU3zZ/wCEP/8AKp/9prmfib8fD448FX3h/wD4Rv7D9qeJvP8At3m7djhsbfLXOceteGUUAenfCj4nxeBdC8X2E2lvetrtskCuswjEO1JVyflOf9Z7dKqW3xHSAqf7I3Y7faevP+5XnlFAHv3w5/aI/wCEMsNTtv8AhF/tv229N5u/tDy9n7qKPb/qjn/VZzx1xjjnrP8Ahrn/AKkn/wAq3/2mvlWigD6q/wCGuf8AqSf/ACrf/aaP+Guf+pJ/8q3/ANpr5VooA+qv+Guf+pJ/8q3/ANpo/wCGuf8AqSf/ACrf/aa+VaKAPqr/AIa5/wCpJ/8AKt/9po/4a5/6kn/yrf8A2mvlWigD6q/4a5/6kn/yrf8A2mj/AIa5/wCpJ/8AKt/9pr5VooA+hfEn7Sk2q6/pmqW/haGB7O1ubYxy3zShxM8DZyEXGPIx3zu9q4b4m/Fm88e6JBptzpNpZRxXK3IeGR2JIVlA+Y/7ZrzOigAooooA/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Series of x-rays taken over 18 months in a patient with primary biliary cirrhosis showing a marked collapse of thoracic and lumbar vertebrae.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_16_25859=[""].join("\n");
var outline_f25_16_25859=null;
var title_f25_16_25860="Praziquantel: Drug information";
var content_f25_16_25860=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Praziquantel: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?24/16/24836?source=see_link\">",
"    see \"Praziquantel: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/55/32628?source=see_link\">",
"    see \"Praziquantel: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F212673\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Biltricide&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F212674\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Biltricide&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F212701\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Anthelmintic",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F212676\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Schistosomiasis:",
"     </b>",
"     Oral: 20 mg/kg/dose 3 times/day for 1 day at 4- to 6-hour intervals",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Clonorchiasis/opisthorchiasis:",
"     </b>",
"     Oral: 25 mg/kg/dose 3 times/day for 1 day at 4- to 6-hour intervals",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cysticercosis (unlabeled use):",
"     </b>",
"     Oral: 50 mg/kg/day divided every 8 hours for 14 days (Takayanagui, 2004)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tapeworms (unlabeled use):",
"     </b>",
"     Oral: 5-10 mg/kg as a single dose (25 mg/kg for",
"     <i>",
"      Hymenolepis nana",
"     </i>",
"     ) (Liu, 1996)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F212691\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/55/32628?source=see_link\">",
"      see \"Praziquantel: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Children &ge;4 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F212677\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F212657\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Biltricide&reg;: 600 mg [scored]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F212644\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F9603850\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer tablets with water during meals. Tablets should be promptly swallowed to avoid bitter taste that may cause gagging or vomiting. Tablets may be halved or quartered; do not chew.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F212658\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of all stages of schistosomiasis caused by all",
"     <i>",
"      Schistosoma",
"     </i>",
"     species; treatment of infection (clonorchiasis and opisthorchiasis) due to liver flukes",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F212697\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Cysticercosis and many intestinal tapeworms",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F212699\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Dizziness, fever, headache, malaise",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Urticaria (rare)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal discomfort, nausea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Postmarketing and/or case reports: Allergic reaction, anorexia, arrhythmia, AV block, bloody diarrhea, bradycardia, ectopic rhythms, eosinophilia, hypersensitivity, liver enzymes increased, myalgia, polyserositis, pruritus, seizure, somnolence, ventricular fibrillation, vertigo, vomiting, weakness",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F212661\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to praziquantel or any component of the formulation; ocular cysticercosis; concurrent use with strong CYP3A4 inducers, particularly rifampin",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F212648\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with cardiac abnormalities.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cerebral cysticercosis: Patients with cerebral cysticercosis require hospitalization.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with moderate-to-severe hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizures: Use not recommended in patients with a history of seizures or signs of central nervous system involvement (eg, subcutaneous nodules suggestive of cysticercosis); may exacerbate condition.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Strong inducers of cytochrome P450: Therapeutic levels of praziquantel may not be achieved with concurrent administration of strong inducers of cytochrome P450 (eg, rifampin); concurrent use is contraindicated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Patient information: Patients should be instructed to not drive or operate machinery on the day of treatment and the day after treatment.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F212694\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2D6 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F212653\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoquinolines (Antimalarial): May decrease the serum concentration of Anthelmintics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cimetidine: May increase the serum concentration of Praziquantel.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May decrease the serum concentration of Praziquantel. Management: Avoid concomitant use of praziquantel with strong CYP3A4 inducers. Discontinue rifampin 4 weeks prior to initiation of praziquantel therapy. Rifampin may be resumed the day following praziquantel completion.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketoconazole (Systemic): May increase the serum concentration of Praziquantel. Management: Praziquantel dose may need to be reduced when used with ketoconazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F212654\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F10822164\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse effects have not been observed in animal reproduction studies. There are no adequate and well-controlled studies in pregnant women. Use in pregnant women only if clearly needed.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F212681\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F10822165\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     Appears in breast milk at a concentration of &frac14; that of maternal serum. Women should be advised to not breast-feed on the day of treatment and for 72 hours after treatment.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F212663\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Biltricide Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     600 mg (6): $90.14",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F13493198\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Culture urine or feces for ova prior to instituting therapy",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F212664\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Biltricide (AE, AU, BF, BH, BJ, CI, CY, DE, EG, ET, FR, GH, GM, GN, GR, HK, IL, IQ, IR, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, NL, OM, QA, SA, SC, SD, SL, SN, SY, TN, TZ, UG, YE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Cesol (DE, MX, PL);",
"     </li>",
"     <li>",
"      Cisticid (BR, CN, MX, PE, VE);",
"     </li>",
"     <li>",
"      Distocide (AE, BH, CY, EG, IL, IQ, IR, JO, KP, KW, LB, LY, OM, QA, SA, SG, SY, YE);",
"     </li>",
"     <li>",
"      Droncit Vet (NO);",
"     </li>",
"     <li>",
"      Fluxide (PH);",
"     </li>",
"     <li>",
"      Kalcide (TW);",
"     </li>",
"     <li>",
"      Opticide (TH);",
"     </li>",
"     <li>",
"      Prazine (IN);",
"     </li>",
"     <li>",
"      Praziquin (AE, BH, CY, EG, IL, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Prazite (TH);",
"     </li>",
"     <li>",
"      Prazitral (AR);",
"     </li>",
"     <li>",
"      Vermaqpharma Vet (NO);",
"     </li>",
"     <li>",
"      Wormicide (TH)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F212647\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Increases the cell permeability to calcium in schistosomes, causing strong contractions and paralysis of worm musculature leading to detachment of suckers from the blood vessel walls and to dislodgment",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F212660\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: 80%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: ~80%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Extensive first-pass effect",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Parent drug: 0.8-1.5 hours; Metabolites: 4.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: 1-3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine ~80% (&gt;99% as metabolites)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Garcia HH, Evans CAW, Nash TE, et al, &ldquo;Current Consensus Guidelines for Treatment of Neurocysticercosis,&rdquo;",
"      <i>",
"       Clin Microbiol Rev",
"      </i>",
"      , 2002, 15(4):747-56.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/16/25860/abstract-text/12364377/pubmed\" id=\"12364377\" target=\"_blank\">",
"        12364377",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Liu LX and Weller PF, &ldquo;Antiparasitic Drug,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1996, 334(18):1178-84.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/16/25860/abstract-text/8602186/pubmed\" id=\"8602186\" target=\"_blank\">",
"        8602186",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Takayanagui OM, &ldquo;Therapy for Neurocysticercosis,&rdquo;",
"      <i>",
"       Expert Rev Neurother",
"      </i>",
"      , 2004, 4(1):129-39.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/16/25860/abstract-text/15853623/pubmed\" id=\"15853623\" target=\"_blank\">",
"        15853623",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9805 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-183.1.191.153-E85F879F22-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_16_25860=[""].join("\n");
var outline_f25_16_25860=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212673\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212674\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212701\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212676\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212691\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212677\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212657\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212644\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9603850\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212658\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212697\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212699\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212661\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212648\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212694\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212653\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212654\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10822164\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212681\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10822165\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212663\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13493198\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212664\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212647\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212660\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9805\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9805|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?24/16/24836?source=related_link\">",
"      Praziquantel: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/55/32628?source=related_link\">",
"      Praziquantel: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_16_25861="Chlorambucil: Patient drug information";
var content_f25_16_25861=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Chlorambucil: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/52/35654?source=see_link\">",
"     see \"Chlorambucil: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?35/9/35989?source=see_link\">",
"     see \"Chlorambucil: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F149339\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Leukeran&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F149340\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Leukeran&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10022360\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700690",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may have unsafe effects on the bone marrow. The bone marrow may not be able to make cells found in the blood as well as it used to for a few weeks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700703",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may cause you to not be able to get pregnant. Talk with the doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700433",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Other types of cancer may rarely happen later in life.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10022362\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691928",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat leukemia.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691947",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat lymphoma.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691757",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat blood problems.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10022361\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701763",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to chlorambucil or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10022366\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697339",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have seizures or are on seizure drugs, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697613",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before getting any vaccines. Use with this drug may either raise the chance of an infection or make the vaccine not work as well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697795",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may bleed more easily. Be careful and avoid injury. Use a soft toothbrush and an electric razor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697622",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before using products that have aspirin, blood thinners, garlic, ginseng, ginkgo, ibuprofen or like products, pain drugs, or vitamin E.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697022",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are a man and have sex, protect your partner from pregnancy. Use birth control that you can trust.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10022367\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698176",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       May not be able to get pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698315",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may have more chance of getting an infection. Wash hands often. Stay away from people with infections, colds, or flu.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698243",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Mouth irritation or sores. Using a soft toothbrush or cotton swabs and rinsing the mouth may help. Do not use mouth rinses that have alcohol in them.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697876",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Anemia, low white blood cell count, and low platelet count.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698291",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Other kinds of cancer may rarely happen later in life.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698319",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Seizures may  rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10022369\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough that does not go away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10022364\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695852",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug at the same time of day.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694329",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There is a liquid (suspension) if you cannot swallow pills. Shake well before use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696107",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Those who have feeding tubes may also use the liquid. Flush the feeding tube before and after this drug is given.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10022365\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10022370\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699391",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a refrigerator. Do not freeze.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10022371\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11323 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-213.131.41.98-90976AC03E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_16_25861=[""].join("\n");
var outline_f25_16_25861=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149339\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149340\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022360\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022362\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022361\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022366\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022367\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022369\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022364\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022365\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022370\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022371\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?34/52/35654?source=related_link\">",
"      Chlorambucil: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?35/9/35989?source=related_link\">",
"      Chlorambucil: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_16_25862="Left ventricular dysfunction after orthotopic cardiac transplantation";
var content_f25_16_25862=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Left ventricular dysfunction after orthotopic cardiac transplantation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/16/25862/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/16/25862/contributors\">",
"     Allen S Anderson, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/16/25862/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/16/25862/contributors\">",
"     Sharon A Hunt, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/16/25862/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/16/25862/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?25/16/25862/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 31, 2007.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The development of left ventricular (LV) dysfunction after cardiac transplantation, which can be both systolic and diastolic, should be of major concern. The causes of LV dysfunction in the transplanted heart can be different, more ominous, and in some cases more responsive to treatment than those seen in the native heart. As a result, familiarity with the potential etiologies, coupled with an aggressive and systematic approach, is essential to identify the etiology and begin prompt treatment.",
"   </p>",
"   <p>",
"    Early LV dysfunction, observed intraoperatively or in the immediate postoperative period, is distinguished from late LV dysfunction, which develops after the first few postoperative weeks to years after surgery; the timing of its development helps in establishing the etiology of LV dysfunction after transplantation.",
"   </p>",
"   <p>",
"    The most common cause of LV dysfunction after transplantation is cardiac allograft rejection, which can occur at any time [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25862/abstract/1\">",
"     1",
"    </a>",
"    ]. Diagnostic procedures such as endomyocardial biopsy, echocardiography, cardiac catheterization, and coronary angiography are important tools, but all have limitations. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/24/28040?source=see_link\">",
"     \"Acute cardiac allograft rejection: Diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/26/7592?source=see_link\">",
"     \"Endomyocardial biopsy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EARLY LV DYSFUNCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;LV dysfunction that occurs early (within days) after transplantation is usually due to one of three causes: hyperacute rejection, reperfusion injury, or a suboptimal donor heart.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Hyperacute rejection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperacute rejection, the most ominous cause of perioperative LV dysfunction, is extremely rare and is precipitated by the presence of preformed recipient antibodies (IgG or IgM) that crossreact with endothelial epitopes on the allograft; IgM antibodies are of the most concern [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25862/abstract/2\">",
"     2",
"    </a>",
"    ]. This form of rejection occurs within the first 24 hours after transplant and may be evident with the onset of allograft perfusion in situ. Widespread endothelial damage leads to global ischemia and catastrophic allograft failure.",
"   </p>",
"   <p>",
"    Hyperacute rejection is most often due to inadvertent implantation of an ABO-mismatched. It may also be seen in highly sensitized patients, such as multiparous women or those with multiple prior transfusions.",
"   </p>",
"   <p>",
"    Current therapies are inadequate for hyperacute rejection and death usually ensues. Fortunately, the incidence of this complication is quite low because of preoperative screening and prospective crossmatching of sensitized transplant candidates [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25862/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Reperfusion injury during surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Allograft injury can result from reperfusion ischemia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    prolonged cold ischemia time, which refers to the time from cross clamping the donor with subsequent excision and immersion of the heart in iced saline to removal of the cross clamp after implantation in the recipient. This may be only a transient complication (myocardial stunning), lasting for 12 to 24 hours after transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25862/abstract/4\">",
"     4",
"    </a>",
"    ]. However, contraction band necrosis and other evidence of ischemic injury can be seen in biopsy specimens [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25862/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/15/6394?source=see_link\">",
"     \"Ischemic reperfusion injury of the heart\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cold ischemia times greater than five hours are associated with a higher incidence of allograft dysfunction and decreased survival [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25862/abstract/6\">",
"     6",
"    </a>",
"    ]. Although advances in organ preservation have led to longer tolerable ischemia times and improved allograft function [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25862/abstract/7\">",
"     7",
"    </a>",
"    ], primary allograft dysfunction remains a significant cause of early allograft failure after transplantation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Suboptimal donor heart",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the pool of potential heart recipients has increased, the donor pool has remained relatively stable [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25862/abstract/8\">",
"     8",
"    </a>",
"    ]. As a result, some transplant programs have begun to consider and accept hearts from \"suboptimal\" donors (eg, patients over age 63 and those with mild left ventricular hypertrophy) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25862/abstract/9-11\">",
"     9-11",
"    </a>",
"    ]. These donor hearts have usually been subjected to higher doses of intravenous inotropes or pressor amines or have evidence of LV dysfunction attributed to the effects of brain death. Hearts from patients with known structural heart disease, particularly coronary disease, and those damaged from trauma are still usually avoided.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     LATE LV DYSFUNCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;LV dysfunction that develops late after transplantation is most often due to allograft rejection or to ischemia caused by allograft coronary artery disease, but may also be due to infectious myocarditis or occasionally without any documentable cause.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Rejection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The development of LV dysfunction in the weeks to months following cardiac transplantation is most often due to acute allograft rejection. Most cases of acute rejection are diagnosed by routine surveillance endomyocardial biopsy at a time when the patient is asymptomatic and LV function is normal [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25862/abstract/8\">",
"     8",
"    </a>",
"    ]. The symptoms that can occur typically represent signs of left ventricular dysfunction such as dyspnea on exertion or at rest, paroxysmal nocturnal dyspnea, orthopnea, palpitations, and syncope or near-syncope. Other clinical findings that suggest the presence of rejection include new right or left sided ventricular gallop sounds on auscultation, elevated jugular venous pressure, or new atrial or ventricular arrhythmias. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/24/28040?source=see_link&amp;anchor=H6#H6\">",
"     \"Acute cardiac allograft rejection: Diagnosis\", section on 'Clinical presentation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Acute cellular rejection occurs with decreasing frequency and severity over time. Episodes may be associated with weaning of steroid therapy, medication noncompliance, or unrecognized drug interactions that lead to decreased serum concentrations of immunosuppressive drugs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of symptomatic rejection is typically made by endomyocardial biopsy. Asymptomatic rejection is usually detected by routine \"protocol\" endomyocardial biopsy; noninvasive imaging techniques (eg, echocardiography) may show regional or global LV dysfunction at this time. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/24/28040?source=see_link&amp;anchor=H8#H8\">",
"     \"Acute cardiac allograft rejection: Diagnosis\", section on 'Surveillance biopsy schedule'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/24/28040?source=see_link&amp;anchor=H11#H11\">",
"     \"Acute cardiac allograft rejection: Diagnosis\", section on 'Histologic findings of acute rejection'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Sampling error associated with endomyocardial biopsy may result in underestimation of the severity of rejection. As a result, the absence of pathologic evidence for severe rejection in the presence of unexplained LV dysfunction, heart failure, or shock should not deter treatment for rejection.",
"   </p>",
"   <p>",
"    The treatment of acute allograft rejection is discussed separately. In severe cases, inotropic agents and even intraaortic balloon pumping may be needed to support the patient while antirejection therapy is initiated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/6/14441?source=see_link\">",
"     \"Acute cardiac allograft rejection: Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Ventricular function and functional class often return to normal with successful treatment of rejection, even if severe. The long-term prognosis can be favorable; however, repeated episodes of severe acute cellular rejection are associated with a greater likelihood of persistent LV dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25862/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/15/22775?source=see_link\">",
"     \"Prognosis after cardiac transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Acute myocarditis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Toxoplasma gondii and cytomegalovirus are two opportunistic infections that can produce acute myocarditis in immunosuppressed transplant recipients. The diagnosis is established by identifying the infectious organisms or multinucleated giant cells in endomyocardial biopsy samples. Standard treatment for these infections is employed, often while attempting to attenuate the degree of chronic immunosuppression. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/47/29433?source=see_link\">",
"     \"Infection in the solid organ transplant recipient\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Nonspecific allograft dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonspecific allograft dysfunction is generally defined as LV systolic dysfunction in the absence of biopsy evidence for rejection (ie, lack of either cellular infiltrate or positive staining for antibodies). Microvascular damage and areas of microinfarction have been observed in biopsy specimens.",
"   </p>",
"   <p>",
"    The precise etiology is unclear. However, intensification of immunosuppression (eg, with antithymocyte globulin) has been associated with clinical improvement, suggesting that immune system activation may be important [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25862/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Recurrent myocardial disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;In rare patients, recurrence of the initial myocardial disease that resulted in failure of the native heart can lead to failure of the cardiac allograft. Examples include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Amyloidosis, a disorder in which transplantation is not often performed because of frequently severe extracardiac amyloid deposition. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/10/23722?source=see_link\">",
"       \"Clinical manifestations and diagnosis of amyloid cardiomyopathy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Giant cell myocarditis and sarcoidosis, which are rare diseases treated with transplantation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/0/19465?source=see_link\">",
"       \"Causes of dilated cardiomyopathy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/19/17722?source=see_link\">",
"       \"Cardiac sarcoidosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hereditary hemochromatosis, in which recurrent disease is avoidable by ongoing therapy to prevent iron overload. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/60/28617?source=see_link\">",
"       \"Clinical manifestations of hereditary hemochromatosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/32/18952?source=see_link\">",
"       \"Treatment of hereditary hemochromatosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     ALLOGRAFT CORONARY ARTERY DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Left ventricular dysfunction after heart transplantation may result from coronary artery disease due to transplant vasculopathy or coronary atherosclerosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Allograft vasculopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Allograft or cardiac transplant vasculopathy refers to the development of a diffuse vasculopathy that is limited to allograft, is related to immunologic and nonimmunologic factors, and can lead to LV dysfunction months to years after transplantation. Transplant vasculopathy should always be considered as a possible cause for delayed LV dysfunction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/25/44441?source=see_link\">",
"     \"Pathogenesis of and risk factors for cardiac allograft vasculopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/9/18585?source=see_link\">",
"     \"Natural history and diagnosis of cardiac allograft vasculopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most centers report an angiographic incidence of transplant vasculopathy of 2 to 28 percent at one year after heart transplantation; by five years, the prevalence rises to 40 to 70 percent. The diagnosis is usually made by coronary angiography, but it is generally acknowledged by angiography provides a gross underestimate of this diffuse, concentric vasculopathy. As a result, many patients who develop clinical events that are presumably due to transplant vasculopathy do not have angiographically significant disease.",
"   </p>",
"   <p>",
"    Because of these limitations, adjuncts to angiography have been sought that might improve the detection of transplant vasculopathy. Intravascular ultrasound provides a more quantitative assessment, but its general clinical utility is as a research tool. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/9/18585?source=see_link&amp;anchor=H12357202#H12357202\">",
"     \"Natural history and diagnosis of cardiac allograft vasculopathy\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinical features and outcomes of transplant vasculopathy are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/9/18585?source=see_link\">",
"     \"Natural history and diagnosis of cardiac allograft vasculopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/1/23576?source=see_link\">",
"     \"Arrhythmias following cardiac transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/12/42184?source=see_link\">",
"     \"Prevention and treatment of cardiac allograft vasculopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Summarized briefly:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Silent myocardial infarction, sudden death, and progressive heart failure are common presentations of transplant vasculopathy. Classic anginal chest pain is infrequent due to afferent and efferent allograft denervation [",
"      <a class=\"abstract\" href=\"UTD.htm?25/16/25862/abstract/14\">",
"       14",
"      </a>",
"      ]. Affected patients progress at a variable rate.",
"     </li>",
"     <li>",
"      Therapy of established vasculopathy is limited [",
"      <a class=\"abstract\" href=\"UTD.htm?25/16/25862/abstract/8,15\">",
"       8,15",
"      </a>",
"      ]. Palliative percutaneous coronary interventions are often performed in patients with discrete lesions amenable to these approaches. Percutaneous coronary intervention is associated with an excellent immediate success rate, but a high rate of rapid progression of this diffuse disease [",
"      <a class=\"abstract\" href=\"UTD.htm?25/16/25862/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Allograft vasculopathy remains the most common barrier to long-term survival [",
"      <a class=\"abstract\" href=\"UTD.htm?25/16/25862/abstract/8,16\">",
"       8,16",
"      </a>",
"      ]. In one report of 54 patients with at least 40 percent stenosis in one or more coronary arteries, overall survival was 67, 44, and 17 percent at one, two, and five years [",
"      <a class=\"abstract\" href=\"UTD.htm?25/16/25862/abstract/16\">",
"       16",
"      </a>",
"      ]. Survival varied with disease severity, being worst in patients with three vessel disease (13 percent at two years).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Retransplantation is reserved for patients with diffuse, three vessel coronary artery disease, decreased left ventricular function, and symptoms of heart failure who have no contraindications to retransplantation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/15/22775?source=see_link&amp;anchor=H10#H10\">",
"     \"Prognosis after cardiac transplantation\", section on 'Repeat cardiac transplantation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Coronary atherosclerosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;More typical native coronary artery disease also can occur after heart transplantation. Ischemia and infarction are often silent due to the lack of allograft innervation.",
"   </p>",
"   <p>",
"    Once LV systolic dysfunction from coronary disease develops, patients are treated with a regimen similar to that in nontransplanted patients. This",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , aggressive control of serum cholesterol with a statin, angiotensin converting enzyme inhibitors, beta blockers, and, if present, control of hypertension. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/26/25000?source=see_link\">",
"     \"Lipid abnormalities after cardiac transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/60/40906?source=see_link\">",
"     \"Secondary prevention of cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Percutaneous or surgical revascularization can be performed in appropriate patients [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25862/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/38/27240?source=see_link\">",
"     \"Bypass surgery versus percutaneous intervention in the management of stable angina pectoris: Recommendations\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/35/4665?source=see_link\">",
"     \"Silent myocardial ischemia: Prognosis and therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?25/36/26179?source=see_link\">",
"       \"Patient information: Heart transplantation (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a short differential diagnosis for LV dysfunction after orthotopic cardiac transplantation that varies with time posttransplant at diagnosis. Both systolic and diastolic dysfunction may be identified.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Early allograft dysfunction occurring in the operative and immediate postoperative periods is often due to preservation injury with ischemia or the use of a suboptimal donor heart. It is associated with a need for increased use of inotropic agents or other circulatory support (such as intraaortic balloon pumping) and may or may not lead to chronic LV dysfunction. Hyperacute rejection also can occur at this time but is now rare.",
"     </li>",
"     <li>",
"      The most important causes of late LV dysfunction are allograft rejection and allograft vasculopathy. Prompt treatment of allograft rejection can result in dramatic improvement even in patients with cardiogenic shock. Empiric therapy may be indicated if the clinical suspicion is high, even in the absence of biopsy-proven rejection. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/6/14441?source=see_link\">",
"       \"Acute cardiac allograft rejection: Treatment\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Other causes of delayed LV dysfunction include typical coronary atherosclerosis, opportunistic myocardial infections, and rarely recurrent myocardial disease. These disorders should be considered when appropriate.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25862/abstract/1\">",
"      Follansbee WP, Kiernan JM, Curtiss EI, et al. Changes in left ventricular systolic function that accompany rejection of the transplanted heart: a serial radionuclide assessment of fifty-three consecutive cases. Am Heart J 1991; 121:548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25862/abstract/2\">",
"      Azimzadeh A, Wolf P, Dalmasso AP, et al. Assessment of hyperacute rejection in a rat-to-primate cardiac xenograft model. Transplantation 1996; 61:1305.",
"     </a>",
"    </li>",
"    <li>",
"     Emery, RW, Miller, LW. Handbook of Cardiac Transplantation, Lippincott Williams &amp; Wilkins, Philadelphia, PA 1996. p.129.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25862/abstract/4\">",
"      Appleyard RF, Cohn LH. Myocardial stunning and reperfusion injury in cardiac surgery. J Card Surg 1993; 8:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25862/abstract/5\">",
"      Garc&iacute;a-Poblete E, Fern&aacute;ndez H, Alvarez L, et al. Structural and ultrastructural study of the myocardium after 24-hour preservation in University of Wisconsin solution. Histol Histopathol 1997; 12:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25862/abstract/6\">",
"      Young JB, Naftel DC, Bourge RC, et al. Matching the heart donor and heart transplant recipient. Clues for successful expansion of the donor pool: a multivariable, multiinstitutional report. The Cardiac Transplant Research Database Group. J Heart Lung Transplant 1994; 13:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25862/abstract/7\">",
"      Jahania MS, Sanchez JA, Narayan P, et al. Heart preservation for transplantation: principles and strategies. Ann Thorac Surg 1999; 68:1983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25862/abstract/8\">",
"      Hosenpud JD, Bennett LE, Keck BM, et al. The Registry of the International Society for Heart and Lung Transplantation: seventeenth official report-2000. J Heart Lung Transplant 2000; 19:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25862/abstract/9\">",
"      Potapov EV, Loebe M, H&uuml;bler M, et al. Medium-term results of heart transplantation using donors over 63 years of age. Transplantation 1999; 68:1834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25862/abstract/10\">",
"      Marelli D, Laks H, Fazio D, et al. The use of donor hearts with left ventricular hypertrophy. J Heart Lung Transplant 2000; 19:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25862/abstract/11\">",
"      Jeevanandam V, Furukawa S, Prendergast TW, et al. Standard criteria for an acceptable donor heart are restricting heart transplantation. Ann Thorac Surg 1996; 62:1268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25862/abstract/12\">",
"      Skowronski EW, Epstein M, Ota D, et al. Right and left ventricular function after cardiac transplantation. Changes during and after rejection. Circulation 1991; 84:2409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25862/abstract/13\">",
"      Costanzo-Nordin MR, Heroux AL, Radvany R, et al. Role of humoral immunity in acute cardiac allograft dysfunction. J Heart Lung Transplant 1993; 12:S143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25862/abstract/14\">",
"      Stark RP, McGinn AL, Wilson RF. Chest pain in cardiac-transplant recipients. Evidence of sensory reinnervation after cardiac transplantation. N Engl J Med 1991; 324:1791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25862/abstract/15\">",
"      Halle AA 3rd, DiSciascio G, Massin EK, et al. Coronary angioplasty, atherectomy and bypass surgery in cardiac transplant recipients. J Am Coll Cardiol 1995; 26:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25862/abstract/16\">",
"      Keogh AM, Valantine HA, Hunt SA, et al. Impact of proximal or midvessel discrete coronary artery stenoses on survival after heart transplantation. J Heart Lung Transplant 1992; 11:892.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3526 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-122.96.59.103-BA6E9C3E55-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_16_25862=[""].join("\n");
var outline_f25_16_25862=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EARLY LV DYSFUNCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Hyperacute rejection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Reperfusion injury during surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Suboptimal donor heart",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      LATE LV DYSFUNCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Rejection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Acute myocarditis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Nonspecific allograft dysfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Recurrent myocardial disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      ALLOGRAFT CORONARY ARTERY DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Allograft vasculopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Coronary atherosclerosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/24/28040?source=related_link\">",
"      Acute cardiac allograft rejection: Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/6/14441?source=related_link\">",
"      Acute cardiac allograft rejection: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/1/23576?source=related_link\">",
"      Arrhythmias following cardiac transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/38/27240?source=related_link\">",
"      Bypass surgery versus percutaneous intervention in the management of stable angina pectoris: Recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/19/17722?source=related_link\">",
"      Cardiac sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/0/19465?source=related_link\">",
"      Causes of dilated cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/10/23722?source=related_link\">",
"      Clinical manifestations and diagnosis of amyloid cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/60/28617?source=related_link\">",
"      Clinical manifestations of hereditary hemochromatosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/26/7592?source=related_link\">",
"      Endomyocardial biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/47/29433?source=related_link\">",
"      Infection in the solid organ transplant recipient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/15/6394?source=related_link\">",
"      Ischemic reperfusion injury of the heart",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/26/25000?source=related_link\">",
"      Lipid abnormalities after cardiac transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/9/18585?source=related_link\">",
"      Natural history and diagnosis of cardiac allograft vasculopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/25/44441?source=related_link\">",
"      Pathogenesis of and risk factors for cardiac allograft vasculopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?25/36/26179?source=related_link\">",
"      Patient information: Heart transplantation (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/12/42184?source=related_link\">",
"      Prevention and treatment of cardiac allograft vasculopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/15/22775?source=related_link\">",
"      Prognosis after cardiac transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/60/40906?source=related_link\">",
"      Secondary prevention of cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/35/4665?source=related_link\">",
"      Silent myocardial ischemia: Prognosis and therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/32/18952?source=related_link\">",
"      Treatment of hereditary hemochromatosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_16_25863="Porphyria cutanea tarda";
var content_f25_16_25863=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F74528%7EDERM%2F78547&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F74528%7EDERM%2F78547&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Porphyria cutanea tarda",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 395px; height: 259px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Vesicles and erosions are visible on the dorsum of the hand in a patient with porphyria cutanea tarda related to underlying hepatitis C virus infection.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jean-Fran&ccedil;ois Dufour, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Porphyria cutanea tarda",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 380px; height: 336px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Macular erythema, erosions, crusts, and scars are present on the hands of this patient with porphyria cutanea tarda.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Stedman's Medical Dictionary. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_16_25863=[""].join("\n");
var outline_f25_16_25863=null;
var title_f25_16_25864="Thyroglossal duct cysts and ectopic thyroid";
var content_f25_16_25864=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Thyroglossal duct cysts and ectopic thyroid",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/16/25864/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/16/25864/contributors\">",
"     Gregory W Randolph, MD, FACS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/16/25864/contributors\">",
"     Dipti V Kamani, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/16/25864/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/16/25864/contributors\">",
"     Sally E Carty, MD, FACS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/16/25864/contributors\">",
"     Douglas S Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/16/25864/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/16/25864/contributors\">",
"     Rosemary B Duda, MD, MPH, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?25/16/25864/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 7, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thyroglossal ducts cysts (TGDC) are the most common form of congenital cyst in the neck. They are cysts of epithelial remnants of the thyroglossal tract and present characteristically as a midline neck mass at the level of the thyrohyoid membrane, closely associated with the hyoid bone. Although most patients with TGDC are children or adolescents, up to one-third are aged 20 years or older [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25864/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Males and females are equally affected.",
"   </p>",
"   <p>",
"    Patients with a TGDC often have ectopic thyroid glands. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Thyroid ectopia'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EMBRYOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The anlage of the thyroid gland forms at the foramen cecum of the tongue, which is located on the dorsum of the tongue posteriorly at the apex of the V-shaped sulcus formed by the circumvallate papillae [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25864/abstract/2\">",
"     2",
"    </a>",
"    ]. During the fourth week of gestation, a ventral diverticulum of the foramen cecum is formed from the first and second pharyngeal pouches (the medial thyroid anlage). This diverticulum, with its narrow neck connected to the tongue, descends in the midline of the neck as the thyroglossal tract to the position of the normal thyroid in the base of the neck, where the thyroid lobes separate, by the seventh week. The path of descent is usually anterior to the hyoid bone, but may be posterior to or through the bone, and ends on the anterior surface of the first few tracheal rings.",
"   </p>",
"   <p>",
"    The tract usually atrophies and disappears by the tenth week of gestation. Portions of the tract and remnants of thyroid tissue associated with it may persist at any point between the tongue and the thyroid (",
"    <a class=\"graphic graphic_figure graphicRef79472 \" href=\"UTD.htm?8/48/8961\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The pyramidal lobe can be thought of as the most caudal remnant of this tract and is present in approximately one-third of normal subjects. The lateral thyroid anlage, consisting of the C-cell precursors, which arises from the neural crest portion of the fourth pharyngeal pouch, ultimately fuses with the descended medial anlage [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25864/abstract/3\">",
"     3",
"    </a>",
"    ]. The pyramidal lobe usually arises from the isthmus of the thyroid, but may arise from the medial aspect of one of the thyroid lobes or both lobes.",
"   </p>",
"   <p>",
"    A thyroglossal duct cyst arises as a cystic expansion of a remnant of the thyroglossal duct tract [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25864/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The stimulus for the expansion is not known; one postulate is that lymphoid tissue associated with the tract hypertrophies at the time of a regional infection, thereby occluding the tract with resultant cyst formation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25864/abstract/4\">",
"     4",
"    </a>",
"    ]. Many cystic remnants of the thyroglossal tract are never detected clinically; a postmortem study of 200 adults found a 7 percent incidence of thyroglossal duct cysts [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25864/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with a TGDC usually present with a midline upper neck mass that is cystic. The mass usually causes no symptoms, but may be slightly tender. Often the patient has or recently had an upper respiratory tract infection, but whether the infection leads to cyst formation or simply increases the likelihood of detection of a preexisting cyst is uncertain.",
"   </p>",
"   <p>",
"    The cyst may occur anywhere along the thyroglossal duct tract from the foramen cecum at the base of the tongue to the level of the suprasternal notch (",
"    <a class=\"graphic graphic_figure graphicRef79472 \" href=\"UTD.htm?8/48/8961\">",
"     figure 1",
"    </a>",
"    ). In most cases, the cyst is at or just below the hyoid bone adjacent to the thyrohyoid membrane [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25864/abstract/2\">",
"     2",
"    </a>",
"    ]. Cysts below the thyrohyoid membrane are rare. There are only two reported cases, one reaching to the suprasternal notch and the second encroaching into the superior mediastinum, descending all the way to the aortic arch. A TGDC in such a location can masquerade as a thymic mass and cause confusion [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25864/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    TGDCs are usually within 2 cm of the midline [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25864/abstract/7\">",
"     7",
"    </a>",
"    ], but can be somewhat more lateral and may even be lateral to the thyroid cartilage (more typically on the left). The typical cyst does, however, maintain a close relationship to the hyoid, thyrohyoid membrane, or thyroid cartilage. Classically, TGDCs move up with swallowing or protrusion of the tongue, emphasizing their close relationship with the",
"    <span class=\"nowrap\">",
"     hyoid/larynx",
"    </span>",
"    complex.",
"   </p>",
"   <p>",
"    The typical close relationship between a TGDC and the thyroid cartilage can result, if the cyst is large, in remodeling of the laryngeal cartilage [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25864/abstract/8\">",
"     8",
"    </a>",
"    ]. However, because the cysts do not typically invade, laryngeal reconstruction is rarely required even after excision of large cysts [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25864/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Familial occurrence of TGDCs has been reported, but is extremely rare, and few cases having been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25864/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. The most common inheritance pattern appears to be autosomal dominant [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25864/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Very rarely, a TGDC may present in an ectopic location (eg, an endolaryngeal cyst). In such cases, an open procedure is preferred over an endoscopic surgical approach [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25864/abstract/13\">",
"     13",
"    </a>",
"    ]. An intrathyroidal cyst with thyroglossal duct cyst-like lining has also been described [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25864/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     THYROID ECTOPIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thyroid ectopia is defined as functioning thyroid tissue found anywhere other than the usual anatomic location of thyroid gland. Ectopic thyroid is usually located along the normal path of thyroid gland descent, but rarely can also be found in mediastinum, heart, esophagus, or diaphragm [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25864/abstract/15\">",
"     15",
"    </a>",
"    ]. Ectopic thyroid tissue is derived from abnormalities in migration of the medial anlage, hence typically does not contain C cells.",
"   </p>",
"   <p>",
"    Failure of thyroid gland descent occurs in approximately 1 in 200,000 normal subjects and 1 in 6000 patients with thyroid disease [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25864/abstract/16\">",
"     16",
"    </a>",
"    ]. The true incidence of thyroid ectopia is not known due to the asymptomatic nature of some ectopic thyroid tissue.",
"   </p>",
"   <p>",
"    The most common site of ectopic thyroid is a lingual thyroid. The wall of a thyroglossal duct cyst (TGDC) is the second most common site for ectopic thyroid tissue. The ectopic tissue is usually found in the form of small groups of follicles, and is present in 25 to 65 percent of cysts examined histologically [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25864/abstract/17\">",
"     17",
"    </a>",
"    ]. Up to 1 to 2 percent of patients presenting with what appears to be a TGDC have an ectopic thyroid gland [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25864/abstract/18,19\">",
"     18,19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Association with hypothyroidism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most cases of thyroid ectopia manifest as simple TGDC in conjunction with a normally developed and located thyroid gland [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25864/abstract/20\">",
"     20",
"    </a>",
"    ]. Some thyroid ectopia function normally, but approximately one-third of patients present with hypothyroidism.",
"   </p>",
"   <p>",
"    If hypothyroidism develops, the mass may enlarge as a result of stimulation by thyrotropin (TSH). Ectopic thyroid tissue may enlarge during puberty or pregnancy. Treatment with thyroid hormone supplementation is usually sufficient for suppression, but surgical excision may become necessary.",
"   </p>",
"   <p>",
"    The preoperative detection of hypothyroidism in a patient with a midline neck mass increases the suspicion of ectopic thyroid [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25864/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/7/26744?source=see_link\">",
"     \"Diagnosis of and screening for hypothyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Lingual thyroid",
"    </span>",
"    &nbsp;&mdash;&nbsp;The entire thyroid gland can fail to descend to its normal adult orthotopic site. If the descent is completely arrested at the level of the base of tongue, a lingual thyroid results. Partial descent can result in an ectopic gland in a sublingual or prelaryngeal position. Excessive migration can result in a substernal ectopic gland [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25864/abstract/16,21,22\">",
"     16,21,22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among ectopic thyroid glands, 90 percent are lingual and 10 percent occur in other sites [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25864/abstract/21\">",
"     21",
"    </a>",
"    ]. In patients presenting with a lingual thyroid, over 70 percent have no thyroid tissue in the normal location [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25864/abstract/2,23,24\">",
"     2,23,24",
"    </a>",
"    ]. A lingual thyroid can represent the only functioning thyroid tissue so excision could lead to severe hypothyroidism, requiring thyroid hormone replacement [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25864/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Enlargement of lingual thyroid tissue can be seen with upper respiratory infections (due to associated lymphoid tissue), during pregnancy, or at puberty, leading to regional symptoms such as dysphagia, dysphonia, dyspnea, or hemoptysis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25864/abstract/16,21,26\">",
"     16,21,26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Carcinoma arising in a lingual thyroid is rare with fewer than 30 cases reported in the literature [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25864/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Carcinoma'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Lateral nonmalignant thyroid tissue",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ectopic nonmalignant cervical thyroid tissue can be divided into (1) midline elements including an ectopic thyroid gland and TGDC remnants and (2) lateral elements including true embryologic rests, paracytic nodules and exophytic nodules (\"lateral aberrant thyroid\") [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25864/abstract/3\">",
"     3",
"    </a>",
"    ]. A patient who has a substantial amount of thyroid tissue within a lymph node in the lateral neck should be suspected to have a nodal metastasis of a small well-differentiated carcinoma of the thyroid [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25864/abstract/27-29\">",
"     27-29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    True embryologic rests of normal thyroid tissue (believed to form as a result of migration error) have been described in several locations, including adjacent to the larynx, aortic arch and heart [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25864/abstract/3\">",
"     3",
"    </a>",
"    ] as well as within lymph nodes in the lateral neck. Strict criteria must be followed in order to exclude foci of well-differentiated thyroid cancer within the node. Such nodal embryologic rests must be small, containing only a few thyroid follicles and with none of the nuclear features of papillary carcinoma, and should be present only in the capsular region of the node [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25864/abstract/3,30,31\">",
"     3,30,31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Exophytic and paracytic nodules",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thyroid tissue that is not within a lymph node can occur in the lateral neck or upper mediastinum through progression of thyroid nodular disease on the surface of the gland.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Exophytic nodules are surface nodules that progressively enlarge and become detached from the main portion of the thyroid gland. Exophytic nodules are not uncommon.",
"     </li>",
"     <li>",
"      Paracytic nodules are nodules that develop at some distance from the thyroid gland as a result of implantation of a small focus of thyroid tissue during a thyroid surgical procedure. Although they are rare, we have seen paracytic nodules develop adjacent to the larynx and behind the carotid artery.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;TGDCs are the most common cause of a midline neck mass, followed by dermoid cysts. Dermoid and sebaceous cysts tend to be quite superficial, less tethered to the underlying structures, including the hyoid bone, as compared with TGDC.",
"   </p>",
"   <p>",
"    Branchial cleft cysts can be confused with TGDCs if they are somewhat medially located. Branchial cleft cysts are often associated with a sinus tract or fistula, whereas TGDCs are not.",
"   </p>",
"   <p>",
"    Lipomas are quite superficial and have ill-defined edges.",
"   </p>",
"   <p>",
"    Other causes of midline neck masses include thyroid nodules, hypertrophic pyramidal lobes of the thyroid, midline lymphadenopathy, medially located salivary gland tumors, sebaceous cysts and lymphatic malformations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Fine needle aspiration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fine needle aspiration (FNA) is often used to diagnose TGDCs or to exclude other diagnoses [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25864/abstract/32\">",
"     32",
"    </a>",
"    ]. The cytomorphologic features include colloid, macrophages, lymphocytes, neutrophils, and ciliated columnar cells, but these are not unique to TGDCs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3174754\">",
"    <span class=\"h1\">",
"     IMAGING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Palpation to confirm the presence of normal thyroid gland is thought not to be reliable by pediatric surgeons [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25864/abstract/33\">",
"     33",
"    </a>",
"    ]. Radionuclide imaging, ultrasonography, and computed tomography (CT) are undoubtedly more reliable tests to identify the presence of thyroid tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25864/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/62/21482?source=see_link\">",
"     \"Overview of the clinical utility of ultrasonography in thyroid disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19294504\">",
"    <span class=\"h2\">",
"     CT imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a suspected case of thyroglossal duct cyst, CT of the neck with contrast is the most preferred imaging modality (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef82790 \" href=\"UTD.htm?6/21/6484\">",
"     image 1",
"    </a>",
"    ). It not only helps to confirm the diagnosis of thyroglossal duct cyst by defining the typical close relationship of the cyst to the hyoid bone, but also provides information regarding the size, extent, and location. It also identifies normal orthotopic thyroid tissue. MR can also define the cysts relationship to the hyoid and other surrounding structures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19294511\">",
"    <span class=\"h2\">",
"     Ultrasonography",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is a very useful modality for thyroid gland and will reveal the cystic nature of a TGDC, but does not provide information about the relationship to surrounding structures including hyoid bone [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25864/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thyroid function should always be assessed preoperatively in all cases of thyroglossal duct cysts. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/33/3608?source=see_link\">",
"     \"Laboratory assessment of thyroid function\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     CARCINOMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the cyst is found to contain thyroid cancer, one must be sure that the carcinoma arose from within the cyst, and is not a cystic metastasis to a midline lymph node from a primary thyroid cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25864/abstract/37\">",
"     37",
"    </a>",
"    ]. Studies suggest, among patients with carcinomas in thyroglossal duct cysts, 11 to 33 percent have carcinoma within the thyroid gland [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25864/abstract/38\">",
"     38",
"    </a>",
"    ]. The carcinoma is considered to have originated in the thyroglossal duct cyst if there is histological evidence of columnar or squamous epithelial lining in the cyst [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25864/abstract/17,39\">",
"     17,39",
"    </a>",
"    ], normal thyroid follicles in the cyst wall [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25864/abstract/17\">",
"     17",
"    </a>",
"    ], and complete absence of lymph-node tissue, and there is ultrasonographic evidence of a normal thyroid gland [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25864/abstract/40\">",
"     40",
"    </a>",
"    ]. If not, the lesion may represent a lymph-node metastasis from a thyroid cancer. The incidence of primary carcinoma of the thyroglossal duct is less than 1 percent in all age groups [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25864/abstract/38,41,42\">",
"     38,41,42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most cases of thyroglossal duct cyst carcinoma are adequately treated by resection with the Sistrunk procedure with a reported cure rate of 95 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25864/abstract/38,43,44\">",
"     38,43,44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    After review of pathology, if a surgeon is certain of the diagnosis of thyroglossal duct cyst carcinoma (ie, primary thyroid gland carcinoma has been ruled out) and thyroid sonography is negative, then surgical treatment of thyroglossal duct cyst is sufficient [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25864/abstract/45\">",
"     45",
"    </a>",
"    ]. A thyroidectomy is performed in cases where a primary thyroid malignancy cannot be excluded. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/17/44313?source=see_link\">",
"     \"Overview of the management of differentiated thyroid cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thyroidectomy is also indicated in rare cases of thyroglossal duct cyst carcinoma that have invasive tumor or have positive regional lymph nodes. This is done in anticipation of the need for I131 treatment and diagnostic whole-body radioiodine scanning [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25864/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Lymph node metastasis of thyroglossal duct cyst carcinoma was previously thought to be rare [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25864/abstract/2\">",
"     2",
"    </a>",
"    ]. However, if prophylactic neck dissections are performed at the time of resection, the incidence of lymph node metastasis is surprisingly high [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25864/abstract/47\">",
"     47",
"    </a>",
"    ]. In a series of 18 patients with papillary cancer arising in a TGDC, most",
"    <span class=\"nowrap\">",
"     (16/18)",
"    </span>",
"    patients underwent neck dissection of the central",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    lateral compartments. Lymph node metastases were found in 75 percent",
"    <span class=\"nowrap\">",
"     (12/16)",
"    </span>",
"    of the patients [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25864/abstract/47\">",
"     47",
"    </a>",
"    ]. In addition, 56 percent had small foci of papillary cancer in their thyroid glands, but these patients accounted for only half of the patients who had nodes [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25864/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Occurrence of distant metastasis is uncommon, reported in less than 2 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25864/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     INFECTED THYROGLOSSAL DUCT CYST",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most TGDCs have some degree of infection or inflammation at presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25864/abstract/48\">",
"     48",
"    </a>",
"    ]. It is essential to avoid surgery during the phase of acute inflammation as this can lead to recurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25864/abstract/49-51\">",
"     49-51",
"    </a>",
"    ]. An infected TGDC should be managed initially with antibiotics, followed by definitive surgery once the infection has resolved. Once the infection clears completely, the patient should undergo an elective Sistrunk procedure. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Sistrunk procedure'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Incision and drainage should only be considered in cases of abscesses that do not respond to antibiotics. Incision and drainage can allow seeding of ductal cells outside the cyst and, in turn, increase chances of recurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25864/abstract/52\">",
"     52",
"    </a>",
"    ]. Additionally, definitive surgery is easier in the absence of scar tissue or a cutaneous fistula [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25864/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Microbiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cysts are usually infected by oropharyngeal flora, hence antibiotics should be directed towards the most common oral organisms, which include various streptococcal species and oral anaerobes [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25864/abstract/52\">",
"     52",
"    </a>",
"    ]. When possible, cultures should be obtained with a fine needle aspirate for gram stain, aerobic and anaerobic culture, fungal stain and culture, acid-fast bacillus stain and mycobacterial culture [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25864/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Successful treatment requires broad-spectrum antibiotics targeted toward oral flora [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25864/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Mild cases may be treated with a course of oral antibiotics such as a first generation cephalosporin (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/37/37462?source=see_link\">",
"     cephalexin",
"    </a>",
"    500 mg PO every 6 hours),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/56/43912?source=see_link\">",
"     amoxicillin-clavulanate",
"    </a>",
"    (500",
"    <span class=\"nowrap\">",
"     mg/125",
"    </span>",
"    mg PO every 8 hours), or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    (600 mg PO every 8 hours). We do not recommend empirical coverage for methicillin-resistant Staphylococcus aureus (MRSA) unless identified by culture. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/7/4216?source=see_link\">",
"     \"Treatment of skin and soft tissue infections due to methicillin-resistant Staphylococcus aureus in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For more severe infections, an antibiotic regimen such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/2/4136?source=see_link\">",
"     cefazolin",
"    </a>",
"    (1 to 1.5 g intravenously [IV]) every 8 hours in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    (600 to 900 mg IV) every 8 hours is recommended (",
"    <a class=\"graphic graphic_table graphicRef87201 \" href=\"UTD.htm?13/19/13628\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/35/31290?source=see_link&amp;anchor=H24#H24\">",
"     \"Overview of control measures to prevent surgical site infection\", section on 'Head and neck surgery'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SURGERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with TGDCs should be treated surgically with the Sistrunk procedure unless the patient is not a surgical candidate. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Sistrunk procedure'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H18\">",
"     'Sclerotherapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    If a TGDC is not removed, as many as half become infected [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25864/abstract/50\">",
"     50",
"    </a>",
"    ], and infection before surgery is a well described cause of recurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25864/abstract/49,50\">",
"     49,50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one retrospective series the recurrence rate after simple cystectomy was 8 percent among children whose cysts had not been infected, compared with 40 percent in children whose cysts had been infected [",
"      <a class=\"abstract\" href=\"UTD.htm?25/16/25864/abstract/50\">",
"       50",
"      </a>",
"      ]. Similarly, among patients who underwent more extensive surgery, the recurrence rate was 1.4 percent in those with non-infected cysts as compared with 14 percent in those with infected cysts [",
"      <a class=\"abstract\" href=\"UTD.htm?25/16/25864/abstract/50\">",
"       50",
"      </a>",
"      ]. Surgery is therefore best performed at first presentation.",
"     </li>",
"     <li>",
"      Approximately 1 to 2 percent of TGDCs ultimately are found to contain cancer [",
"      <a class=\"abstract\" href=\"UTD.htm?25/16/25864/abstract/2,55,56\">",
"       2,55,56",
"      </a>",
"      ]. The clinical features of thyroglossal duct carcinoma are very similar to those of TGDC [",
"      <a class=\"abstract\" href=\"UTD.htm?25/16/25864/abstract/2,55,56\">",
"       2,55,56",
"      </a>",
"      ], and in the majority of cases thyroglossal duct tract carcinomas are not suspected before surgery.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Preoperative evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with a TGDC often have ectopic thyroid glands (see",
"    <a class=\"local\" href=\"#H4\">",
"     'Thyroid ectopia'",
"    </a>",
"    above). In a survey of 368 surgeons (including pediatric, general, and head and neck surgeons), 57 percent had encountered ectopic thyroid tissue among patients with TGDCs [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25864/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Before any surgery is planned, it is important to determine whether patients with a TGDC have thyroid tissue in the normal site. It is essential to determine whether a patient has ectopic thyroid tissue, as this can be involved with benign or malignant thyroid disease.",
"   </p>",
"   <p>",
"    Ectopic thyroid tissue can be confused with a TGDC. All cases of thyroid ectopia should have thyroid function tests, ultrasonography and a thyroid scan performed to locate additional functioning thyroid tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25864/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/33/3608?source=see_link\">",
"     \"Laboratory assessment of thyroid function\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/62/21482?source=see_link\">",
"     \"Overview of the clinical utility of ultrasonography in thyroid disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Sistrunk procedure",
"    </span>",
"    &nbsp;&mdash;&nbsp;The standard operation is resection of the cyst and the midportion of the hyoid bone in continuity and resection of a core of tissue from the hyoid upwards towards the foramen cecum, an operation known as the Sistrunk procedure (",
"    <a class=\"graphic graphic_figure graphicRef64198 \" href=\"UTD.htm?11/26/11683\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25864/abstract/57\">",
"     57",
"    </a>",
"    ]. Arborization of the superior aspect of the thyroglossal tract at and above the hyoid bone may occur, and may be a reason for recurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25864/abstract/49,58\">",
"     49,58",
"    </a>",
"    ]. Recurrence after a Sistrunk procedure is rare. In such a case, a repeat or extended Sistrunk procedure is recommended. This procedure includes removal of a core of the tissue from the hyoid to the foramen cecum to encompass possible superior tract arborization [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25864/abstract/59\">",
"     59",
"    </a>",
"    ]. The goal of a repeat Sistrunk operation is complete excision of the thyroglossal duct tract up to the tongue base, superior and posterior to the hyoid bone [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25864/abstract/60\">",
"     60",
"    </a>",
"    ]. The overall recurrence rate after this procedure is approximately 5 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25864/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We prefer to resect the cyst with a cuff of surrounding tissue and strap muscle to avoid entry into the cyst, which has been implicated in cyst recurrence, and to facilitate complete removal. Patients with infected cysts should receive antibiotic therapy and not undergo incision and drainage, because the latter can lead to scarring and make later surgery more difficult. Preoperative fine-needle aspiration can be helpful to decrease cyst size and in some cases may lead to identification of thyroglossal duct cyst carcinoma, if solid elements of the lesion can be sampled [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25864/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A new modification of the repeat Sistrunk operation, suture-guided trans-hyoid pharyngotomy has also been proposed to allow the surgeon better visibility of normal structures and direct access to the tissues between the hyoid bone and the foramen cecum [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25864/abstract/60\">",
"     60",
"    </a>",
"    ]. A single series of eight of these procedures, all done successfully by a single surgeon has been reported. As the procedure is new and the experience is limited, the suture-guided modification of the Sistrunk operation is not recommended at this time.",
"   </p>",
"   <p>",
"    Histologic examination of a TGDC reveals a cyst with an epithelial lining that is columnar or squamous and may be ciliated. Some normal thyroid tissue is usually present in the wall of the cyst [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25864/abstract/3,17\">",
"     3,17",
"    </a>",
"    ]. Carcinoma of the thyroglossal duct is usually diagnosed only after histologic study because there are a few clinical clues to the presence of cancer within a TGDC. Among the cancers, 88 percent are papillary carcinomas, 6 percent are squamous cell carcinomas, and the rest are Hurthle-cell, follicular, and anaplastic carcinomas [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25864/abstract/38,61\">",
"     38,61",
"    </a>",
"    ]. There are no reports of medullary carcinoma in a TGDC [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25864/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Fine-needle aspiration biopsy is the most reliable method for preoperative diagnosis of thyroid cancer, especially if done with ultrasound guidance [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25864/abstract/63\">",
"     63",
"    </a>",
"    ]. However, given the low incidence of carcinoma in TGDCs, especially in children, preoperative biopsy of all TGDCs may not be cost effective. In one study all 12 patients in whom the cysts contained carcinomas were at least 17 years old [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25864/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SCLEROTHERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Percutaneous ethanol injection is an alternative approach in patients who are not surgical candidates if the presence of malignancy can be excluded [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25864/abstract/64\">",
"     64",
"    </a>",
"    ]. It is effective in only a third of cases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Thyroglossal ducts cysts (TGDC) characteristically present as a midline neck mass at the level of the thyrohyoid membrane, closely associated with the hyoid bone. Although most patients with TGDC are children or adolescents, up to one-third are aged 20 years or older. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      TGDCs usually present as a nontender mass within 2 cm of the midline, but can be more lateral. The typical cyst maintains a close relationship to the hyoid, thyrohyoid membrane, or thyroid cartilage. Classically, TGDCs move with swallowing or protrusion of the tongue. Most TGDCs have some degree of infection or inflammation at presentation. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Differential diagnosis includes dermoid cysts, sebaceous cysts, and thyroid ectopia. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      CT of the neck with contrast and ultrasonography are the preferred imaging modalities. (See",
"      <a class=\"local\" href=\"#H3174754\">",
"       'Imaging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with TGDCs should be treated surgically unless the patient is not a surgical candidate. Surgery should be avoided during the acute inflammation phase, as this can lead to recurrence. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Surgery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Infection is the most common complication of TGDC. An infected TGDC typically presents as a tender mass, with or without fever, and may have a draining sinus; it should be managed initially with antibiotics, followed by definitive surgery once the infection has resolved. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Infected thyroglossal duct cyst'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The standard surgical treatment is resection of the cyst and the midportion of the hyoid bone in continuity and resection of a core of tissue from the hyoid upwards towards the foramen cecum, an operation known as the Sistrunk procedure. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Sistrunk procedure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with a TGDC often have ectopic thyroid glands. Some thyroid ectopia function normally, but approximately a third of patients present with hypothyroidism. Treatment with thyroid hormone supplementation is usually sufficient for suppression, but surgical excision may become necessary. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Thyroid ectopia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The preoperative detection of hypothyroidism in a patient with a midline neck mass increases the suspicion of ectopic thyroid tissue. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Association with hypothyroidism'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Ectopic thyroid tissue can be confused with a TGDC. All cases of thyroid ectopia should have thyroid function tests, ultrasonography, and a thyroid scan performed to locate additional functioning thyroid tissue. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Preoperative evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Before any surgery is planned, it is important to determine whether patients with a TGDC have thyroid tissue in the normal site or any ectopic thyroid tissue, as this can be involved with benign or malignant thyroid disease. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Preoperative evaluation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25864/abstract/1\">",
"      Brown RL, Azizkhan RG. Pediatric head and neck lesions. Pediatr Clin North Am 1998; 45:889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25864/abstract/2\">",
"      Allard RH. The thyroglossal cyst. Head Neck Surg 1982; 5:134.",
"     </a>",
"    </li>",
"    <li>",
"     Livolsi, V. Surgical Pathology of the Thyroid Gland, WB Saunders, Philadelphia 1990.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25864/abstract/4\">",
"      Noyek AM, Friedberg J. Thyroglossal duct and ectopic thyroid disorders. Otolaryngol Clin North Am 1981; 14:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25864/abstract/5\">",
"      Ellis PD, van Nostrand AW. The applied anatomy of thyroglossal tract remnants. Laryngoscope 1977; 87:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25864/abstract/6\">",
"      Chon SH, Shinn SH, Lee CB, et al. Thyroglossal duct cyst within the mediastinum: an extremely unusual location. J Thorac Cardiovasc Surg 2007; 133:1671.",
"     </a>",
"    </li>",
"    <li>",
"     Congenital lesions: Thyroglossal duct cysts and branchial cleft anomalies. In: Masters of Surgery, 3, Little Brown, Boston 1997. p.383.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25864/abstract/8\">",
"      Slotnick D, Som PM, Giebfried J, Biller HF. Thyroglossal duct cysts that mimic laryngeal masses. Laryngoscope 1987; 97:742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25864/abstract/9\">",
"      Shaari CM, Ho BT, Som PM, Urken ML. Large thyroglossal duct cyst with laryngeal extension. Head Neck 1994; 16:586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25864/abstract/10\">",
"      Issa MM, deVries P. Familial occurrence of thyroglossal duct cyst. J Pediatr Surg 1991; 26:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25864/abstract/11\">",
"      Greinwald JH Jr, Leichtman LG, Simko EJ. Hereditary thyroglossal duct cysts. Arch Otolaryngol Head Neck Surg 1996; 122:1094.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25864/abstract/12\">",
"      Schader I, Robertson S, Maoate K, Beasley S. Hereditary thyroglossal duct cysts. Pediatr Surg Int 2005; 21:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25864/abstract/13\">",
"      Loh WS, Chong SM, Loh KS. Intralaryngeal thyroglossal duct cyst: implications for the migratory pathway of the thyroglossal duct. Ann Otol Rhinol Laryngol 2006; 115:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25864/abstract/14\">",
"      P&eacute;rez-Mart&iacute;nez A, Bento-Bravo L, Mart&iacute;nez-Bermejo MA, et al. An intra-thyroid thyroglossal duct cyst. Eur J Pediatr Surg 2005; 15:428.",
"     </a>",
"    </li>",
"    <li>",
"     Pediatric Otolaryngology, 4, Saunders, Philadelphia 2002. p.1738.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25864/abstract/16\">",
"      Di Benedetto V. Ectopic thyroid gland in the submandibular region simulating a thyroglossal duct cyst: a case report. J Pediatr Surg 1997; 32:1745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25864/abstract/17\">",
"      LiVolsi VA, Perzin KH, Savetsky L. Carcinoma arising in median ectopic thyroid (including thyroglossal duct tissue). Cancer 1974; 34:1303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25864/abstract/18\">",
"      Radkowski D, Arnold J, Healy GB, et al. Thyroglossal duct remnants. Preoperative evaluation and management. Arch Otolaryngol Head Neck Surg 1991; 117:1378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25864/abstract/19\">",
"      deMello DE, Lima JA, Liapis H. Midline cervical cysts in children. Thyroglossal anomalies. Arch Otolaryngol Head Neck Surg 1987; 113:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25864/abstract/20\">",
"      Massine RE, Durning SJ, Koroscil TM. Lingual thyroid carcinoma: a case report and review of the literature. Thyroid 2001; 11:1191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25864/abstract/21\">",
"      Leung AK. Ectopic thyroid gland and thyroxine-binding globulin excess. Acta Paediatr Scand 1986; 75:872.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25864/abstract/22\">",
"      Leung AK, Wong AL, Robson WL. Ectopic thyroid gland simulating a thyroglossal duct cyst: a case report. Can J Surg 1995; 38:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25864/abstract/23\">",
"      Conklin WT, Davis RM, Dabb RW, Reilly CM. Hypothyroidism following removal of a \"thyroglossal duct cyst\". Plast Reconstr Surg 1981; 68:930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25864/abstract/24\">",
"      Neinas FW, Gorman CA, Devine KD, Woolner LB. Lingual thyroid. Clinical characteristics of 15 cases. Ann Intern Med 1973; 79:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25864/abstract/25\">",
"      Ling L, Zhou SH, Wang SQ, Wang LJ. Misdiagnosed ectopic thyroid carcinoma: report of two cases. Chin Med J (Engl) 2004; 117:1588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25864/abstract/26\">",
"      Mussak EN, Kacker A. Surgical and medical management of midline ectopic thyroid. Otolaryngol Head Neck Surg 2007; 136:870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25864/abstract/27\">",
"      WOOLNER LB, BEAHRS OH, BLACK BM, et al. Classification and prognosis of thyroid carcinoma. A study of 885 cases observed in a thirty year period. Am J Surg 1961; 102:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25864/abstract/28\">",
"      WOOLNER LB, LEMMON ML, BEAHRS OH, et al. Occult papillary carcinoma of the thyroid gland: a study of 140 cases observed in a 30-year period. J Clin Endocrinol Metab 1960; 20:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25864/abstract/29\">",
"      Crile, G. Papillary carcinoma of the thyroid and lateral cervical region. Surg Gyn Obstet 1947; 85:757.",
"     </a>",
"    </li>",
"    <li>",
"     Henry JF. Surgical anatomy and embryology of the thyroid and parathyroid glands and recurrent laryngeal nerve. In: Textbook of Endocrine Surgery, WB Saunders, Philadelphia 1997.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25864/abstract/31\">",
"      Meyer JS, Steinberg LS. Microscopically benign thyroid follicles in cervical lymph nodes. Serial section study of lymph node inclusions and entire thyroid gland in 5 cases. Cancer 1969; 24:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25864/abstract/32\">",
"      Shahin A, Burroughs FH, Kirby JP, Ali SZ. Thyroglossal duct cyst: a cytopathologic study of 26 cases. Diagn Cytopathol 2005; 33:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25864/abstract/33\">",
"      Pinczower E, Crockett DM, Atkinson JB, Kun S. Preoperative thyroid scanning in presumed thyroglossal duct cysts. Arch Otolaryngol Head Neck Surg 1992; 118:985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25864/abstract/34\">",
"      Tunkel DE, Domenech EE. Radioisotope scanning of the thyroid gland prior to thyroglossal duct cyst excision. Arch Otolaryngol Head Neck Surg 1998; 124:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25864/abstract/35\">",
"      Gupta P, Maddalozzo J. Preoperative sonography in presumed thyroglossal duct cysts. Arch Otolaryngol Head Neck Surg 2001; 127:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25864/abstract/36\">",
"      Rosenberg TL, Brown JJ, Jefferson GD. Evaluating the adult patient with a neck mass. Med Clin North Am 2010; 94:1017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25864/abstract/37\">",
"      NUTTALL FQ. CYSTIC METASTASES FROM PAPILLARY ADENOCARCINOMA OF THE THYROID WITH COMMENTS CONCERNING CARCINOMA ASSOCIATED WITH THYROGLOSSAL REMNANTS. Am J Surg 1965; 109:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25864/abstract/38\">",
"      Heshmati HM, Fatourechi V, van Heerden JA, et al. Thyroglossal duct carcinoma: report of 12 cases. Mayo Clin Proc 1997; 72:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25864/abstract/39\">",
"      Joseph TJ, Komorowski RA. Thyroglossal duct carcinoma. Hum Pathol 1975; 6:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25864/abstract/40\">",
"      Page CP, Kemmerer WT, Haff RC, Mazzaferri EL. Thyroid carcinomas arising in thyroglossal ducts. Ann Surg 1974; 180:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25864/abstract/41\">",
"      Reede DL, Bergeron RT, Som PM. CT of thyroglossal duct cysts. Radiology 1985; 157:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25864/abstract/42\">",
"      Peretz A, Leiberman E, Kapelushnik J, Hershkovitz E. Thyroglossal duct carcinoma in children: case presentation and review of the literature. Thyroid 2004; 14:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25864/abstract/43\">",
"      Weiss SD, Orlich CC. Primary papillary carcinoma of a thyroglossal duct cyst: report of a case and literature review. Br J Surg 1991; 78:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25864/abstract/44\">",
"      Jaques DA, Chambers RG, Oertel JE. Thyroglossal tract carcinoma. A review of the literature and addition of eighteen cases. Am J Surg 1970; 120:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25864/abstract/45\">",
"      Plaza CP, L&oacute;pez ME, Carrasco CE, et al. Management of well-differentiated thyroglossal remnant thyroid carcinoma: time to close the debate? Report of five new cases and proposal of a definitive algorithm for treatment. Ann Surg Oncol 2006; 13:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25864/abstract/46\">",
"      Hans SS, Lee PT, Proctor B. Carcinoma arising in thyroglossal duct remnants. Am Surg 1976; 42:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25864/abstract/47\">",
"      Hartl DM, Al Ghuzlan A, Chami L, et al. High rate of multifocality and occult lymph node metastases in papillary thyroid carcinoma arising in thyroglossal duct cysts. Ann Surg Oncol 2009; 16:2595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25864/abstract/48\">",
"      Brereton RJ, Symonds E. Thyroglossal cysts in children. Br J Surg 1978; 65:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25864/abstract/49\">",
"      Ducic Y, Chou S, Drkulec J, et al. Recurrent thyroglossal duct cysts: a clinical and pathologic analysis. Int J Pediatr Otorhinolaryngol 1998; 44:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25864/abstract/50\">",
"      Flageole H, Laberge JM, Nguyen LT, et al. Reoperation for cysts of the thyroglossal duct. Can J Surg 1995; 38:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25864/abstract/51\">",
"      Kaselas Ch, Tsikopoulos G, Chortis Ch, Kaselas B. Thyroglossal duct cyst's inflammation. When do we operate? Pediatr Surg Int 2005; 21:991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25864/abstract/52\">",
"      Foley DS, Fallat ME. Thyroglossal duct and other congenital midline cervical anomalies. Semin Pediatr Surg 2006; 15:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25864/abstract/53\">",
"      Pollock WF, Stevenson EO. Cysts and sinuses of the thyroglossal duct. Am J Surg 1966; 112:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25864/abstract/54\">",
"      Al-Dajani N, Wootton SH. Cervical lymphadenitis, suppurative parotitis, thyroiditis, and infected cysts. Infect Dis Clin North Am 2007; 21:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25864/abstract/55\">",
"      Shepard GH, Rosenfeld L. Carcinoma of thyroglossal duct remnants. Review of the literature and addition of two cases. Am J Surg 1968; 116:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25864/abstract/56\">",
"      Trail ML, Zeringue GP, Chicola JP. Carcinoma in thyroglossal duct remnants. Laryngoscope 1977; 87:1685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25864/abstract/57\">",
"      Sistrunk WE. THE SURGICAL TREATMENT OF CYSTS OF THE THYROGLOSSAL TRACT. Ann Surg 1920; 71:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25864/abstract/58\">",
"      Hawkins DB, Jacobsen BE, Klatt EC. Cysts of the thyroglossal duct. Laryngoscope 1982; 92:1254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25864/abstract/59\">",
"      Patel NN, Hartley BE, Howard DJ. Management of thyroglossal tract disease after failed Sistrunk's procedure. J Laryngol Otol 2003; 117:710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25864/abstract/60\">",
"      Perkins JA, Inglis AF, Sie KC, Manning SC. Recurrent thyroglossal duct cysts: a 23-year experience and a new method for management. Ann Otol Rhinol Laryngol 2006; 115:850.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25864/abstract/61\">",
"      Topf P, Fried MP, Strome M. Vagaries of thyroglossal duct cysts. Laryngoscope 1988; 98:740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25864/abstract/62\">",
"      Falvo L, Giacomelli L, Vanni B, et al. Papillary thyroid carcinoma in thyroglossal duct cyst: case reports and literature review. Int Surg 2006; 91:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25864/abstract/63\">",
"      Chen KT. Cytology of thyroglossal cyst papillary carcinoma. Diagn Cytopathol 1993; 9:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25864/abstract/64\">",
"      Baskin HJ. Percutaneous ethanol injection of thyroglossal duct cysts. Endocr Pract 2006; 12:355.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2155 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.167.4.114-3ADB073D65-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_16_25864=[""].join("\n");
var outline_f25_16_25864=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EMBRYOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      THYROID ECTOPIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Association with hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Lingual thyroid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Lateral nonmalignant thyroid tissue",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Exophytic and paracytic nodules",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Fine needle aspiration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3174754\">",
"      IMAGING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19294504\">",
"      CT imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19294511\">",
"      Ultrasonography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      CARCINOMA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      INFECTED THYROGLOSSAL DUCT CYST",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Microbiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Antibiotics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SURGERY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Preoperative evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Sistrunk procedure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SCLEROTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/2155\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/2155|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?6/21/6484\" title=\"diagnostic image 1\">",
"      CT imaging thyroglossal duct cyst",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/2155|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?8/48/8961\" title=\"figure 1\">",
"      Thyroglossal duct remnant",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?11/26/11683\" title=\"figure 2\">",
"      TGDC excision",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/2155|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/19/13628\" title=\"table 1\">",
"      Antimicrobial prophylaxis for head and neck surgery",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/7/26744?source=related_link\">",
"      Diagnosis of and screening for hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/33/3608?source=related_link\">",
"      Laboratory assessment of thyroid function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/35/31290?source=related_link\">",
"      Overview of control measures to prevent surgical site infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/62/21482?source=related_link\">",
"      Overview of the clinical utility of ultrasonography in thyroid disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/17/44313?source=related_link\">",
"      Overview of the management of differentiated thyroid cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/7/4216?source=related_link\">",
"      Treatment of skin and soft tissue infections due to methicillin-resistant Staphylococcus aureus in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_16_25865="Severe pelvic fracture in the adult trauma patient";
var content_f25_16_25865=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Severe pelvic fracture in the adult trauma patient",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/16/25865/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/16/25865/contributors\">",
"     Clay Cothren Burlew, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/16/25865/contributors\">",
"     Ernest E Moore, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/16/25865/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/16/25865/contributors\">",
"     Heidi L Frankel, MD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/16/25865/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/16/25865/contributors\">",
"     Kathryn A Collins, MD, PhD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?25/16/25865/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 22, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H293633624\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with severe pelvic fractures present many challenges for the trauma team. Pelvic injuries often occur in conjunction with other life-threatening injuries, and there is not universal agreement on all aspects of management. Following initial resuscitation, current management algorithms in the United States incorporate variable timeframes for bony stabilization and hemorrhage control using preperitoneal pelvic packing or angioembolization. We suggest early fixation and pelvic packing for hemodynamically unstable patients, reserving angioembolization for noncoagulopathic patients who continue to bleed from a pelvic source in spite of pelvic packing. The management of severe pelvic fractures is optimized using a multidisciplinary approach involving the trauma surgeon, orthopedic surgeon, vascular interventionalist, anesthesiologist, and the transfusion services. &nbsp; &nbsp;",
"   </p>",
"   <p>",
"    Methods to treat severe pelvic fractures, including controlling ongoing hemorrhage, are reviewed here. The diagnosis and initial trauma management of patients with pelvic fractures are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/7/22650?source=see_link\">",
"     \"Pelvic trauma: Initial evaluation and management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1329894718\">",
"    <span class=\"h1\">",
"     ANATOMIC CONSIDERATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Blunt injury to the pelvis can produce complex fractures that often result in moderate to severe hemorrhage. The Young and Burgess classification uses the force vector to categorize pelvic fractures as due to lateral compression (LC),",
"    <span class=\"nowrap\">",
"     anterior/posterior",
"    </span>",
"    compression (APC), or vertical shear (VS) (",
"    <a class=\"graphic graphic_figure graphicRef81214 \" href=\"UTD.htm?26/40/27268\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef55023 \" href=\"UTD.htm?37/61/38875\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25865/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Within each category, the amount of ligamentous injury, bony fracture, and overall displacement of the hemipelvis further categorizes the patient's pelvic injury from type I (less severe) to type III (most severe). However, a patient's fracture pattern may not adhere to a single category; a combination of LC, APC, and VS may be present. Higher grades, particularly APC and VS, are more commonly associated with hemodynamic instability and the need for transfusion and intervention. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/7/22650?source=see_link&amp;anchor=H7#H7\">",
"     \"Pelvic trauma: Initial evaluation and management\", section on 'Fracture types'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pelvic fractures can also be described as biomechanically stable or unstable within the Academy of",
"    <span class=\"nowrap\">",
"     Orthopedics/Orthopedic",
"    </span>",
"    Trauma Association classification system [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25865/abstract/3\">",
"     3",
"    </a>",
"    ]. Unstable pelvic fractures require two or more breaks in the pelvic ring. It is important to note that biomechanical instability of the pelvic fracture does not necessarily imply hemodynamic stability. The fracture components and ligamentous instability may result in a rotationally unstable (partially stable pelvis, type B) or a rotationally and vertically unstable (completely unstable, type C) pelvis (",
"    <a class=\"graphic graphic_figure graphicRef76038 \" href=\"UTD.htm?31/20/32066\">",
"     figure 2",
"    </a>",
"    ). Generally, APC I and II, and LC I, II, and III injuries are considered rotationally unstable while APC III, VS, and combined injuries are both rotationally and vertically unstable.",
"   </p>",
"   <p>",
"    Fractures that create soft tissue defects are termed &ldquo;open&rdquo; fractures; however, the break can occur in the rectum, vagina, or skin and these associated injuries complicate management. (See",
"    <a class=\"local\" href=\"#H255194905\">",
"     'Management of associated soft tissue injury'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Movement of the bony surfaces of the pelvic bones can lead to shearing and avulsion of the pelvic vasculature (",
"    <a class=\"graphic graphic_figure graphicRef60420 \" href=\"UTD.htm?39/52/40777\">",
"     figure 3",
"    </a>",
"    ). The veins of the presacral pelvic plexus are particularly vulnerable. Greater than 85 percent of bleeding due to pelvic fractures is venous or from the open surfaces of the bone [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25865/abstract/4\">",
"     4",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H293633879\">",
"    <span class=\"h1\">",
"     TRAUMA EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;We perform initial resuscitation, diagnostic evaluation, and management of the trauma patient with blunt or penetrating trauma based upon protocols from the Advanced Trauma Life Support (ATLS) program, established by the American College of Surgeons Committee on Trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25865/abstract/5\">",
"     5",
"    </a>",
"    ]. The initial resuscitation and evaluation of the patient with blunt or penetrating abdominal or thoracic trauma is discussed in detail elsewhere.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/11/35002?source=see_link\">",
"       \"Initial management of trauma in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/39/34426?source=see_link\">",
"       \"Initial evaluation and management of blunt thoracic trauma in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/5/19545?source=see_link\">",
"       \"Initial evaluation and management of blunt abdominal trauma in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Severe pelvic fractures are life-threatening injuries. Blood pressure and pulses should be monitored closely. A systolic blood pressure &lt;90 mmHg in adults is assumed to be due to hemorrhage until proven otherwise, and a diagnosis of pelvic fracture as a cause of hemodynamic instability should trigger resuscitation using a massive transfusion protocol. Traumatic coagulopathy will exacerbate bleeding, and a diagnosis should be actively sought. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/55/29562?source=see_link\">",
"     \"Initial evaluation and management of shock in adult trauma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/25/38294?source=see_link\">",
"     \"Massive blood transfusion\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/44/23242?source=see_link\">",
"     \"Coagulopathy associated with trauma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pelvic fracture as the primary source of hemodynamic instability should be quickly differentiated from other life-threatening injuries such as hemothorax, cardiac tamponade, or hemoperitoneum, using chest radiograph, pelvic radiograph, and Focused Abdominal Sonography for Trauma (FAST). Identifying associated injuries is important, since these may impact management [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25865/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H293634561\">",
"     'Fracture-related injuries'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    If the patient's primary source of bleeding is due to the pelvic fracture, temporary external stabilization with a sheet or binder is relatively simple to accomplish. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/7/22650?source=see_link&amp;anchor=H25#H25\">",
"     \"Pelvic trauma: Initial evaluation and management\", section on 'Initial stabilization and approach'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H113250380\">",
"     'Fracture stabilization'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H293634722\">",
"    <span class=\"h2\">",
"     History and physical",
"    </span>",
"    &nbsp;&mdash;&nbsp;Injured patients complaining of pelvic pain or tenderness to pelvic palpation are assumed to have a pelvic fracture, until proven otherwise. About 80 percent of pelvic fractures can be detected on clinical examination [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25865/abstract/8\">",
"     8",
"    </a>",
"    ]. Overlying abrasions or contusions are commonly seen. Patients who cannot relate pain, such as patients who are intubated or those with altered mental status, should undergo computed tomography (CT) of the pelvis. The initial approach to the diagnosis and resuscitation in patients with pelvic fractures in the emergency department is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/7/22650?source=see_link&amp;anchor=H13#H13\">",
"     \"Pelvic trauma: Initial evaluation and management\", section on 'Clinical features'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although formerly used as a technique on clinical exam to identify pelvic instability, &ldquo;rocking&rdquo; the pelvis by pressing down on the iliac crest from front to back and side to side should",
"    <strong>",
"     not",
"    </strong>",
"    be used because it risks disrupting any pelvic hematoma that has formed, potentially &ldquo;re-opening&rdquo; an unstable pelvis, and increases the risk for further vascular injury.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H293634729\">",
"    <span class=\"h2\">",
"     FAST scan",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Focused Assessment with Sonography in Trauma (FAST) scan is frequently used in the initial evaluation of abdominal trauma. Although the FAST exam is available in most major trauma centers, diagnostic peritoneal lavage (DPL) or aspiration (DPA) may be needed [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25865/abstract/9-13\">",
"     9-13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/11/35002?source=see_link&amp;anchor=H11715769#H11715769\">",
"     \"Initial management of trauma in adults\", section on 'Ultrasound (FAST exam)'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/11/35002?source=see_link&amp;anchor=H11715837#H11715837\">",
"     \"Initial management of trauma in adults\", section on 'Diagnostic peritoneal tap or lavage'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hemodynamically unstable patients with a positive FAST scan should be taken emergently for exploratory surgery to identify and control intraabdominal bleeding. (See",
"    <a class=\"local\" href=\"#H255195485\">",
"     'Management'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H293634736\">",
"    <span class=\"h2\">",
"     Pelvic imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pelvic imaging, either with plain films or computed tomography (CT), is relied upon to identify bony disruptions and classify the pelvic fracture [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25865/abstract/14-18\">",
"     14-18",
"    </a>",
"    ]. The initial diagnostic approach to pelvic fracture is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/7/22650?source=see_link&amp;anchor=H18#H18\">",
"     \"Pelvic trauma: Initial evaluation and management\", section on 'Diagnostic tests'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In hemodynamically unstable patients, CT evaluation of the pelvic fracture should be deferred. Transport of the hypotensive patient is potentially unsafe because ongoing monitoring and management of acute hemodynamic decompensation may be compromised. Hemodynamically stable patients undergoing further imaging should be accompanied by a senior member of the trauma team who should be prepared to abort the study and transport the patient directly to the operating room if the patient becomes hemodynamically unstable.",
"   </p>",
"   <p>",
"    CT scanning, particularly with three-dimensional reconstruction, is useful for planning definitive fracture repair by defining the geometry of the pelvic fracture, identifying occult fractures not seen on plain film, quantifying pelvic displacement, and evaluating the integrity of the ligaments. Pelvic bleeding may also be seen as contrast extravasation, but this finding should not be used in isolation as an indication for arteriography [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25865/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H255195485\">",
"     'Management'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H293634561\">",
"    <span class=\"h2\">",
"     Fracture-related injuries",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pelvic injury is indicative of a high energy trauma and patients with pelvic fractures frequently have severe associated injuries [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25865/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. In one retrospective review of 3576 patients with pelvic fracture, 21 percent had chest trauma, 17 percent had head injuries, 8 percent had injuries of the liver or spleen and 8 percent had &ge;2 long bone fractures [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25865/abstract/6\">",
"     6",
"    </a>",
"    ]. The mean injury severity score (ISS) for patients with severe pelvic fracture was 18, with no significant differences in ISS between rotationally unstable, vertically unstable, or combined injuries [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25865/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H1329894718\">",
"     'Anatomic considerations'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The clinical evaluation may identify injuries that are directly related to bony fracture. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Urethral injuries &ndash; Urethral injury is suggested by the presence of blood at the meatus, or",
"      <span class=\"nowrap\">",
"       scrotal/perineal",
"      </span>",
"      bruising. The rectal exam in males may also reveal a high-riding prostate. Some patients with urethral injury may require a suprapubic catheter which can be placed percutaneously or surgically. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/47/40697?source=see_link&amp;anchor=H21#H21\">",
"       \"Placement and management of urinary bladder catheters\", section on 'Suprapubic catheter placement'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Bladder rupture &ndash; Gross hematuria is a sign of bladder rupture which is commonly associated with severe pelvic fractures.",
"     </li>",
"     <li>",
"      Iliac vessel injury &ndash; Although rare, a stretch injury of the external iliac artery as it passes over the pelvic brim may result in an intimal tear which may cause arterial thrombosis and lower extremity ischemia [",
"      <a class=\"abstract\" href=\"UTD.htm?25/16/25865/abstract/23,24\">",
"       23,24",
"      </a>",
"      ]. In addition to routine palpation of the extremity pulses, ankle-brachial indices (ABIs) should be obtained bilaterally. Significant differences (&gt;0.20) in the index values between the extremities may indicate injury on the side with the lower ABI. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/16/10506?source=see_link&amp;anchor=H58544655#H58544655\">",
"       \"Noninvasive diagnosis of arterial disease\", section on 'Ankle-brachial index'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/3/13368?source=see_link\">",
"       \"Acute arterial occlusion of the lower extremities (acute limb ischemia)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Rectal injury &ndash; All patients with a pelvic fracture should undergo digital rectal examination to evaluate for the presence of blood or bony spicules indicative of rectal perforation [",
"      <a class=\"abstract\" href=\"UTD.htm?25/16/25865/abstract/25\">",
"       25",
"      </a>",
"      ]. Patients with a suspected rectal injury should undergo an exam under anesthesia in the operating room with sigmoidoscopy to definitively exclude a rectal injury.",
"     </li>",
"     <li>",
"      Vaginal injury &ndash; Vaginal examination with a speculum should be performed in women with pelvic fractures to exclude an open fracture. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/2/44071?source=see_link\">",
"       \"Evaluation and management of lower genital tract trauma in women\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Perineal injury &ndash; The perineum should be inspected for external lacerations that communicate with the pelvic fracture (ie, an open pelvic fracture). (See",
"      <a class=\"local\" href=\"#H255194905\">",
"       'Management of associated soft tissue injury'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Nerve injury &ndash; A sensory and motor examination of the lower extremities should be performed to identify any deficits that may be due to an associated spine injury or nerve root avulsion. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/45/23257?source=see_link&amp;anchor=H19#H19\">",
"       \"Lumbosacral plexus syndromes\", section on 'Trauma'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/11/26810?source=see_link\">",
"       \"Acute traumatic spinal cord injury\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H255195485\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of severe pelvic fracture involves control of retroperitoneal bleeding using external fracture stabilization combined with retroperitoneal pelvic packing or angioembolization. Following an interval of ongoing resuscitation and management of other urgent injuries, internal fracture fixation should be performed, when indicated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42517110\">",
"    <span class=\"h2\">",
"     General approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemodynamically unstable patients with indications for surgery (eg, positive FAST scan) should be taken directly to the operating room to identify and manage hemorrhage (",
"    <a class=\"graphic graphic_algorithm graphicRef74206 \" href=\"UTD.htm?24/40/25230\">",
"     algorithm 1",
"    </a>",
"    ). If bleeding in the thorax or abdomen is under control and the patient is hemodynamically stable, the pelvic fracture can be stabilized using an external fixation device. If ongoing hemodynamic instability is thought to be due to retroperitoneal bleeding from the pelvic fracture, then, in addition to external fixation, we suggest preperitoneal pelvic packing. Alternatively, in an appropriately equipped operating room, intraoperative angiography and embolization may be an option. (See",
"    <a class=\"local\" href=\"#H113250380\">",
"     'Fracture stabilization'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Although there are no direct comparisons, based upon observational studies evaluating each therapy, combined with our clinical experience, we suggest operative control with preperitoneal pelvic packing rather than angioembolization to tamponade bleeding in hemodynamically unstable patients, reserving angioembolization for the few patients who demonstrate persistent bleeding in spite of these maneuvers [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25865/abstract/26-30\">",
"     26-30",
"    </a>",
"    ]. A minority of patients who undergo arteriography have a lesion that is amenable to embolization, and arteriography does not address the potentially severe venous bleeding that is the source in more than 85 percent of patients who have lethal pelvic injuries [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25865/abstract/4,27,28,31,32\">",
"     4,27,28,31,32",
"    </a>",
"    ]. Predicting who might benefit from emergent angioembolization remains a challenge [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25865/abstract/33\">",
"     33",
"    </a>",
"    ]. Management in the operating room also allows examination of the rectum and vagina under anesthesia, and washout of any open wounds.",
"   </p>",
"   <p>",
"    For patients who are responsive to fluid resuscitation and without other urgent indications for surgery, either preperitoneal pelvic packing or angioembolization is appropriate [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25865/abstract/29,30,34-39\">",
"     29,30,34-39",
"    </a>",
"    ]. The use of arteriography and angioembolization to control retroperitoneal bleeding depends upon ready availability of a vascular interventionalist, support staff, and appropriate equipment and supplies associated with the procedure. (See",
"    <a class=\"local\" href=\"#H1329894754\">",
"     'Arteriography and angioembolization'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H113250380\">",
"    <span class=\"h2\">",
"     Fracture stabilization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fracture stabilization decreases pelvic volume, promotes tamponade of venous bleeding, and prevents shifting of the bony elements which can lead to secondary hemorrhage. Prompt external fracture stabilization is an important step in the initial management of the hemodynamically unstable patient with pelvic fractures. Definitive fracture stabilization can be accomplished with external or internal fixation.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      External stabilization &ndash; For patients who are hemodynamically unstable, immediate fixation may be needed, which can be performed by wrapping a sheet around the pelvis (",
"      <a class=\"graphic graphic_picture graphicRef62544 \" href=\"UTD.htm?19/31/19958\">",
"       picture 1",
"      </a>",
"      ), using a commercially-available binder, or placing an external frame. Although the sheet or binder helps to realign the pelvis and is ideal for &ldquo;open book&rdquo; pelvic fracture, temporary stabilization does not improve pelvic alignment if the posterior elements are completely disrupted. Other disadvantages of binders are the potential for abdominal compartment syndrome, and necrosis of the skin overlying bony prominences [",
"      <a class=\"abstract\" href=\"UTD.htm?25/16/25865/abstract/40\">",
"       40",
"      </a>",
"      ]. Thus, if a sheet or binder has been placed, it is important that it is replaced with an external frame as soon as possible [",
"      <a class=\"abstract\" href=\"UTD.htm?25/16/25865/abstract/5,15,29,41-44\">",
"       5,15,29,41-44",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/7/22650?source=see_link&amp;anchor=H25#H25\">",
"       \"Pelvic trauma: Initial evaluation and management\", section on 'Initial stabilization and approach'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      External fixation &ndash; External frames (anterior external fixator or posterior pelvic C-clamp) can be placed in the emergency department or operating room and are usually placed by an orthopedic surgeon, but, occasionally, placement by the trauma surgeon may be needed. The external frame, particularly the C-clamp, also allows operative access to the abdomen and pelvis. Once the frame is in place, it may serve as definitive fixation (ie, six to eight weeks) or removed once the fracture is internally stabilized.",
"     </li>",
"     <li>",
"      Internal fracture fixation &ndash; The decision for and timing of internal fixation is highly individualized, depending upon the nature of the pelvic fracture, the presence and severity of associated injuries and the patient&rsquo;s medical comorbidities, which may limit the timing or ability to return to the operating room. Definitive open reduction and internal fixation (ORIF) is often performed within 10 days of injury, but for some patients, particularly those with other major associated thoracic or abdominal injuries, definitive treatment of the pelvic fracture may be accomplished by external fixation alone.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H255193898\">",
"    <span class=\"h2\">",
"     Preperitoneal pelvic packing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preperitoneal pelvic packing refers to a surgical procedure in which laparotomy sponges are placed into the preperitoneal space to tamponade bleeding and reduce the available volume of the retroperitoneal space [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25865/abstract/45-47\">",
"     45-47",
"    </a>",
"    ]. In the hemodynamically unstable patient, we suggest preperitoneal pelvic packing for controlling hemorrhage from severe pelvic fractures, rather than angioembolization. External fixation of the pelvis can be performed concurrently with preperitoneal pelvic packing. (See",
"    <a class=\"local\" href=\"#H113250380\">",
"     'Fracture stabilization'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Preperitoneal pelvic packing is performed through a small suprapubic incision. Six laparotomy pads (four in children) are placed directly into the space around the bladder (",
"    <a class=\"graphic graphic_figure graphicRef63131 \" href=\"UTD.htm?28/45/29399\">",
"     figure 4",
"    </a>",
"    ). The original technique described for control of retroperitoneal bleeding consisted of transabdominal (transperitoneal) packing of the retroperitoneum for hemorrhage control; however, sufficient tamponade was difficult to achieve [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25865/abstract/30,47\">",
"     30,47",
"    </a>",
"    ], and thus, this technique was modified to directly pack the pelvic space through a preperitoneal approach [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25865/abstract/45,48\">",
"     45,48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pelvic packing is removed typically within 48 hours; however, on occasion, repacking may be needed if there is persistent bleeding at the second-look operation.",
"    <strong>",
"    </strong>",
"    Approximately 15 percent of patients with severe pelvic fractures will have ongoing transfusion requirements despite correction of coagulopathy after preperitoneal packing [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25865/abstract/30\">",
"     30",
"    </a>",
"    ]. Persistent bleeding may indicate the need for arteriography to identify the source.",
"   </p>",
"   <p>",
"    Preperitoneal pelvic packing can lead to infectious complications, which may affect the timing and choice of definitive stabilization. In a review that evaluated 75 patients who underwent preperitoneal pelvic packing for pelvic fracture, pelvic space infection occurred in 15 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25865/abstract/26\">",
"     26",
"    </a>",
"    ]. The majority occurred in patients with open fracture associated",
"    <span class=\"nowrap\">",
"     bowel/bladder",
"    </span>",
"    injuries.&nbsp;A significantly lower rate of pelvic space infection was found in those patients who were packed only once (6 versus 47 percent) compared with those who underwent more than one packing procedure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1329894754\">",
"    <span class=\"h2\">",
"     Arteriography and angioembolization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Angioembolization is a technique in which bleeding sites are controlled by using intraarterial catheters to selectively place thrombotic agents into branches of the internal iliac arteries that are feeding the area of bleeding. Advocates of emergent angioembolization (hemodynamically unstable patients) have argued that the technique can be safe in selected patients and effective in controlling pelvic arterial hemorrhage [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25865/abstract/29,49,50\">",
"     29,49,50",
"    </a>",
"    ]. The technique is less successful if bleeding is of venous origin or from the raw surfaces of the disrupted bone.",
"   </p>",
"   <p>",
"    The reported indications for arteriography have included low blood pressure in spite of red blood cell transfusion, large retroperitoneal hematoma, and active contrast extravasation indicative of arterial bleeding on computed tomography of the pelvis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25865/abstract/29,34-39\">",
"     29,34-39",
"    </a>",
"    ]. Numerous authors have sought to predict mortality and the need for arteriography based upon fracture classification and physiologic criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25865/abstract/29,34,50-52\">",
"     29,34,50-52",
"    </a>",
"    ]. In general, type II and III pelvic fractures are at a greater risk for arterial hemorrhage. However, predicting who would or would not benefit from angioembolization remains difficult [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25865/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    At the time of diagnostic arteriography, the entire pelvic vasculature must be evaluated because multiple sites of hemorrhage are common in complex pelvic fractures [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25865/abstract/53\">",
"     53",
"    </a>",
"    ]. Ideally, selective embolization at a targeted site of bleeding is performed using",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/4/18499?source=see_link\">",
"     absorbable gelatin",
"    </a>",
"    . However, if the patient's bleeding is severe and not localized, nonselective embolization of the internal iliac artery and possibly bilateral internal iliac embolization can be used; however, nonselective embolization increases the risk for complications such as gluteal claudication, pelvic ischemia, and tissue necrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25865/abstract/54-56\">",
"     54-56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H255194905\">",
"    <span class=\"h2\">",
"     Management of associated soft tissue injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the challenges faced with complex pelvic fractures, patients with open pelvic fractures often require management of extensive soft tissue destruction.",
"   </p>",
"   <p>",
"    On examination, external lacerations should be inspected to determine if there is a communication with the pelvic fracture (ie, an open pelvic fracture). Larger defects such as perineal degloving are obvious (",
"    <a class=\"graphic graphic_picture graphicRef53235 \" href=\"UTD.htm?20/6/20577\">",
"     picture 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    During the initial evaluation in the emergency department, large degloving injuries of the perineum should be packed through the skin opening and taken to the operating room. Local exploration of the wound in the emergency department should",
"    <strong>",
"     not",
"    </strong>",
"    be done. Rapid exsanguination can occur due to loss of tamponade by violating the retroperitoneal space.",
"   </p>",
"   <p>",
"    Associated injuries to the vagina and rectum should be ruled out with a speculum exam and sigmoidoscopy, respectively. In patients with external wounds due to the pelvic fracture, bleeding should be controlled first, and then the examination is performed.",
"   </p>",
"   <p>",
"    Soft tissue wounds should be surgically debrided and irrigated to remove bony fragments and other foreign materials. The wound can be left to heal by secondary intention. Negative pressure wound therapy is a useful adjunct to control drainage and reduce the size of the defect. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/63/27642?source=see_link\">",
"     \"Basic principles of wound management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/41/26264?source=see_link\">",
"     \"Negative pressure wound therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    To reduce potential contamination of the open pelvic or perineal wounds, which can lead to pelvic sepsis and osteomyelitis, a temporary diverting sigmoid colostomy is typically performed once the patient is hemodynamically stabile [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25865/abstract/57,58\">",
"     57,58",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/12/28873?source=see_link\">",
"     \"Surgical principles of ostomy construction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1329894775\">",
"    <span class=\"h1\">",
"     RESUSCITATION AND CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The period of acute resuscitation typically encompasses the first 12 hours following injury and combines several key principles including optimization of tissue perfusion, restoring normothermia, and restoring normal coagulation parameters. Early optimization determines when the patient can return to the operating room to replace pelvic packing or definitively manage other injuries that were previously handled using damage control techniques. Specific goals of resuscitation include a base deficit &lt;6, normal coagulation indices, and a core temperature &gt;37&ordm; C. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/55/29562?source=see_link\">",
"     \"Initial evaluation and management of shock in adult trauma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Fluid management algorithms are aimed at restoring tissue perfusion and reducing the base deficit. The resuscitation of injured patients with pelvic fractures may require infusion volumes of 10 L during the initial resuscitative phase to attain an adequate preload. Although early colloid administration is appealing, evidence to date does not support this concept in patients who do not demonstrate acute traumatic coagulopathy. Managing crystalloid volume remains a challenging aspect of early care, balancing optimal cardiac performance against excessive tissue edema which can contribute to pulmonary edema, abdominal compartment syndrome, and poor wound healing. A goal-directed resuscitation approach consisting of initial volume loading to attain adequate preload, followed by the judicious use of inotropic agents or vasopressors can be used to limit the amount of crystalloid administered to the patient [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25865/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although the optimal hemoglobin (Hg) level remains debated, we prefer to maintain the Hg &gt;10",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    to optimize oxygen delivery during the initial resuscitation phase. Thereafter, transfusion for Hg &lt;7",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    (euvolemic patient) limits the adverse inflammatory effects of stored RBCs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/52/5961?source=see_link\">",
"     \"Indications for red cell transfusion in the adult\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/25/38294?source=see_link\">",
"     \"Massive blood transfusion\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Invasive monitoring using pulmonary artery catheters remains controversial; however, the added information (eg, cardiac function, metabolic status, peripheral tone), may be useful in managing multiply-injured patients who require advanced inotropic support. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/62/6120?source=see_link&amp;anchor=H23#H23\">",
"     \"Shock in adults: Types, presentation, and diagnostic approach\", section on 'Pulmonary artery catheterization'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/10/44199?source=see_link\">",
"     \"Pulmonary artery catheterization: Interpretation of tracings\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H108725406\">",
"    <span class=\"h2\">",
"     Abdominal compartment syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Retroperitoneal hemorrhage increases the risk for abdominal compartment syndrome (ACS) due to a volume effect from retroperitoneal bleeding. In addition, secondary tissue edema from crystalloid fluid resuscitation may be superimposed. Patients with severe pelvic fractures should be monitored for ACS and treated, as indicated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/17/20761?source=see_link\">",
"     \"Abdominal compartment syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When operative decompression is needed, a variety of techniques can be used to provide temporary abdominal closure. The diagnosis and management of abdominal compartment syndrome is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/4/1097?source=see_link\">",
"     \"Management of the open abdomen in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/41/26264?source=see_link&amp;anchor=H18#H18\">",
"     \"Negative pressure wound therapy\", section on 'Open abdomen'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H108725425\">",
"    <span class=\"h2\">",
"     Deep vein thrombosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with severe pelvic fractures requiring surgical fixation have multiple risk factors for deep venous thromboembolism including the presence of multiple fractures of the pelvis and lower extremities, decreased venous blood flow in the lower extremities (immobility, paralysis). Following injury, pulmonary embolus can occur very early in the patient's hospital course [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25865/abstract/60\">",
"     60",
"    </a>",
"    ]. Patients should receive prophylaxis (mechanical and pharmacologic) for deep vein thrombosis, unless contraindicated. &nbsp;(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/52/41802?source=see_link&amp;anchor=H38#H38\">",
"     \"Prevention of venous thromboembolic disease in surgical patients\", section on 'High risk general and abdominal-pelvic surgery patients'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/52/41802?source=see_link&amp;anchor=H27#H27\">",
"     \"Prevention of venous thromboembolic disease in surgical patients\", section on 'Intermittent pneumatic compression'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients with complex pelvic fractures or other injuries that contradict pharmacologic prophylaxis, a removable inferior vena cava filter is an alternative. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/28/16840?source=see_link\">",
"     \"Placement of inferior vena cava filters and their complications\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1329894782\">",
"    <span class=\"h1\">",
"     MORTALITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mortality associated with severe pelvic fractures ranges from 8 to 40 percent and depends upon the presence of associated injuries and the severity of the pelvic fracture. In spite of appropriate multidisciplinary management, mortality for patients with severe pelvic fractures who present in shock remains &gt;40 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25865/abstract/21,51,57,61-65\">",
"     21,51,57,61-65",
"    </a>",
"    ]. These higher mortality rates reflect, in part, the other injuries associated with the pelvic fracture. Injury severity score, not the type of pelvic instability, is the most important predictor of mortality in patients with pelvic fracture [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25865/abstract/7,51,61\">",
"     7,51,61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Early mortality (&lt;24 hours) is often from inability to control hemorrhage. About one-third of patients die as a result of hemorrhage [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25865/abstract/7,22,66,67\">",
"     7,22,66,67",
"    </a>",
"    ]. Late mortality is related to associated injuries (eg, traumatic brain injury) or sepsis-induced multiple organ failure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    Basics topic (see",
"    <a class=\"medical medical_basics\" href=\"UTD.htm?5/21/5459?source=see_link\">",
"     \"Patient information: Pelvic fracture (The Basics)\"",
"    </a>",
"    )",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H293634174\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Injury to the bony pelvis is indicative of a high energy trauma and patients with severe pelvic fractures frequently have associated injuries, which may be remote from or directly related to the pelvic fracture. Directly associated injuries include bladder injury, urethral injury, spinal injury, vascular injury, rectal injury and vaginal injury. Mortality in patients with severe pelvic fractures ranges from 8 to 40 percent and is correlated more to the injury severity score, which reflects these associated injuries, rather than to the type of pelvic fracture. (See",
"      <a class=\"local\" href=\"#H293634561\">",
"       'Fracture-related injuries'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1329894782\">",
"       'Mortality'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pelvic fractures can be described as mechanically stable or unstable. Two or more breaks in the pelvic ring are needed to create an unstable pelvic fracture. Pelvic fractures are classified as rotationally unstable, vertically unstable, or both. The hemodynamic status of the patient is not necessarily related to the type of mechanical stability of the pelvis. Fractures that create soft tissue defects are termed &ldquo;open&rdquo; fractures, and associated injuries complicate management. (See",
"      <a class=\"local\" href=\"#H1329894718\">",
"       'Anatomic considerations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hemodynamically unstable patients with pelvic fracture and indications for surgery (eg, positive FAST scan) should be taken directly to the operating room to identify and manage the source of hemorrhage, which may be intrathoracic, intraabdominal, or due to the pelvic fracture (",
"      <a class=\"graphic graphic_algorithm graphicRef74206 \" href=\"UTD.htm?24/40/25230\">",
"       algorithm 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H42517110\">",
"       'General approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients in whom hemodynamic instability is thought to be due to retroperitoneal bleeding from the pelvic fracture, we suggest operative control of hemorrhage using external fracture fixation plus preperitoneal pelvic packing to tamponade bleeding, rather than external pelvic fracture fixation plus arteriography and angioembolization (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The majority of severe bleeding due to pelvic fractures is venous in origin and only a small percentage of patients will have a bleeding site that is amenable to embolization. Fracture fixation decreases pelvic volume, promotes tamponade of venous bleeding, and prevents shifting of the bony elements limiting secondary hemorrhage. Preperitoneal pelvic packing involves the placement of laparotomy sponges into the preperitoneal space via an incision, which reduces the available volume of the retroperitoneal space and tamponades pelvic bleeding. (See",
"      <a class=\"local\" href=\"#H113250380\">",
"       'Fracture stabilization'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H255193898\">",
"       'Preperitoneal pelvic packing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Angioembolization may be an option to control pelvic arterial hemorrhage from pelvic fracture under certain circumstances. These include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Patients who have evidence for postoperative bleeding following external fracture fixation and preperitoneal pelvic packing.",
"     </li>",
"     <li>",
"      Patients who are hemodynamically stable but demonstrate evidence for ongoing bleeding that cannot be attributed to another source.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If arteriography identifies arterial bleeding, selective arterial embolization should be performed to minimize the potential for tissue ischemia or necrosis, rather than performing nonselective embolization, whenever possible. (See",
"      <a class=\"local\" href=\"#H1329894754\">",
"       'Arteriography and angioembolization'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Following an interval of ongoing resuscitation and management of other urgent injuries, the decision for and timing of internal fixation is highly individualized, depending upon the nature of the pelvic fracture, the presence and severity of associated injuries, and the patient&rsquo;s medical comorbidities. For some patients, definitive treatment of the pelvic fracture may be accomplished by external fixation alone. (See",
"      <a class=\"local\" href=\"#H113250380\">",
"       'Fracture stabilization'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with severe pelvic fractures have multiple risk factors for deep vein thrombosis and should receive thromboprophylaxis. Intermittent pneumatic compression should be used until bleeding is controlled and pharmacologic prophylaxis can be instituted. For those patients who have contraindications to pharmacologic prophylaxis, a removable inferior vena cava filter is an alternative. (See",
"      <a class=\"local\" href=\"#H108725425\">",
"       'Deep vein thrombosis'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/21/31066?source=see_link&amp;anchor=H172458244#H172458244\">",
"       \"Overview of inpatient management in the adult trauma patient\", section on 'Thromboprophylaxis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25865/abstract/1\">",
"      Young JW, Burgess AR, Brumback RJ, Poka A. Pelvic fractures: value of plain radiography in early assessment and management. Radiology 1986; 160:445.",
"     </a>",
"    </li>",
"    <li>",
"     Young, JWR, Burgess, AR. Fractures of the pelvis. In: Imaging in Trauma and Critical Care, Mirvis SE, Young JWR (Eds), Williams &amp; Wilkins, Baltimore 1992. p.382.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25865/abstract/3\">",
"      Fracture and dislocation compendium. Orthopaedic Trauma Association Committee for Coding and Classification. J Orthop Trauma 1996; 10 Suppl 1:v.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25865/abstract/4\">",
"      Huittinen VM, Sl&auml;tis P. Postmortem angiography and dissection of the hypogastric artery in pelvic fractures. Surgery 1973; 73:454.",
"     </a>",
"    </li>",
"    <li>",
"     Advance trauma life support, 8, American College of Surgeons, Chicago 2009..",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25865/abstract/6\">",
"      Giannoudis PV, Grotz MR, Tzioupis C, et al. Prevalence of pelvic fractures, associated injuries, and mortality: the United Kingdom perspective. J Trauma 2007; 63:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25865/abstract/7\">",
"      Lunsjo K, Tadros A, Hauggaard A, et al. Associated injuries and not fracture instability predict mortality in pelvic fractures: a prospective study of 100 patients. J Trauma 2007; 62:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25865/abstract/8\">",
"      Pehle B, Nast-Kolb D, Oberbeck R, et al. [Significance of physical examination and radiography of the pelvis during treatment in the shock emergency room]. Unfallchirurg 2003; 106:642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25865/abstract/9\">",
"      Ruchholtz S, Waydhas C, Lewan U, et al. Free abdominal fluid on ultrasound in unstable pelvic ring fracture: is laparotomy always necessary? J Trauma 2004; 57:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25865/abstract/10\">",
"      Branney SW, Wolfe RE, Moore EE, et al. Quantitative sensitivity of ultrasound in detecting free intraperitoneal fluid. J Trauma 1995; 39:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25865/abstract/11\">",
"      Dolich MO, McKenney MG, Varela JE, et al. 2,576 ultrasounds for blunt abdominal trauma. J Trauma 2001; 50:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25865/abstract/12\">",
"      Friese RS, Malekzadeh S, Shafi S, et al. Abdominal ultrasound is an unreliable modality for the detection of hemoperitoneum in patients with pelvic fracture. J Trauma 2007; 63:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25865/abstract/13\">",
"      Tayal VS, Nielsen A, Jones AE, et al. Accuracy of trauma ultrasound in major pelvic injury. J Trauma 2006; 61:1453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25865/abstract/14\">",
"      Guillamondegui OD, Pryor JP, Gracias VH, et al. Pelvic radiography in blunt trauma resuscitation: a diminishing role. J Trauma 2002; 53:1043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25865/abstract/15\">",
"      Berg EE, Chebuhar C, Bell RM. Pelvic trauma imaging: a blinded comparison of computed tomography and roentgenograms. J Trauma 1996; 41:994.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25865/abstract/16\">",
"      McCormick JP, Morgan SJ, Smith WR. Clinical effectiveness of the physical examination in diagnosis of posterior pelvic ring injuries. J Orthop Trauma 2003; 17:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25865/abstract/17\">",
"      Gonzalez RP, Fried PQ, Bukhalo M. The utility of clinical examination in screening for pelvic fractures in blunt trauma. J Am Coll Surg 2002; 194:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25865/abstract/18\">",
"      Duane TM, Tan BB, Golay D, et al. Blunt trauma and the role of routine pelvic radiographs: a prospective analysis. J Trauma 2002; 53:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25865/abstract/19\">",
"      Brasel KJ, Pham K, Yang H, et al. Significance of contrast extravasation in patients with pelvic fracture. J Trauma 2007; 62:1149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25865/abstract/20\">",
"      Diamond IR, Hamilton PA, Garber AB, et al. Extravasation of intravenous computed tomography scan contrast in blunt abdominal and pelvic trauma. J Trauma 2009; 66:1102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25865/abstract/21\">",
"      Poole GV, Ward EF. Causes of mortality in patients with pelvic fractures. Orthopedics 1994; 17:691.",
"     </a>",
"    </li>",
"    <li>",
"     Scalea, TM, Stein, DM, O'Toole, RV. Pelvic Fractures. In: Trauma, 6, Feliciano, DV, Mattox, KL, Moore, EE (Eds), McGraw-Hill, New York 2008. p.759.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25865/abstract/23\">",
"      Cestero RF, Plurad D, Green D, et al. Iliac artery injuries and pelvic fractures: a national trauma database analysis of associated injuries and outcomes. J Trauma 2009; 67:715.",
"     </a>",
"    </li>",
"    <li>",
"     Frykberg, ER, Schinco, MA. Peripheral vascular injuries. In: Trauma, 6, Feliciano, DV, Mattox, KL, Moore, EE (Eds), McGraw-Hill, New  York 2008. p.941.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25865/abstract/25\">",
"      Esposito TJ, Ingraham A, Luchette FA, et al. Reasons to omit digital rectal exam in trauma patients: no fingers, no rectum, no useful additional information. J Trauma 2005; 59:1314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25865/abstract/26\">",
"      Burlew CC, Moore EE, Smith WR, et al. Preperitoneal pelvic packing/external fixation with secondary angioembolization: optimal care for life-threatening hemorrhage from unstable pelvic fractures. J Am Coll Surg 2011; 212:628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25865/abstract/27\">",
"      Spahn DR, Cerny V, Coats TJ, et al. Management of bleeding following major trauma: a European guideline. Crit Care 2007; 11:R17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25865/abstract/28\">",
"      Suzuki T, Smith WR, Moore EE. Pelvic packing or angiography: competitive or complementary? Injury 2009; 40:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25865/abstract/29\">",
"      Biffl WL, Smith WR, Moore EE, et al. Evolution of a multidisciplinary clinical pathway for the management of unstable patients with pelvic fractures. Ann Surg 2001; 233:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25865/abstract/30\">",
"      Cothren CC, Osborn PM, Moore EE, et al. Preperitonal pelvic packing for hemodynamically unstable pelvic fractures: a paradigm shift. J Trauma 2007; 62:834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25865/abstract/31\">",
"      Hamill J, Holden A, Paice R, Civil I. Pelvic fracture pattern predicts pelvic arterial haemorrhage. Aust N Z J Surg 2000; 70:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25865/abstract/32\">",
"      Costantini TW, Bosarge PL, Fortlage D, et al. Arterial embolization for pelvic fractures after blunt trauma: are we all talk? Am J Surg 2010; 200:752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25865/abstract/33\">",
"      Gourlay D, Hoffer E, Routt M, Bulger E. Pelvic angiography for recurrent traumatic pelvic arterial hemorrhage. J Trauma 2005; 59:1168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25865/abstract/34\">",
"      Eastridge BJ, Starr A, Minei JP, et al. The importance of fracture pattern in guiding therapeutic decision-making in patients with hemorrhagic shock and pelvic ring disruptions. J Trauma 2002; 53:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25865/abstract/35\">",
"      Pereira SJ, O'Brien DP, Luchette FA, et al. Dynamic helical computed tomography scan accurately detects hemorrhage in patients with pelvic fracture. Surgery 2000; 128:678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25865/abstract/36\">",
"      Miller PR, Moore PS, Mansell E, et al. External fixation or arteriogram in bleeding pelvic fracture: initial therapy guided by markers of arterial hemorrhage. J Trauma 2003; 54:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25865/abstract/37\">",
"      Brown CV, Kasotakis G, Wilcox A, et al. Does pelvic hematoma on admission computed tomography predict active bleeding at angiography for pelvic fracture? Am Surg 2005; 71:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25865/abstract/38\">",
"      Blackmore CC, Jurkovich GJ, Linnau KF, et al. Assessment of volume of hemorrhage and outcome from pelvic fracture. Arch Surg 2003; 138:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25865/abstract/39\">",
"      Salim A, Teixeira PG, DuBose J, et al. Predictors of positive angiography in pelvic fractures: a prospective study. J Am Coll Surg 2008; 207:656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25865/abstract/40\">",
"      Jowett AJ, Bowyer GW. Pressure characteristics of pelvic binders. Injury 2007; 38:118.",
"     </a>",
"    </li>",
"    <li>",
"     Ertel, W, Karim, E, Keel, M, Trentz, O. Therapeutic strategies and outcome of polytraumatized patients with pelvic injuries. Eur J Trauma 2000; 26:278.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25865/abstract/42\">",
"      Ochsner MG, Knudson MM, Pachter HL, et al. Significance of minimal or no intraperitoneal fluid visible on CT scan associated with blunt liver and splenic injuries: a multicenter analysis. J Trauma 2000; 49:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25865/abstract/43\">",
"      Mason WT, Khan SN, James CL, et al. Complications of temporary and definitive external fixation of pelvic ring injuries. Injury 2005; 36:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25865/abstract/44\">",
"      Taeger G, Ruchholtz S, Waydhas C, et al. Damage control orthopedics in patients with multiple injuries is effective, time saving, and safe. J Trauma 2005; 59:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25865/abstract/45\">",
"      Ertel W, Keel M, Eid K, et al. Control of severe hemorrhage using C-clamp and pelvic packing in multiply injured patients with pelvic ring disruption. J Orthop Trauma 2001; 15:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25865/abstract/46\">",
"      Giannoudis PV, Pape HC. Damage control orthopaedics in unstable pelvic ring injuries. Injury 2004; 35:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25865/abstract/47\">",
"      Smith WR, Moore EE, Osborn P, et al. Retroperitoneal packing as a resuscitation technique for hemodynamically unstable patients with pelvic fractures: report of two representative cases and a description of technique. J Trauma 2005; 59:1510.",
"     </a>",
"    </li>",
"    <li>",
"     Pohlmann, T, Gansslen, A, Hufner, T, Tscherne, H. Extraperitoneal packing at laparotomy. OTA-AAST Annual Meeting 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25865/abstract/49\">",
"      Panetta T, Sclafani SJ, Goldstein AS, et al. Percutaneous transcatheter embolization for massive bleeding from pelvic fractures. J Trauma 1985; 25:1021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25865/abstract/50\">",
"      Rossaint R, Duranteau J, Stahel PF, Spahn DR. Nonsurgical treatment of major bleeding. Anesthesiol Clin 2007; 25:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25865/abstract/51\">",
"      Starr AJ, Griffin DR, Reinert CM, et al. Pelvic ring disruptions: prediction of associated injuries, transfusion requirement, pelvic arteriography, complications, and mortality. J Orthop Trauma 2002; 16:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25865/abstract/52\">",
"      Niwa T, Takebayashi S, Igari H, et al. The value of plain radiographs in the prediction of outcome in pelvic fractures treated with embolisation therapy. Br J Radiol 2000; 73:945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25865/abstract/53\">",
"      O'Neill PA, Riina J, Sclafani S, Tornetta P 3rd. Angiographic findings in pelvic fractures. Clin Orthop Relat Res 1996; :60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25865/abstract/54\">",
"      Suzuki T, Kataoka Y, Minehara H, et al. Transcatheter arterial embolization for pelvic fractures may potentially cause a triad of sequela: gluteal necrosis, rectal necrosis, and lower limb paresis. J Trauma 2008; 65:1547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25865/abstract/55\">",
"      Yasumura K, Ikegami K, Kamohara T, Nohara Y. High incidence of ischemic necrosis of the gluteal muscle after transcatheter angiographic embolization for severe pelvic fracture. J Trauma 2005; 58:985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25865/abstract/56\">",
"      DuBose J, Inaba K, Barmparas G, et al. Bilateral internal iliac artery ligation as a damage control approach in massive retroperitoneal bleeding after pelvic fracture. J Trauma 2010; 69:1507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25865/abstract/57\">",
"      Naam NH, Brown WH, Hurd R, et al. Major pelvic fractures. Arch Surg 1983; 118:610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25865/abstract/58\">",
"      Sinnott R, Rhodes M, Brader A. Open pelvic fracture: an injury for trauma centers. Am J Surg 1992; 163:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25865/abstract/59\">",
"      Moore FA, McKinley BA, Moore EE, et al. Inflammation and the Host Response to Injury, a large-scale collaborative project: patient-oriented research core--standard operating procedures for clinical care. III. Guidelines for shock resuscitation. J Trauma 2006; 61:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25865/abstract/60\">",
"      Menaker J, Stein DM, Scalea TM. Incidence of early pulmonary embolism after injury. J Trauma 2007; 63:620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25865/abstract/61\">",
"      Smith W, Williams A, Agudelo J, et al. Early predictors of mortality in hemodynamically unstable pelvis fractures. J Orthop Trauma 2007; 21:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25865/abstract/62\">",
"      Mucha P Jr, Welch TJ. Hemorrhage in major pelvic fractures. Surg Clin North Am 1988; 68:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25865/abstract/63\">",
"      Heetveld MJ, Harris I, Schlaphoff G, et al. Hemodynamically unstable pelvic fractures: recent care and new guidelines. World J Surg 2004; 28:904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25865/abstract/64\">",
"      Demetriades D, Karaiskakis M, Toutouzas K, et al. Pelvic fractures: epidemiology and predictors of associated abdominal injuries and outcomes. J Am Coll Surg 2002; 195:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25865/abstract/65\">",
"      Gustavo Parreira J, Coimbra R, Rasslan S, et al. The role of associated injuries on outcome of blunt trauma patients sustaining pelvic fractures. Injury 2000; 31:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25865/abstract/66\">",
"      Verbeek D, Sugrue M, Balogh Z, et al. Acute management of hemodynamically unstable pelvic trauma patients: time for a change? Multicenter review of recent practice. World J Surg 2008; 32:1874.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25865/abstract/67\">",
"      Hauschild O, Strohm PC, Culemann U, et al. Mortality in patients with pelvic fractures: results from the German pelvic injury register. J Trauma 2008; 64:449.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15151 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-1FB45B5B38-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_16_25865=[""].join("\n");
var outline_f25_16_25865=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H293634174\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H293633624\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1329894718\">",
"      ANATOMIC CONSIDERATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H293633879\">",
"      TRAUMA EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H293634722\">",
"      History and physical",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H293634729\">",
"      FAST scan",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H293634736\">",
"      Pelvic imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H293634561\">",
"      Fracture-related injuries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H255195485\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H42517110\">",
"      General approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H113250380\">",
"      Fracture stabilization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H255193898\">",
"      Preperitoneal pelvic packing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1329894754\">",
"      Arteriography and angioembolization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H255194905\">",
"      Management of associated soft tissue injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1329894775\">",
"      RESUSCITATION AND CARE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H108725406\">",
"      Abdominal compartment syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H108725425\">",
"      Deep vein thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1329894782\">",
"      MORTALITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H293634174\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/15151\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/15151|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?24/40/25230\" title=\"algorithm 1\">",
"      Management of hemodynamically unstable pelvic fracture",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/15151|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/40/27268\" title=\"figure 1\">",
"      Pelvic ring fracture classification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?31/20/32066\" title=\"figure 2\">",
"      Pelvic fractures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?39/52/40777\" title=\"figure 3\">",
"      Pelvic circulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/45/29399\" title=\"figure 4\">",
"      Pelvic packing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/15151|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?19/31/19958\" title=\"picture 1\">",
"      Binding injured pelvis with sheet",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?20/6/20577\" title=\"picture 2\">",
"      Perineal degloving injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/15151|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?37/61/38875\" title=\"table 1\">",
"      Young and Burgess classification of pelvic fractures",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/17/20761?source=related_link\">",
"      Abdominal compartment syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/3/13368?source=related_link\">",
"      Acute arterial occlusion of the lower extremities (acute limb ischemia)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/11/26810?source=related_link\">",
"      Acute traumatic spinal cord injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/63/27642?source=related_link\">",
"      Basic principles of wound management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/44/23242?source=related_link\">",
"      Coagulopathy associated with trauma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/2/44071?source=related_link\">",
"      Evaluation and management of lower genital tract trauma in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/52/5961?source=related_link\">",
"      Indications for red cell transfusion in the adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/5/19545?source=related_link\">",
"      Initial evaluation and management of blunt abdominal trauma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/39/34426?source=related_link\">",
"      Initial evaluation and management of blunt thoracic trauma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/55/29562?source=related_link\">",
"      Initial evaluation and management of shock in adult trauma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/11/35002?source=related_link\">",
"      Initial management of trauma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/45/23257?source=related_link\">",
"      Lumbosacral plexus syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/4/1097?source=related_link\">",
"      Management of the open abdomen in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/25/38294?source=related_link\">",
"      Massive blood transfusion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/41/26264?source=related_link\">",
"      Negative pressure wound therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/16/10506?source=related_link\">",
"      Noninvasive diagnosis of arterial disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/21/31066?source=related_link\">",
"      Overview of inpatient management in the adult trauma patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?5/21/5459?source=related_link\">",
"      Patient information: Pelvic fracture (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/7/22650?source=related_link\">",
"      Pelvic trauma: Initial evaluation and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/47/40697?source=related_link\">",
"      Placement and management of urinary bladder catheters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/28/16840?source=related_link\">",
"      Placement of inferior vena cava filters and their complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/52/41802?source=related_link\">",
"      Prevention of venous thromboembolic disease in surgical patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/10/44199?source=related_link\">",
"      Pulmonary artery catheterization: Interpretation of tracings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/62/6120?source=related_link\">",
"      Shock in adults: Types, presentation, and diagnostic approach",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/12/28873?source=related_link\">",
"      Surgical principles of ostomy construction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_16_25866="Therapeutic use and adverse effects of progesterone receptor antagonists and selective progesterone receptor modulators";
var content_f25_16_25866=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Therapeutic use and adverse effects of progesterone receptor antagonists and selective progesterone receptor modulators",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/16/25866/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/16/25866/contributors\">",
"     Irving M Spitz, MD, DSc, FRCP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/16/25866/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/16/25866/contributors\">",
"     Peter J Snyder, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/16/25866/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/16/25866/contributors\">",
"     Kathryn A Martin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?25/16/25866/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 15, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Progesterone is essential for the initiation and maintenance of pregnancy. After the discovery of the progesterone receptor (PR) in 1970, it was realized that a progesterone receptor antagonist could have a major impact on female reproductive health.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/45/1753?source=see_link\">",
"     Mifepristone",
"    </a>",
"    was the first clinically available progesterone receptor antagonist. Since then, several hundred similar compounds have been synthesized. These compounds may display progesterone agonist, antagonist or mixed",
"    <span class=\"nowrap\">",
"     agonist/antagonist",
"    </span>",
"    activity and thus function as progesterone receptor agonists, progesterone receptor antagonists (PAs), or selective progesterone receptor modulators (SPRMs).",
"   </p>",
"   <p>",
"    The term SPRM is in keeping with the terminology adopted for SERMs. From a pharmacological, biochemical and clinical perspective, a working definition of a SPRM is that it represents a class of progesterone receptor ligands that exerts clinically relevant, tissue selective, mixed progesterone agonist and antagonist effects, which may be full or partial on various progesterone target tissues in an in vivo situation depending on the biological action studied.",
"   </p>",
"   <p>",
"    The clinical applications (other than medical termination of pregnancy) and adverse effects of progesterone receptor antagonists (PAs) and selective progesterone receptor modulators (SPRMs) will be reviewed here. The chemistry, pharmacokinetics, pharmacology, metabolism, mechanism of action and biological effects of PAs and SPRMs are discussed elsewhere [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25866/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/47/8952?source=see_link\">",
"     \"Pharmacology and mechanism of action of progesterone receptor modulators (PRMs)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/38/33386?source=see_link\">",
"     \"Mifepristone for the medical termination of pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL USES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tissue responsiveness to PAs and SPRMs differs markedly. As an example, with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/45/1753?source=see_link\">",
"     mifepristone",
"    </a>",
"    , the tissue possessing the most sensitivity is the endometrium; a single dose of 2.5 mg is sufficient to delay endometrial maturation and the appearance of progesterone-dependent markers [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25866/abstract/4\">",
"     4",
"    </a>",
"    ]. A dose of 50 mg is required to shed the endometrium and produce menstrual bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25866/abstract/5,6\">",
"     5,6",
"    </a>",
"    ], while a single dose of 200 mg is needed to terminate pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25866/abstract/7\">",
"     7",
"    </a>",
"    ]. Even higher doses are required for an antiglucocorticoid effect.",
"   </p>",
"   <p>",
"    The PA,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/45/1753?source=see_link\">",
"     mifepristone",
"    </a>",
"    , was first introduced for medical termination of pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25866/abstract/8\">",
"     8",
"    </a>",
"    ]. However, this PA should not be regarded exclusively as a medical abortifacient. Both PAs and SPRMs have other proven applications both for short-term and long-term use (",
"    <a class=\"graphic graphic_table graphicRef75597 \" href=\"UTD.htm?41/24/42379\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25866/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     SHORT TERM GYNECOLOGICAL AND OBSTETRICAL INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;These indications are usually for single doses and almost all relate to the use of the PA",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/45/1753?source=see_link\">",
"     mifepristone",
"    </a>",
"    &nbsp;(",
"    <a class=\"graphic graphic_table graphicRef75597 \" href=\"UTD.htm?41/24/42379\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Cervical dilatation",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/45/1753?source=see_link\">",
"     Mifepristone",
"    </a>",
"    dilates and softens the cervix and this is the rationale for its use in pregnancy termination, in early fetal demise and in fetal death. Unlike its dramatic effect in the pregnant uterus, mifepristone administered 30 hours prior to hysteroscopy is not effective in ripening the cervix of non-pregnant women [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25866/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Termination of pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/45/1753?source=see_link\">",
"     mifepristone",
"    </a>",
"    for termination of first or second trimester pregnancy is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/38/33386?source=see_link\">",
"     \"Mifepristone for the medical termination of pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/47/28409?source=see_link&amp;anchor=H10#H10\">",
"     \"Termination of pregnancy: Second trimester\", section on 'Systemic abortifacients'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Menstrual regulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;This is also known as endometrial (menstrual) aspiration or extraction and is usually performed surgically in women with menses delay.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/45/1753?source=see_link\">",
"     Mifepristone",
"    </a>",
"    followed by the administration of a prostaglandin has been shown to be very effective in menstrual regulation.",
"   </p>",
"   <p>",
"    In one study,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/45/1753?source=see_link\">",
"     mifepristone",
"    </a>",
"    was followed by gemeprost and there was a complete abortion in 189 of 193 women who presented with menses delay of 11 days or less and were shown retrospectively to be pregnant [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25866/abstract/11\">",
"     11",
"    </a>",
"    ]. In a second study, a total of 720 women with a menstrual delay of up to seven days received mifepristone (150 mg) followed in 36 to 48 hours by vaginal",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    (400 mcg). The success was 92.4 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25866/abstract/12\">",
"     12",
"    </a>",
"    ]. Although the success rate is somewhat less than the results of the previously quoted study, this may be related to differences in protocol design. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/38/33386?source=see_link\">",
"     \"Mifepristone for the medical termination of pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Early fetal demise",
"    </span>",
"    &nbsp;&mdash;&nbsp;This encompasses missed miscarriage (presence of non-viable",
"    <span class=\"nowrap\">",
"     embryo/fetus)",
"    </span>",
"    and anembryonic pregnancy. The majority of these women are treated by surgical evacuation, but medical therapy appears to be effective, as well.",
"   </p>",
"   <p>",
"    Several studies have reported the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/45/1753?source=see_link\">",
"     mifepristone",
"    </a>",
"    either alone or in combination with prostaglandin analogs in the medical management of early fetal demise with efficacy ranging from 74 to 93 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25866/abstract/13-18\">",
"     13-18",
"    </a>",
"    ] with the exception of one small study (",
"    <a class=\"graphic graphic_table graphicRef65083 \" href=\"UTD.htm?18/30/18924\">",
"     table 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25866/abstract/19\">",
"     19",
"    </a>",
"    ]. Vaginal",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    alone may be as effective as the combination of mifepristone and vaginal misoprostol in the management of missed abortion and is associated with less bleeding (",
"    <a class=\"graphic graphic_table graphicRef65083 \" href=\"UTD.htm?18/30/18924\">",
"     table 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25866/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a study comparing medical therapy versus surgical intervention,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/45/1753?source=see_link\">",
"     mifepristone",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    were administered to 100 women with an ultrasonically-confirmed missed abortion while 100 women underwent surgical evacuation under general anesthesia for their missed abortion. There were no significant differences in complications between the medical and surgical groups [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25866/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Spontaneous incomplete abortions, presenting with bleeding and pain, are usually treated with dilatation and curettage although most can resolve without treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25866/abstract/22\">",
"     22",
"    </a>",
"    ]. A randomized trial demonstrated that 400 mg",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/45/1753?source=see_link\">",
"     mifepristone",
"    </a>",
"    and 400 mcg",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    did not increase the rate of complete abortion compared to expected management alone. A total of 82 percent of women randomized to mifepristone and misoprostol and 76 percent randomized to expectant management had an empty sac after five days [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25866/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Fetal death",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/45/1753?source=see_link\">",
"     mifepristone",
"    </a>",
"    softens and dilates the cervix, it has the ability to induce labor following intrauterine fetal death. A dose of 200 mg two or three times a day for two days has been used successfully [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25866/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. Another approach has been to administer",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    following a single dose of 200 mg mifepristone [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25866/abstract/25\">",
"     25",
"    </a>",
"    ]. This indication is approved in several European countries. If labor has not started within 72 hours, alternate methods should be used. The management of intrauterine death is reviewed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/36/31306?source=see_link\">",
"     \"Incidence, etiology, and prevention of stillbirth\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Labor induction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several placebo-controlled studies have evaluated",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/45/1753?source=see_link\">",
"     mifepristone",
"    </a>",
"    for the induction of labor in the third trimester in women with a viable fetus [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25866/abstract/26-32\">",
"     26-32",
"    </a>",
"    ]. Women receiving mifepristone appear to be less likely to have an unfavorable cervix at 48 hours and are more likely to deliver within 48 hours. In most [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25866/abstract/29-32\">",
"     29-32",
"    </a>",
"    ] but not all [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25866/abstract/27\">",
"     27",
"    </a>",
"    ] studies, mifepristone-treated women were less likely to undergo Caesarean delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25866/abstract/29-32\">",
"     29-32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In spite of these potential beneficial effects, there are a number of adverse effects, which may be related to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/45/1753?source=see_link\">",
"     mifepristone",
"    </a>",
"    's ability to cross the fetal placental barrier [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25866/abstract/33\">",
"     33",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An increased number of uterine contractions and non-reassuring fetal heart patterns with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/45/1753?source=see_link\">",
"       mifepristone",
"      </a>",
"      compared with placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?25/16/25866/abstract/32\">",
"       32",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      An increased incidence of uterine hypertonia and tachysystole.",
"     </li>",
"     <li>",
"      Severe fetal bradycardia after initiation of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/0/5125?source=see_link\">",
"       oxytocin",
"      </a>",
"      in women pretreated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/45/1753?source=see_link\">",
"       mifepristone",
"      </a>",
"      compared with those who received prostaglandins [",
"      <a class=\"abstract\" href=\"UTD.htm?25/16/25866/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Because of these potential complications, the routine use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/45/1753?source=see_link\">",
"     mifepristone",
"    </a>",
"    for induction of labor cannot be recommended. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/37/31322?source=see_link\">",
"     \"Principles of labor induction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Potential use for in vitro fertilization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because it delays the LH surge and ovulation,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/45/1753?source=see_link\">",
"     mifepristone",
"    </a>",
"    may have application in superovulation induction programs by inhibiting a premature LH surge",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    premature luteinization [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25866/abstract/35,36\">",
"     35,36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/45/1753?source=see_link\">",
"     Mifepristone",
"    </a>",
"    also arrests endometrial maturation and there is an absence of up-regulation of several genes which are usually strongly up-regulated in the period of endometrial receptivity [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25866/abstract/36\">",
"     36",
"    </a>",
"    ]. By retarding endometrial maturation, mifepristone thus \"shifts\" the implantation window [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25866/abstract/37\">",
"     37",
"    </a>",
"    ]. This may possibly lead to a better synchronization of embryonic and endometrial maturation and to increased pregnancy rates [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25866/abstract/38\">",
"     38",
"    </a>",
"    ]. It should also be noted that mifepristone crosses the blood-follicle barrier and follicular fluid levels are similar to those in blood 34 hours after a 100 mg dose [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25866/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Emergency contraception",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39412?source=see_link\">",
"     Ulipristal",
"    </a>",
"    acetate and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/45/1753?source=see_link\">",
"     mifepristone",
"    </a>",
"    have similar chemical structures. Both are highly effective for use in emergency contraception. A disadvantage of antiprogestins is that the delay in ovulation results in a delay in subsequent menses, which may provoke anxiety about possible pregnancy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/5/31833?source=see_link&amp;anchor=H10#H10\">",
"     \"Emergency contraception\", section on 'Antiprogestins'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39412?source=see_link\">",
"     Ulipristal",
"    </a>",
"    is available worldwide for emergency contraception. In the US, it is marketed under the name ella&reg;. It can be used for emergency contraception up to 120 hours after intercourse.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/45/1753?source=see_link\">",
"     Mifepristone",
"    </a>",
"    is not available in the US for emergency contraception; it is used for medical termination of intrauterine pregnancy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/38/33386?source=see_link\">",
"     \"Mifepristone for the medical termination of pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     LONG-TERM GYNECOLOGICAL INDICATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Contraception",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/45/1753?source=see_link\">",
"     Mifepristone",
"    </a>",
"    as well as other PAs have contraceptive potential through a number of mechanisms, including blocking the LH surge, interference with endometrial development (antiproliferative effect), induction of bleeding when administered in the late luteal phase (thus preventing implantation), interference with corpus luteum function, oocyte passage through the fallopian tubes, sperm transport and function, and oocyte maturation and fertilization [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25866/abstract/4,5,40,41\">",
"     4,5,40,41",
"    </a>",
"    ]. In contrast, SPRMs do not appear to be effective in blocking the LH surge and ovulation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25866/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Daily doses of 2 to 10 mg",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/45/1753?source=see_link\">",
"     mifepristone",
"    </a>",
"    suppress follicular development, block the LH surge, and delay ovulation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25866/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. Because of anovulation, there may be an unopposed estrogen effect on the endometrium, although this risk may be mitigated by its noncompetitive anti-estrogenic activity [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25866/abstract/45\">",
"     45",
"    </a>",
"    ]. Most mifepristone studies have been conducted in women not at risk of pregnancy. However, in a study of 98 women randomly assigned to receive mifepristone 2 or 5 mg for 120 days, ovulation was suppressed in the majority of cycles (90 and 95 percent, respectively), and no pregnancies occurred in 200 months of exposure in 50 sexually active women who had not used other forms of contraception during the study [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25866/abstract/46\">",
"     46",
"    </a>",
"    ]. In addition, no cases of endometrial hyperplasia were seen. Thus, although data are limited, mifepristone may have contraceptive potential by inhibiting ovulation.",
"   </p>",
"   <p>",
"    The threshold dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/45/1753?source=see_link\">",
"     mifepristone",
"    </a>",
"    capable of inhibiting ovulation is 2 mg daily. With a dose of 1 mg daily, ovulation usually occurs [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25866/abstract/47\">",
"     47",
"    </a>",
"    ]. Although this dose does not inhibit the LH surge, it delays endometrial maturation and the appearance of progesterone-dependent markers [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25866/abstract/4,5,48\">",
"     4,5,48",
"    </a>",
"    ]. These results raise the prospect of endometrial contraception, ie, prevention of endometrial maturation without disruption of ovulation. This approach is effective in monkeys [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25866/abstract/49\">",
"     49",
"    </a>",
"    ]. However, mifepristone at a very low dose (0.5 mg daily or 5 or 10 mg once weekly) administered to women not using contraception, did not prevent pregnancy, notwithstanding a delay in endometrial maturation and in appearance of progesterone-dependent markers [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25866/abstract/4,50-52\">",
"     4,50-52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Once-weekly administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/45/1753?source=see_link\">",
"     mifepristone",
"    </a>",
"    in doses as high as 25 mg does not consistently inhibit ovulation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25866/abstract/53\">",
"     53",
"    </a>",
"    ]. However, this regimen does interfere with normal endometrial development. No pregnancies occurred when once weekly administration of mifepristone (25 and 50 mg) was given for six months to a total of 76 women. There were a total of 456 months of women-months of use [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25866/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Luteal phase contraception [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25866/abstract/55\">",
"     55",
"    </a>",
"    ] is another potential application of PAs. One of the main difficulties of this type of treatment is the timing of administration, since there is no prospective, reliable and non-invasive way to detect the onset of ovulation and the beginning of the luteal phase. Administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/45/1753?source=see_link\">",
"     mifepristone",
"    </a>",
"    in the early luteal phase (200 mg 48 hours after the LH surge) has minimal or no effect on ovulation and bleeding patterns, but is an effective contraceptive [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25866/abstract/4,56,57\">",
"     4,56,57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/45/1753?source=see_link\">",
"     mifepristone",
"    </a>",
"    in the late luteal phase produces menstrual bleeding. As already discussed above, when administered together with prostaglandins, it has been shown to be an effective menses regulator [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25866/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. A single dose of mifepristone either alone or together with prostaglandins has been administered to women between the implantation period and the expected menses as a monthly alternative to regular oral contraception. This treatment failed to induce bleeding in a significant number of women and induction of bleeding did not necessarily terminate an ongoing pregnancy. This treatment was thus not effective in preventing pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25866/abstract/5,40,58\">",
"     5,40,58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Irregular bleeding due to progestin-only contraception",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bleeding is one of the main drawbacks of estrogen-free contraception, and may lead to treatment discontinuation in a large percentage of women. Because of the potential antiproliferative effect on the endometrium, low doses of PAs may be used to reduce the occurrence of bleeding irregularities induced by progestin-only contraceptive methods [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25866/abstract/40,59\">",
"     40,59",
"    </a>",
"    ]. The PA Org 31710, administered monthly (150 mg) to women using the desogestrel only contraceptive pill (75",
"    <span class=\"nowrap\">",
"     mcg/day),",
"    </span>",
"    permitted the restoration of a regular bleeding pattern, with a significantly lower frequency of irregular, prolonged, or frequent bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25866/abstract/59\">",
"     59",
"    </a>",
"    ]. However, Org 31710 or Org 33628 (another PA) in combination with desogestrel fail to provide sufficient ovulation inhibition compared to desogestrel alone [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25866/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In women using",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/47/25336?source=see_link\">",
"     levonorgestrel",
"    </a>",
"    releasing subdermal contraceptive implants, bleeding has been correlated to vascular fragility, independently of estradiol or progesterone circulating levels. In a double-blind placebo controlled study [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25866/abstract/61\">",
"     61",
"    </a>",
"    ], women using a levonorgestrel-releasing contraceptive implant were treated with 50 mg",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/45/1753?source=see_link\">",
"     mifepristone",
"    </a>",
"    once every four weeks. The frequency of bleeding tended to decrease independently of treatment in all women over the 360 days of the study. Women receiving mifepristone had shorter episodes of bleeding. Furthermore women using mifepristone found the treatment more acceptable.",
"   </p>",
"   <p>",
"    Other trials have also reported improved bleeding patterns in women given intermittent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/45/1753?source=see_link\">",
"     mifepristone",
"    </a>",
"    with high dose progestin preparations [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25866/abstract/62-64\">",
"     62-64",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Uterine myoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;A limited number of studies have been conducted with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/45/1753?source=see_link\">",
"     mifepristone",
"    </a>",
"    and more recently with asoprisnil. Mifepristone treatment was often continued for three to six months and doses used included 5, 10, 12.5, 25, or 50 mg [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25866/abstract/65-69\">",
"     65-69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A systematic review and meta-analysis of six clinical trials for uterine myomata has been published. A total of 166 women received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/45/1753?source=see_link\">",
"     mifepristone",
"    </a>",
"    (5 to 50",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    for three to six months). Results showed [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25866/abstract/70\">",
"     70",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Leiomyoma volumes were reduced by 26 to 74 percent",
"     </li>",
"     <li>",
"      Rates of amenorrhea ranged from 63 to 100 percent",
"     </li>",
"     <li>",
"      The prevalence and severity of dysmenorrhea, menorrhagia, and pelvic pressure were reduced (although no trials were placebo-controlled)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Uterine volumes also decreased with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/45/1753?source=see_link\">",
"     mifepristone",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25866/abstract/68,71\">",
"     68,71",
"    </a>",
"    ]. When treatment was stopped, uterine volumes increased, but remained below baseline.",
"   </p>",
"   <p>",
"    Thus, doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/45/1753?source=see_link\">",
"     mifepristone",
"    </a>",
"    as low as 5",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    may be effective for the treatment of uterine myomata. In a small trial of women with symptomatic myoma randomly assigned to mifepristone (5",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25866/abstract/4,5,40\">",
"     4,5,40",
"    </a>",
"    ], women in the mifepristone group experienced an improvement in leiomyoma-specific quality of life and significantly greater reduction in uterine volume when compared to placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25866/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Larger, randomized placebo- or GnRH agonist-controlled trials are needed to determine the safety and efficacy (including whether there is myoma regrowth after cessation of treatment). Of particular concern is the potential for endometrial thickening observed on ultrasound. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/47/8952?source=see_link\">",
"     \"Pharmacology and mechanism of action of progesterone receptor modulators (PRMs)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A randomized trial of asoprisnil (5, 10, and 25 mg) for the management of myomas also reported reduction of uterine volumes and suppression of uterine bleeding in a dose-dependent manner. There was a significant reduction in bloating with the two highest doses and in pelvic pressure with 25 mg by week 12 [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25866/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Endometriosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three small clinical trials have been reported using three dose schedules of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/45/1753?source=see_link\">",
"     mifepristone",
"    </a>",
"    (5 mg or 50 mg per day for six months or 100 mg per day for three months) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25866/abstract/74-76\">",
"     74-76",
"    </a>",
"    ]. With all schedules, there was an improvement in symptoms, and with the 50 mg dose, there was a 55 percent mean regression of visible endometriosis after six months of treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25866/abstract/74-76\">",
"     74-76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a placebo-controlled, parallel group trial in 130 women with laparoscopic evidence of endometriosis, asoprisnil (5, 10, or 25 mg for 12 weeks) reduced dysmenorrhea and non-menstrual pain more than placebo. Higher doses were associated with amenorrhea. The treatment also dose-dependently induced amenorrhea [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25866/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Unlike long-acting GnRH analogs which are generally used in the medical treatment of endometriosis and uterine myoma,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/45/1753?source=see_link\">",
"     mifepristone",
"    </a>",
"    treatment was not associated with a decrease in bone mineral density [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25866/abstract/65\">",
"     65",
"    </a>",
"    ]. This indicates that the effect of mifepristone is selective. It is antiproliferative in the endometrium but not in bone [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25866/abstract/78\">",
"     78",
"    </a>",
"    ]. Thus treatment with PAs and SPRMs offers distinct advantages over GnRH agonists in the management of endometriosis and myoma [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25866/abstract/45\">",
"     45",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/14/18666?source=see_link&amp;anchor=H8#H8\">",
"     \"Overview of treatment of uterine leiomyomas (fibroids)\", section on 'Gonadotropin-releasing hormone agonists'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Other potential applications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since both PAs and SPRMs induce amenorrhea, they may be indicted in the treatment of dysfunctional uterine bleeding. A single study has been reported in abstract form showing encouraging results with asoprisnil [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25866/abstract/79\">",
"     79",
"    </a>",
"    ]. The possibility of using PRMs and SPRMs as a form of non-estrogen hormone therapy for post-menopausal women remains unexplored. Studies in oophorectomized monkeys have given encouraging results in this regard [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25866/abstract/80\">",
"     80",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     NON-GYNECOLOGICAL APPLICATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Cushing's syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;In high doses,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/45/1753?source=see_link\">",
"     mifepristone",
"    </a>",
"    is a potent glucocorticoid antagonist and may be used in the treatment of various forms of Cushing's syndrome, such as adrenal carcinoma and ectopic ACTH secreting tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25866/abstract/81,82\">",
"     81,82",
"    </a>",
"    ]. Mifepristone normalizes the Cushingoid phenotype, ameliorates depression, decreases hypertension, eliminates abnormal carbohydrate metabolism and corrects glucocorticoid-induced gonadal and thyroid hormone suppression [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25866/abstract/81,82\">",
"     81,82",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, this drug cannot be used in Cushing's disease where the hypothalamic-pituitary-adrenal axis is intact but regulated at a higher set point. Under these circumstances the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/45/1753?source=see_link\">",
"     mifepristone",
"    </a>",
"    -induced increase in ACTH and cortisol secretion may overcome the glucocorticoid receptor blockade [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25866/abstract/81,83\">",
"     81,83",
"    </a>",
"    ]. Mifepristone however could be used to prepare a patient for surgery. Moreover, it has fewer side effects than other agents used to treat these patients.",
"   </p>",
"   <p>",
"    However, there is a danger of the development of hypoadrenalism, a life-threatening condition which requires immediate treatment. Because of glucocorticoid receptor blockade, serum cortisol levels are increased with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/45/1753?source=see_link\">",
"     mifepristone",
"    </a>",
"    . Thus if hypoadrenalism develops, the diagnosis may be difficult to confirm. Treatment should be instituted if symptoms suggest this diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Glucocorticoid antagonism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Animal studies suggest that glucocorticoid antagonism may also be of value in the treatment of burns, glucocorticoid-dependent hypertension, arthritis, and glaucoma [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25866/abstract/83\">",
"     83",
"    </a>",
"    ]. No clinical studies have been reported.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/45/1753?source=see_link\">",
"     Mifepristone",
"    </a>",
"    has also recently been used successfully in chronic central serous chorioretinopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25866/abstract/84\">",
"     84",
"    </a>",
"    ]. HIV-1 encodes a 96 amino acid virion- associated accessory protein, Vpr, which functions as a transcriptional activator of several viral promoters including the HIV-1. Vpr also enhances glucocorticoid activity by functioning as a potent GR coactivator. Since AIDS patients have several manifestations of glucocorticoid excess, it is possible that Vpr may contribute to these findings. By blocking GR, mifepristone may therefore improve the clinical manifestations and course in AIDS patients [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25866/abstract/85\">",
"     85",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Since cognition is adversely affected by high and sustained levels of glucocorticoid hormones [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25866/abstract/86\">",
"     86",
"    </a>",
"    ], studies are currently being conducted to determine whether",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/45/1753?source=see_link\">",
"     mifepristone",
"    </a>",
"    can decelerate the rate of cortisol-induced cognitive decline [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25866/abstract/87,88\">",
"     87,88",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A small double-blind study comprising nine patients has been performed in patients with mild to moderate Alzheimer disease. Patients were treated with either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/45/1753?source=see_link\">",
"     mifepristone",
"    </a>",
"    200 mg per day or placebo for six weeks. In a study of nine patients with Alzheimer disease, the mifepristone-treated patients performed better on the Alzheimer disease assessment scale cognitive subtest score although this did not reach statistical significance [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25866/abstract/87,88\">",
"     87,88",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Major depression with psychotic features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many patients with psychotic depression have non-suppression of cortisol following",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    . In addition, they may have increased urinary cortisol and serum ACTH [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25866/abstract/89\">",
"     89",
"    </a>",
"    ]. Five patients with major depression and psychotic features received 600 mg of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/45/1753?source=see_link\">",
"     mifepristone",
"    </a>",
"    daily for four days in a double-blind placebo-controlled trial, and there was substantial improvement [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25866/abstract/90\">",
"     90",
"    </a>",
"    ]. In a second study, 30 patients who met DSM-IV criteria by clinician interview were randomly assigned to receive 50 mg, 600 mg, or 1200 mg mifepristone once daily for seven days. Patients receiving the two highest doses showed an improvement in symptomatology [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25866/abstract/89\">",
"     89",
"    </a>",
"    ]. Mifepristone in a dose of 200",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    for up to eight weeks has also been shown to have some benefit in major depression without psychotic features [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25866/abstract/91\">",
"     91",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Bipolar Disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since high cortisol levels are also found in bipolar disorders, treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/45/1753?source=see_link\">",
"     mifepristone",
"    </a>",
"    has been evaluated in this situation. In a study of 20 bipolar patients treated with mifepristone (600",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    or placebo, selective improvements in neurocognitive function were seen [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25866/abstract/92\">",
"     92",
"    </a>",
"    ]. This included spatial working memory performance, verbal fluency, spatial recognition memory and mood. In contrast to the improvement noted in patients with bipolar disorder, mifepristone had no effect on neurocognitive function or symptoms in patients with schizophrenia [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25866/abstract/93\">",
"     93",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Steroid receptor-containing tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many tumors, both benign and malignant, are steroid-dependent. Even non-steroid-dependent tumors may contain steroid receptors. For this reason, PAs may be used in the treatment of some cancers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Breast cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several small studies have been performed in breast carcinoma using both",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/45/1753?source=see_link\">",
"     mifepristone",
"    </a>",
"    and onapristone (another PA), with mixed results [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25866/abstract/94-97\">",
"     94-97",
"    </a>",
"    ]. As an example, in a trial of 19 patients with advanced breast cancer receiving onapristone 100",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    the following results were seen:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One patient was withdrawn after 4.5 months while her disease was static.",
"     </li>",
"     <li>",
"      Of the remaining 18 patients, 10 (56 percent) showed a partial response and two (11 percent) durable static disease (&gt;six months), giving an overall tumor remission rate of 67 percent.",
"     </li>",
"     <li>",
"      The median duration of remission was 70 weeks.",
"     </li>",
"     <li>",
"      Transient liver function test abnormalities developed in a number of patients, mainly during the first six weeks of treatment. Because of abnormalities in liver function, onapristone has been withdrawn from clinical studies [",
"      <a class=\"abstract\" href=\"UTD.htm?25/16/25866/abstract/98\">",
"       98",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although clinical results have been somewhat disappointing, further studies are warranted. It is hoped that newly developed potent PAs will be more effective than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/45/1753?source=see_link\">",
"     mifepristone",
"    </a>",
"    in the treatment of breast cancer.",
"   </p>",
"   <p>",
"    Data from a study in BRCA1 and p53 deficient mice suggest that long-term treatment with a PA or SPRM may represent a possible future option for women with a mutated BRCA1 gene [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25866/abstract/99\">",
"     99",
"    </a>",
"    ]. In this model, mice develop early mammary cancer that was blocked by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/45/1753?source=see_link\">",
"     mifepristone",
"    </a>",
"    . PR was overexpressed in the mutant mammary epithelial cells because of a defect in degradation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25866/abstract/99\">",
"     99",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Other tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies in animals have suggested that PAs could be used in other tumors, including meningiomas, gliomas, as well as in ovarian and prostate cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25866/abstract/45\">",
"     45",
"    </a>",
"    ]. In one study, the effect of 200 mg",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/45/1753?source=see_link\">",
"     mifepristone",
"    </a>",
"    daily in 34 patients with refractory ovarian cancer was evaluated. Three had a complete and six a partial response. The survival from commencement of treatment ranged from 22 to 39 months and one patient continued to respond for over three years [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25866/abstract/100\">",
"     100",
"    </a>",
"    ]. It has also been reported that mifepristone had a beneficial effect in a woman with a uterine leiomyosarcoma which stained positively for the PR [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25866/abstract/101\">",
"     101",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/45/1753?source=see_link\">",
"     mifepristone",
"    </a>",
"    in patients with meningiomas is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/36/44616?source=see_link\">",
"     \"Treatment of benign (WHO grade I) meningioma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     ADVERSE EFFECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;This relates almost exclusively to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/45/1753?source=see_link\">",
"     mifepristone",
"    </a>",
"    since there is only very limited clinical experience with other PAs and SPRMs [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25866/abstract/102\">",
"     102",
"    </a>",
"    ]. Because of its specific action at the progesterone and glucocorticoid receptors, serious adverse effects are rare and mifepristone is generally well tolerated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Pregnancy termination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Deaths possibly related to",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?1/45/1753?source=see_link\">",
"      mifepristone",
"     </a>",
"     /",
"     <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=see_link\">",
"      misoprostol",
"     </a>",
"    </span>",
"    use have been reported. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/38/33386?source=see_link&amp;anchor=H14#H14\">",
"     \"Mifepristone for the medical termination of pregnancy\", section on 'Side effects and complications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Non-pregnant women and men",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Common side effects observed during long-term treatment with doses of up to 200 mg daily include fatigue, nausea, anorexia and vomiting. Weight loss, skin rashes, cessation of menses in premenopausal women, transient thinning of the hair and hot flashes have also been reported [",
"      <a class=\"abstract\" href=\"UTD.htm?25/16/25866/abstract/68,103-105\">",
"       68,103-105",
"      </a>",
"      ]. There is a suggestion that the incidence of hot flushes may be dose-dependent [",
"      <a class=\"abstract\" href=\"UTD.htm?25/16/25866/abstract/68\">",
"       68",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Low libido and gynecomastia in men have been documented, presumably due to the fact that",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/45/1753?source=see_link\">",
"       mifepristone",
"      </a>",
"      binds with low affinity to androgen receptors [",
"      <a class=\"abstract\" href=\"UTD.htm?25/16/25866/abstract/104\">",
"       104",
"      </a>",
"      ]. However, it should be noted that mifepristone has little antiandrogenic effects in animals.",
"     </li>",
"     <li>",
"      Biochemical hypothyroidism has also been observed [",
"      <a class=\"abstract\" href=\"UTD.htm?25/16/25866/abstract/106\">",
"       106",
"      </a>",
"      ]. This is related to the antiglucocorticoid effect of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/45/1753?source=see_link\">",
"       mifepristone",
"      </a>",
"      which inhibits iodide uptake induced by",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/49/32528?source=see_link\">",
"       hydrocortisone",
"      </a>",
"      and TSH [",
"      <a class=\"abstract\" href=\"UTD.htm?25/16/25866/abstract/107\">",
"       107",
"      </a>",
"      ]. Alternatively, this could be an effect of glucocorticoid antagonism at the pituitary level since basal TSH levels are low in Cushing's syndrome and there is a suppressed TSH response to thyrotropin releasing hormone [",
"      <a class=\"abstract\" href=\"UTD.htm?25/16/25866/abstract/108\">",
"       108",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      On occasion, long-term",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/45/1753?source=see_link\">",
"       mifepristone",
"      </a>",
"      administration in doses ranging from 5 mg to 200 mg daily has been associated with transient elevation in hepatic enzymes [",
"      <a class=\"abstract\" href=\"UTD.htm?25/16/25866/abstract/68,76,109-111\">",
"       68,76,109-111",
"      </a>",
"      ]. As noted above, onapristone, which is closely related structurally to mifepristone, was withdrawn from clinical trials because of its effect on hepatic enzymes [",
"      <a class=\"abstract\" href=\"UTD.htm?25/16/25866/abstract/94,98\">",
"       94,98",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Low serum potassium levels have also been reported in patients with breast cancer on treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/45/1753?source=see_link\">",
"       mifepristone",
"      </a>",
"      , 200 mg daily, as well as in a patient with Cushing's syndrome receiving up to 2000 mg daily [",
"      <a class=\"abstract\" href=\"UTD.htm?25/16/25866/abstract/82,95\">",
"       82,95",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We have evaluated the long-term safety profile of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/45/1753?source=see_link\">",
"     mifepristone",
"    </a>",
"    in 25 patients with meningioma who received mifepristone in doses of 200 mg daily for up to 13 years. In 1620 months of treatment, there were no untoward effects on serum biochemical and hematological parameters. In particular, no alterations in potassium or increases in transaminases beyond the normal range were observed [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25866/abstract/112\">",
"     112",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In view of the antiglucocorticoid properties of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/45/1753?source=see_link\">",
"     mifepristone",
"    </a>",
"    , hypoadrenalism must be considered as a possible consequence of long-term treatment. Although this has been reported with doses exceeding 200",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    it is an uncommon occurrence in humans with an intact pituitary-adrenal axis. In one study, a severe exanthem was observed in normal males nine days after receiving a high dose of 10",
"    <span class=\"nowrap\">",
"     mg/kg/day",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25866/abstract/113\">",
"     113",
"    </a>",
"    ]. This has not been observed in other studies. It is anticipated that the incidence of untoward effects will be low in the doses proposed for long-term treatment with mifepristone in conditions such as myoma, endometriosis and contraception.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Endometrial hyperplasia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endometrial thickening on ultrasound has been reported in up to 20 percent of women receiving treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/45/1753?source=see_link\">",
"     mifepristone",
"    </a>",
"    for meningioma [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25866/abstract/114-117\">",
"     114-117",
"    </a>",
"    ]. In many, but not all patients, the endometrial histology had been interpreted as showing hyperplasia. However endometrial thickening is not synonymous with endometrial hyperplasia on histology but may be related to edematous changes in the myometrium and related connective tissue, to cyst formation, to the collection of fluid in the lumen of dilated glands or to the presence of benign stromal thickening with an increase in collagen production in the stromal cells [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25866/abstract/118-120\">",
"     118-120",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Very high doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/45/1753?source=see_link\">",
"     mifepristone",
"    </a>",
"    (400 mg daily administered for one year) are associated with simple endometrial hyperplasia [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25866/abstract/116\">",
"     116",
"    </a>",
"    ]. Proliferative patterns rather than secretory effects have been observed in premenopausal women with myoma treated with 50 mg of mifepristone daily for up to six months [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25866/abstract/66\">",
"     66",
"    </a>",
"    ]. With doses of 2 or 5 mg, there was decreased endometrial proliferation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25866/abstract/120\">",
"     120",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a trial of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/45/1753?source=see_link\">",
"     mifepristone",
"    </a>",
"    in 40 women with uterine myomas, 10 of the 36 women who underwent endometrial biopsies were reported to have hyperplasia, an incidence of 28 percent after six months of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25866/abstract/68\">",
"     68",
"    </a>",
"    ]. When the slides were reviewed by a specialized gynecological pathologist, the incidence of apparent hyperplasia in these patients decreased to 14 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25866/abstract/71\">",
"     71",
"    </a>",
"    ]. Further re-evaluation of the same slides by a specially constituted panel of expert gynecological pathologists which convened at the National Institutes of Health (NIH) in April 2006, concluded that none of these patients had a histological appearance which warranted any concern [",
"    <a class=\"abstract\" href=\"UTD.htm?25/16/25866/abstract/121\">",
"     121",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The controversy with regard to interpretation of the endometrial findings, relates to the fact that the endometrial changes seen with long term PAs and SPRMs are unique and new criteria have to be applied to validly interpret the histology. This analysis had drawbacks since duration of exposure was not taken into account. Furthermore, since the samples were blinded, the specific treatment and dose of drug was unknown to the pathologists. It is possible that each compound will have its own distinct morphological appearance depending on dose and duration of exposure.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25866/abstract/1\">",
"      Chwalisz K, Garg R, Brenner RM, et al. Selective progesterone receptor modulators (SPRMs): a novel therapeutic concept in endometriosis. Ann N Y Acad Sci 2002; 955:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25866/abstract/2\">",
"      Spitz IM. Progesterone antagonists and progesterone receptor modulators. Expert Opin Investig Drugs 2003; 12:1693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25866/abstract/3\">",
"      Spitz IM. Progesterone antagonists and progesterone receptor modulators: an overview. Steroids 2003; 68:981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25866/abstract/4\">",
"      Bygdeman M, Danielsson KG, Marions L, Swahn ML. Contraceptive use of antiprogestin. Eur J Contracept Reprod Health Care 1999; 4:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25866/abstract/5\">",
"      Spitz IM, Croxatto HB, Robbins A. Antiprogestins: mechanism of action and contraceptive potential. Annu Rev Pharmacol Toxicol 1996; 36:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25866/abstract/6\">",
"      Shoupe D, Mishell DR Jr, Lahteenmaki P, et al. Effects of the antiprogesterone RU 486 in normal women. I. Single-dose administration in the midluteal phase. Am J Obstet Gynecol 1987; 157:1415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25866/abstract/7\">",
"      Christin-Maitre S, Bouchard P, Spitz IM. Medical termination of pregnancy. N Engl J Med 2000; 342:946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25866/abstract/8\">",
"      Herrmann W, Wyss R, Riondel A, et al. [The effects of an antiprogesterone steroid in women: interruption of the menstrual cycle and of early pregnancy]. C R Seances Acad Sci III 1982; 294:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25866/abstract/9\">",
"      Spitz, IM. Progestins, progesterone antagonists and progesterone receptor modulators. Steroids 2000; 65:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25866/abstract/10\">",
"      Ben-Chetrit A, Eldar-Geva T, Lindenberg T, et al. Mifepristone does not induce cervical softening in non-pregnant women. Hum Reprod 2004; 19:2372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25866/abstract/11\">",
"      Menstrual regulation by mifepristone plus prostaglandin: results from a multicentre trial. World Health Organization Task Force on Post-Ovulatory Methods of Fertility Regulation. Hum Reprod 1995; 10:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25866/abstract/12\">",
"      Xiao B, von Hertzen H, Zhao H, Piaggio G. Menstrual induction with mifepristone and misoprostol. Contraception 2003; 68:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25866/abstract/13\">",
"      Lelaidier C, Baton-Saint-Mleux C, Fernandez H, et al. Mifepristone (RU 486) induces embryo expulsion in first trimester non-developing pregnancies: a prospective randomized trial. Hum Reprod 1993; 8:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25866/abstract/14\">",
"      Schaff EA, Fielding SL, Eisinger S, Stadalius L. Mifepristone and misoprostol for early abortion when no gestational sac is present. Contraception 2001; 63:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25866/abstract/15\">",
"      Hughes J, Ryan M, Hinshaw K, et al. The costs of treating miscarriage: a comparison of medical and surgical management. Br J Obstet Gynaecol 1996; 103:1217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25866/abstract/16\">",
"      el-Refaey H, Hinshaw K, Henshaw R, et al. Medical management of missed abortion and anembryonic pregnancy. BMJ 1992; 305:1399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25866/abstract/17\">",
"      Wagaarachchi PT, Ashok PW, Narvekar N, et al. Medical management of early fetal demise using a combination of mifepristone and misoprostol. Hum Reprod 2001; 16:1849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25866/abstract/18\">",
"      Wagaarachchi PT, Ashok PW, Smith NC, Templeton A. Medical management of early fetal demise using sublingual misoprostol. BJOG 2002; 109:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25866/abstract/19\">",
"      Nielsen S, Hahlin M, Platz-Christensen JJ. Unsuccessful treatment of missed abortion with a combination of an antiprogesterone and a prostaglandin E1 analogue. Br J Obstet Gynaecol 1997; 104:1094.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25866/abstract/20\">",
"      Gr&oslash;nlund A, Gr&oslash;nlund L, Clevin L, et al. Management of missed abortion: comparison of medical treatment with either mifepristone + misoprostol or misoprostol alone with surgical evacuation. A multi-center trial in Copenhagen county, Denmark. Acta Obstet Gynecol Scand 2002; 81:1060.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25866/abstract/21\">",
"      Chia KV, Ogbo VI. Medical termination of missed abortion. J Obstet Gynaecol 2002; 22:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25866/abstract/22\">",
"      Nielsen S, Hahlin M. Expectant management of first-trimester spontaneous abortion. Lancet 1995; 345:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25866/abstract/23\">",
"      Cabrol D, Bouvier D'Yvoire M, Mermet E, et al. Induction of labour with mifepristone after intrauterine fetal death. Lancet 1985; 2:1019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25866/abstract/24\">",
"      Cabrol D, Dubois C, Cronje H, et al. Induction of labor with mifepristone (RU 486) in intrauterine fetal death. Am J Obstet Gynecol 1990; 163:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25866/abstract/25\">",
"      Wagaarachchi PT, Ashok PW, Narvekar NN, et al. Medical management of late intrauterine death using a combination of mifepristone and misoprostol. BJOG 2002; 109:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25866/abstract/26\">",
"      Neilson JP. Mifepristone for induction of labour. Cochrane Database Syst Rev 2000; :CD002865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25866/abstract/27\">",
"      Elliott CL, Brennand JE, Calder AA. The effects of mifepristone on cervical ripening and labor induction in primigravidae. Obstet Gynecol 1998; 92:804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25866/abstract/28\">",
"      Frydman R, Lelaidier C, Baton-Saint-Mleux C, et al. Labor induction in women at term with mifepristone (RU 486): a double-blind, randomized, placebo-controlled study. Obstet Gynecol 1992; 80:972.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25866/abstract/29\">",
"      Giacalone PL, Targosz V, Laffargue F, et al. Cervical ripening with mifepristone before labor induction: a randomized study. Obstet Gynecol 1998; 92:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25866/abstract/30\">",
"      Lelaidier C, Baton C, Benifla JL, et al. Mifepristone for labour induction after previous caesarean section. Br J Obstet Gynaecol 1994; 101:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25866/abstract/31\">",
"      Stenlund PM, Ekman G, Aedo AR, Bygdeman M. Induction of labor with mifepristone--a randomized, double-blind study versus placebo. Acta Obstet Gynecol Scand 1999; 78:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25866/abstract/32\">",
"      Wing DA, Fassett MJ, Mishell DR. Mifepristone for preinduction cervical ripening beyond 41 weeks' gestation: a randomized controlled trial. Obstet Gynecol 2000; 96:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25866/abstract/33\">",
"      Hill NC, Selinger M, Ferguson J, MacKenzie IZ. The placental transfer of mifepristone (RU 486) during the second trimester and its influence upon maternal and fetal steroid concentrations. Br J Obstet Gynaecol 1990; 97:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25866/abstract/34\">",
"      Giacalone PL, Daur&eacute;s JP, Faure JM, et al. The effects of mifepristone on uterine sensitivity to oxytocin and on fetal heart rate patterns. Eur J Obstet Gynecol Reprod Biol 2001; 97:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25866/abstract/35\">",
"      Messinis IE, Krishnan M, Kazem R, et al. Effect of mifepristone on folliculogenesis in women treated with recombinant FSH. Clin Endocrinol (Oxf) 1997; 46:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25866/abstract/36\">",
"      Escudero EL, Boerrigter PJ, Bennink HJ, et al. Mifepristone is an effective oral alternative for the prevention of premature luteinizing hormone surges and/or premature luteinization in women undergoing controlled ovarian hyperstimulation for in vitro fertilization. J Clin Endocrinol Metab 2005; 90:2081.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25866/abstract/37\">",
"      Hegele-Hartung C, Mootz U, Beier HM. Luteal control of endometrial receptivity and its modification by progesterone antagonists. Endocrinology 1992; 131:2446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25866/abstract/38\">",
"      Paulson RJ, Sauer MV, Lobo RA. Potential enhancement of endometrial receptivity in cycles using controlled ovarian hyperstimulation with antiprogestins: a hypothesis. Fertil Steril 1997; 67:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25866/abstract/39\">",
"      Cekan S, Aedo AR, Segerst&eacute;en E, et al. Levels of the antiprogestin RU 486 and its metabolites in human blood and follicular fluid following oral administration of a single dose. Hum Reprod 1989; 4:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25866/abstract/40\">",
"      Spitz IM, Van Look PF, Coelingh Bennink HJ. The use of progesterone antagonists and progesterone receptor modulators in contraception. Steroids 2000; 65:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25866/abstract/41\">",
"      Gemzell-Danielsson K, Marions L. Mechanisms of action of mifepristone and levonorgestrel when used for emergency contraception. Hum Reprod Update 2004; 10:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25866/abstract/42\">",
"      Chwalisz K, Elger W, Stickler T, et al. The effects of 1-month administration of asoprisnil (J867), a selective progesterone receptor modulator, in healthy premenopausal women. Hum Reprod 2005; 20:1090.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25866/abstract/43\">",
"      Croxatto HB, Salvatierra AM, Croxatto HD, Fuentealba B. Effects of continuous treatment with low dose mifepristone throughout one menstrual cycle. Hum Reprod 1993; 8:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25866/abstract/44\">",
"      Cameron ST, Critchley HO, Thong KJ, et al. Effects of daily low dose mifepristone on endometrial maturation and proliferation. Hum Reprod 1996; 11:2518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25866/abstract/45\">",
"      Spitz IM, Chwalisz K. Progesterone receptor modulators and progesterone antagonists in women's health. Steroids 2000; 65:807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25866/abstract/46\">",
"      Brown A, Cheng L, Lin S, Baird DT. Daily low-dose mifepristone has contraceptive potential by suppressing ovulation and menstruation: a double-blind randomized control trial of 2 and 5 mg per day for 120 days. J Clin Endocrinol Metab 2002; 87:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25866/abstract/47\">",
"      Croxatto HB, Kov&aacute;cs L, Massai R, et al. Effects of long-term low-dose mifepristone on reproductive function in women. Hum Reprod 1998; 13:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25866/abstract/48\">",
"      Sarkar NN. The potential of mifepristone (RU486) as a female contraceptive drug. Int J Clin Pract 2002; 56:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25866/abstract/49\">",
"      Borman SM, Schwinof KM, Niemeyer C, et al. Low-dose antiprogestin treatment prevents pregnancy in rhesus monkeys and is reversible after 1 year of treatment. Hum Reprod 2003; 18:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25866/abstract/50\">",
"      Marions L, Danielsson KG, Swahn ML, Bygdeman M. Contraceptive efficacy of low doses of mifepristone. Fertil Steril 1998; 70:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25866/abstract/51\">",
"      Marions L, Viski S, Danielsson KG, et al. Contraceptive efficacy of daily administration of 0.5 mg mifepristone. Hum Reprod 1999; 14:2788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25866/abstract/52\">",
"      Cheng J, Weng L, Han X. [Study on weekly low doses of mifepristone for contraception]. Zhonghua Fu Chan Ke Za Zhi 2001; 36:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25866/abstract/53\">",
"      Chen X, Xiao B. Effect of once weekly administration of mifepristone on ovarian function in normal women. Contraception 1997; 56:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25866/abstract/54\">",
"      Pei K, Xiao B, Jing X, et al. Weekly contraception with mifepristone. Contraception 2007; 75:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25866/abstract/55\">",
"      Croxatto HB. Mifepristone for luteal phase contraception. Contraception 2003; 68:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25866/abstract/56\">",
"      Gemzell-Danielsson K, Swahn ML, Svalander P, Bygdeman M. Early luteal phase treatment with mifepristone (RU 486) for fertility regulation. Hum Reprod 1993; 8:870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25866/abstract/57\">",
"      Hapangama DK, Brown A, Glasier AF, Baird DT. Feasibility of administering mifepristone as a once a month contraceptive pill. Hum Reprod 2001; 16:1145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25866/abstract/58\">",
"      Swahn ML, Bygdeman M, Chen JK, et al. Once-a-month treatment with a combination of mifepristone and the prostaglandin analogue misoprostol. Hum Reprod 1999; 14:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25866/abstract/59\">",
"      Gemzell-Danielsson K, van Heusden AM, Killick SR, et al. Improving cycle control in progestogen-only contraceptive pill users by intermittent treatment with a new anti-progestogen. Hum Reprod 2002; 17:2588.",
"     </a>",
"    </li>",
"    <li>",
"     Verbost, PM, et al. ORG 33628 and ORG 31710 control vaginal bleeding in progestin-only contraceptive regimens. Seminars in Reproductive Medicine, in press.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25866/abstract/61\">",
"      Cheng L, Zhu H, Wang A, et al. Once a month administration of mifepristone improves bleeding patterns in women using subdermal contraceptive implants releasing levonorgestrel. Hum Reprod 2000; 15:1969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25866/abstract/62\">",
"      Jain JK, Nicosia AF, Nucatola DL, et al. Mifepristone for the prevention of breakthrough bleeding in new starters of depo-medroxyprogesterone acetate. Steroids 2003; 68:1115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25866/abstract/63\">",
"      Massai MR, Pavez M, Fuentealba B, et al. Effect of intermittent treatment with mifepristone on bleeding patterns in Norplant implant users. Contraception 2004; 70:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25866/abstract/64\">",
"      Weisberg E, Hickey M, Palmer D, et al. A pilot study to assess the effect of three short-term treatments on frequent and/or prolonged bleeding compared to placebo in women using Implanon. Hum Reprod 2006; 21:295.",
"     </a>",
"    </li>",
"    <li>",
"     Yen SC. Use of antiprogestins in the management of endometriosis and leiomyoma. In: Clinical Applications of Mifepristone (RU496) and other Antiprogestins, Donaldson MS, Dorflinger L, Brown SS, Benet LZ (Eds), National Academy Press, Washington, DC 1993. p.189.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25866/abstract/66\">",
"      Murphy AA, Castellano PZ. RU486: pharmacology and potential use in the treatment of endometriosis and leiomyomata uteri. Curr Opin Obstet Gynecol 1994; 6:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25866/abstract/67\">",
"      Yang Y, Zheng S, Li K. [Treatment of uterine leiomyoma by two different doses of mifepristone]. Zhonghua Fu Chan Ke Za Zhi 1996; 31:624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25866/abstract/68\">",
"      Eisinger SH, Meldrum S, Fiscella K, et al. Low-dose mifepristone for uterine leiomyomata. Obstet Gynecol 2003; 101:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25866/abstract/69\">",
"      Zeng C, Gu M, Huang H. [A clinical control study on the treatment of uterine leiomyoma with gonadotrophin releasing hormone agonist or mifepristone]. Zhonghua Fu Chan Ke Za Zhi 1998; 33:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25866/abstract/70\">",
"      Steinauer J, Pritts EA, Jackson R, Jacoby AF. Systematic review of mifepristone for the treatment of uterine leiomyomata. Obstet Gynecol 2004; 103:1331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25866/abstract/71\">",
"      Eisinger SH, Bonfiglio T, Fiscella K, et al. Twelve-month safety and efficacy of low-dose mifepristone for uterine myomas. J Minim Invasive Gynecol 2005; 12:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25866/abstract/72\">",
"      Fiscella K, Eisinger SH, Meldrum S, et al. Effect of mifepristone for symptomatic leiomyomata on quality of life and uterine size: a randomized controlled trial. Obstet Gynecol 2006; 108:1381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25866/abstract/73\">",
"      Chwalisz K, Larsen L, Mattia-Goldberg C, et al. A randomized, controlled trial of asoprisnil, a novel selective progesterone receptor modulator, in women with uterine leiomyomata. Fertil Steril 2007; 87:1399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25866/abstract/74\">",
"      Kettel LM, Murphy AA, Morales AJ, et al. Rapid regression of uterine leiomyomas in response to daily administration of gonadotropin-releasing hormone antagonist. Fertil Steril 1993; 60:642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25866/abstract/75\">",
"      Kettel LM, Murphy AA, Morales AJ, et al. Treatment of endometriosis with the antiprogesterone mifepristone (RU486). Fertil Steril 1996; 65:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25866/abstract/76\">",
"      Kettel LM, Murphy AA, Morales AJ, Yen SS. Preliminary report on the treatment of endometriosis with low-dose mifepristone (RU 486). Am J Obstet Gynecol 1998; 178:1151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25866/abstract/77\">",
"      Chwalisz, K, Mattia-Goldberg, K, Lee, M, et al. Treatment of endometriosis with the novel selective progesterone receptor modulator (SPRM) asoprisnil. Fertil Steril 2004; 82 Suppl 2:S83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25866/abstract/78\">",
"      Grow DR, Williams RF, Hsiu JG, Hodgen GD. Antiprogestin and/or gonadotropin-releasing hormone agonist for endometriosis treatment and bone maintenance: a 1-year primate study. J Clin Endocrinol Metab 1996; 81:1933.",
"     </a>",
"    </li>",
"    <li>",
"     Critchley, H, Williams, A, Cameron, I, et al. Effects of Asoprisnil, a selective progesterone receptor modulator (SPRM), in women with treatment resistant heacy menstrual bleeding. SGI Annual Scientific Meeting. Reno, USA, 2007.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25866/abstract/80\">",
"      Slayden OD, Zelinski MB, Chwalisz K, et al. Chronic progesterone antagonist-estradiol therapy suppresses breakthrough bleeding and endometrial proliferation in a menopausal macaque model. Hum Reprod 2006; 21:3081.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25866/abstract/81\">",
"      Nieman LK, Chrousos GP, Kellner C, et al. Successful treatment of Cushing's syndrome with the glucocorticoid antagonist RU 486. J Clin Endocrinol Metab 1985; 61:536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25866/abstract/82\">",
"      Chu JW, Matthias DF, Belanoff J, et al. Successful long-term treatment of refractory Cushing's disease with high-dose mifepristone (RU 486). J Clin Endocrinol Metab 2001; 86:3568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25866/abstract/83\">",
"      Spitz IM, Bardin CW. Mifepristone (RU 486)--a modulator of progestin and glucocorticoid action. N Engl J Med 1993; 329:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25866/abstract/84\">",
"      Nielsen JS, Weinreb RN, Yannuzzi L, Jampol LM. Mifepristone treatment of chronic central serous chorioretinopathy. Retina 2007; 27:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25866/abstract/85\">",
"      Mirani M, Elenkov I, Volpi S, et al. HIV-1 protein Vpr suppresses IL-12 production from human monocytes by enhancing glucocorticoid action: potential implications of Vpr coactivator activity for the innate and cellular immunity deficits observed in HIV-1 infection. J Immunol 2002; 169:6361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25866/abstract/86\">",
"      McEwen BS, Davis PG, Parsons B, Pfaff DW. The brain as a target for steroid hormone action. Annu Rev Neurosci 1979; 2:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25866/abstract/87\">",
"      Pomara N, Doraiswamy PM, Tun H, Ferris S. Mifepristone (RU 486) for Alzheimer's disease. Neurology 2002; 58:1436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25866/abstract/88\">",
"      Belanoff JK, Jurik J, Schatzberg LD, et al. Slowing the progression of cognitive decline in Alzheimer's disease using mifepristone. J Mol Neurosci 2002; 19:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25866/abstract/89\">",
"      Belanoff JK, Rothschild AJ, Cassidy F, et al. An open label trial of C-1073 (mifepristone) for psychotic major depression. Biol Psychiatry 2002; 52:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25866/abstract/90\">",
"      Belanoff JK, Flores BH, Kalezhan M, et al. Rapid reversal of psychotic depression using mifepristone. J Clin Psychopharmacol 2001; 21:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25866/abstract/91\">",
"      Murphy BE. Antiglucocorticoid therapies in major depression: a review. Psychoneuroendocrinology 1997; 22 Suppl 1:S125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25866/abstract/92\">",
"      Young AH, Gallagher P, Watson S, et al. Improvements in neurocognitive function and mood following adjunctive treatment with mifepristone (RU-486) in bipolar disorder. Neuropsychopharmacology 2004; 29:1538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25866/abstract/93\">",
"      Gallagher P, Watson S, Smith MS, et al. Effects of adjunctive mifepristone (RU-486) administration on neurocognitive function and symptoms in schizophrenia. Biol Psychiatry 2005; 57:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25866/abstract/94\">",
"      Klijn JG, Setyono-Han B, Foekens JA. Progesterone antagonists and progesterone receptor modulators in the treatment of breast cancer. Steroids 2000; 65:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25866/abstract/95\">",
"      Romieu G, Maudelonde T, Ulmann A, et al. The antiprogestin RU486 in advanced breast cancer: preliminary clinical trial. Bull Cancer 1987; 74:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25866/abstract/96\">",
"      Perrault D, Eisenhauer EA, Pritchard KI, et al. Phase II study of the progesterone antagonist mifepristone in patients with untreated metastatic breast carcinoma: a National Cancer Institute of Canada Clinical Trials Group study. J Clin Oncol 1996; 14:2709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25866/abstract/97\">",
"      Bakker GH, Setyono-Han B, Portengen H, et al. Treatment of breast cancer with different antiprogestins: preclinical and clinical studies. J Steroid Biochem Mol Biol 1990; 37:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25866/abstract/98\">",
"      Robertson JF, Willsher PC, Winterbottom L, et al. Onapristone, a progesterone receptor antagonist, as first-line therapy in primary breast cancer. Eur J Cancer 1999; 35:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25866/abstract/99\">",
"      Poole AJ, Li Y, Kim Y, et al. Prevention of Brca1-mediated mammary tumorigenesis in mice by a progesterone antagonist. Science 2006; 314:1467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25866/abstract/100\">",
"      Rocereto TF, Saul HM, Aikins JA Jr, Paulson J. Phase II study of mifepristone (RU486) in refractory ovarian cancer. Gynecol Oncol 2000; 77:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25866/abstract/101\">",
"      Koivisto-Korander R, Leminen A, Heikinheimo O. Mifepristone as treatment of recurrent progesterone receptor-positive uterine leiomyosarcoma. Obstet Gynecol 2007; 109:512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25866/abstract/102\">",
"      Sitruk-Ware R, Spitz IM. Pharmacological properties of mifepristone: toxicology and safety in animal and human studies. Contraception 2003; 68:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25866/abstract/103\">",
"      Grunberg SM, Weiss MH, Spitz IM, et al. Treatment of unresectable meningiomas with the antiprogesterone agent mifepristone. J Neurosurg 1991; 74:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25866/abstract/104\">",
"      Grunberg SM. Role of antiprogestational therapy for meningiomas. Hum Reprod 1994; 9 Suppl 1:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25866/abstract/105\">",
"      Lamberts SW, Koper JW, de Jong FH. The endocrine effects of long-term treatment with mifepristone (RU 486). J Clin Endocrinol Metab 1991; 73:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25866/abstract/106\">",
"      Heikinheimo O, Ranta S, Grunberg S, et al. Alterations in the pituitary-thyroid and pituitary-adrenal axes--consequences of long-term mifepristone treatment. Metabolism 1997; 46:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25866/abstract/107\">",
"      Takiyama Y, Tanaka H, Takiyama Y, Makino I. The effects of hydrocortisone and RU486 (mifepristone) on iodide uptake in porcine thyroid cells in primary culture. Endocrinology 1994; 135:1972.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25866/abstract/108\">",
"      Rubello D, Sonino N, Casara D, et al. Acute and chronic effects of high glucocorticoid levels on hypothalamic-pituitary-thyroid axis in man. J Endocrinol Invest 1992; 15:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25866/abstract/109\">",
"      Cameron ST, Thong KJ, Baird DT. Effect of daily low dose mifepristone on the ovarian cycle and on dynamics of follicle growth. Clin Endocrinol (Oxf) 1995; 43:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25866/abstract/110\">",
"      Murphy AA, Morales AJ, Kettel LM, Yen SS. Regression of uterine leiomyomata to the antiprogesterone RU486: dose-response effect. Fertil Steril 1995; 64:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25866/abstract/111\">",
"      Murphy AA, Kettel LM, Morales AJ, et al. Regression of uterine leiomyomata in response to the antiprogesterone RU 486. J Clin Endocrinol Metab 1993; 76:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25866/abstract/112\">",
"      Spitz IM, Grunberg SM, Chabbert-Buffet N, et al. Management of patients receiving long-term treatment with mifepristone. Fertil Steril 2005; 84:1719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25866/abstract/113\">",
"      Laue L, Lotze MT, Chrousos GP, et al. Effect of chronic treatment with the glucocorticoid antagonist RU 486 in man: toxicity, immunological, and hormonal aspects. J Clin Endocrinol Metab 1990; 71:1474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25866/abstract/114\">",
"      Martineau PA, Levental M. Large endometrial polyp in a patient on long-term mifepristone therapy. J Ultrasound Med 2000; 19:487.",
"     </a>",
"    </li>",
"    <li>",
"     Grunberg, SM, Rankin, C, Townsend, J, et al. Phase III double-blind randomized placebo-controlled study of mifepristone (RU-486) for the treatment of unresectable meningioma. American Society of Clinical Oncology. San Francisco, CA, 2001.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25866/abstract/116\">",
"      Newfield RS, Spitz IM, Isacson C, New MI. Long-term mifepristone (RU486) therapy resulting in massive benign endometrial hyperplasia. Clin Endocrinol (Oxf) 2001; 54:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25866/abstract/117\">",
"      de Keizer RJ, Smit JW. Mifepristone treatment in patients with surgically incurable sphenoid-ridge meningioma: a long-term follow-up. Eye (Lond) 2004; 18:954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25866/abstract/118\">",
"      Fleischer AC, Wheeler JE, Yeh IT, et al. Sonographic assessment of the endometrium in osteopenic postmenopausal women treated with idoxifene. J Ultrasound Med 1999; 18:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25866/abstract/119\">",
"      Liedman R, Lindahl B, Andolf E, et al. Disaccordance between estimation of endometrial thickness as measured by transvaginal ultrasound compared with hysteroscopy and directed biopsy in breast cancer patients treated with tamoxifen. Anticancer Res 2000; 20:4889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/16/25866/abstract/120\">",
"      Baird DT, Brown A, Critchley HO, et al. Effect of long-term treatment with low-dose mifepristone on the endometrium. Hum Reprod 2003; 18:61.",
"     </a>",
"    </li>",
"    <li>",
"     NIH meeting: Progesterone receptor modulators and the endometrium- changes and consequences. Washington, USA, 2006.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7424 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-200.131.240.2-D8D1174216-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_16_25866=[""].join("\n");
var outline_f25_16_25866=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL USES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      SHORT TERM GYNECOLOGICAL AND OBSTETRICAL INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Cervical dilatation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Termination of pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Menstrual regulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Early fetal demise",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Fetal death",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Labor induction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Potential use for in vitro fertilization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Emergency contraception",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      LONG-TERM GYNECOLOGICAL INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Contraception",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Irregular bleeding due to progestin-only contraception",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Uterine myoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Endometriosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Other potential applications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      NON-GYNECOLOGICAL APPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Cushing's syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Glucocorticoid antagonism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Major depression with psychotic features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Bipolar Disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Steroid receptor-containing tumors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Breast cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Other tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      ADVERSE EFFECTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Pregnancy termination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Non-pregnant women and men",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Endometrial hyperplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/7424\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7424|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?41/24/42379\" title=\"table 1\">",
"      Clin Applications SPRMs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?18/30/18924\" title=\"table 2\">",
"      Mifepristone early fetal demise",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/5/31833?source=related_link\">",
"      Emergency contraception",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/36/31306?source=related_link\">",
"      Incidence, etiology, and prevention of stillbirth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/38/33386?source=related_link\">",
"      Mifepristone for the medical termination of pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/14/18666?source=related_link\">",
"      Overview of treatment of uterine leiomyomas (fibroids)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/47/8952?source=related_link\">",
"      Pharmacology and mechanism of action of progesterone receptor modulators (PRMs)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/37/31322?source=related_link\">",
"      Principles of labor induction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/47/28409?source=related_link\">",
"      Termination of pregnancy: Second trimester",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/36/44616?source=related_link\">",
"      Treatment of benign (WHO grade I) meningioma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_16_25867="DSM-IV criteria for MR";
var content_f25_16_25867=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F81641&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F81641&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    DSM-IV criteria for mental retardation",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        <strong>",
"         1. Intellectual functioning is markedly below average (IQ of 70 or less on a standard, individually administered test).",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        <strong>",
"         2. More trouble functioning than would be expected for age and cultural group in 2 or more of the following areas:",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Communication",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Self-care",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Home living",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Social and interpersonal skills",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Using community resources",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Self-direction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Academic ability",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Work",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Free time",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Health",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Safety",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         3. Starts before age 18.",
"        </strong>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_16_25867=[""].join("\n");
var outline_f25_16_25867=null;
var title_f25_16_25868="Drugs for acute vertigo";
var content_f25_16_25868=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F68052&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F68052&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Drugs for acute vertigo",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Drug",
"      </td>",
"      <td class=\"subtitle1\">",
"       Dose",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"2\">",
"       Antihistamines",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Dimenhydrinate",
"      </td>",
"      <td>",
"       50 mg every four to six hours",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Diphenhydramine",
"      </td>",
"      <td>",
"       25 to 50 mg every four to six hours",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Meclizine",
"      </td>",
"      <td>",
"       25 to 50 mg every six hours",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"2\">",
"       Benzodiazepines",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Alprazolam",
"      </td>",
"      <td>",
"       0.5 mg immediate release every eight hours",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Clonazepam",
"      </td>",
"      <td>",
"       0.25 to 0.5 mg every eight hours",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Diazepam",
"      </td>",
"      <td>",
"       5 to 10 mg every twelve hours",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Lorazepam",
"      </td>",
"      <td>",
"       1 to 2 mg every eight hours",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"2\">",
"       Antiemetics",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Domperidone",
"      </td>",
"      <td>",
"       10 to 20 mg every six to eight hours",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Metoclopramide",
"      </td>",
"      <td>",
"       5 to 10 mg every six hours",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Ondansetron",
"      </td>",
"      <td>",
"       8 mg every twelve hours",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Prochlorperazine",
"      </td>",
"      <td>",
"       5 to 10 mg every six hours",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"2\">",
"       For acute emergency ward use:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle3_left\" colspan=\"2\">",
"       Antihistamines",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Diphenhydramine",
"      </td>",
"      <td>",
"       10 to 50 mg IM or IV",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle3_left\" colspan=\"2\">",
"       Antiemetics",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Metoclopramide",
"      </td>",
"      <td>",
"       10 to 20 mg IM",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Ondansetron",
"      </td>",
"      <td>",
"       4 mg IM or IV",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Prochlorperazine",
"      </td>",
"      <td>",
"       5 to 10 mg IM or IV",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Promethazine",
"      </td>",
"      <td>",
"       10 to 50 mg IM or IV",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     IM: intramuscular; IV: intravenous.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_16_25868=[""].join("\n");
var outline_f25_16_25868=null;
var title_f25_16_25869="T cruzi seroprevalence";
var content_f25_16_25869=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F58263&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F58263&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Countries in which vector-borne",
"    <em>",
"     T. cruzi",
"    </em>",
"    transmission occurs (as of 2009)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Region",
"       </td>",
"       <td class=\"subtitle1\">",
"        Endemic countries",
"       </td>",
"       <td class=\"subtitle1\">",
"        Estimated seroprevalence, percent*",
"       </td>",
"       <td class=\"subtitle1\">",
"        Estimated number of infected individuals*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        North America",
"       </td>",
"       <td>",
"        United States&bull;",
"       </td>",
"       <td>",
"        NDA",
"       </td>",
"       <td>",
"        300,167",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mexico",
"       </td>",
"       <td>",
"        1.03",
"       </td>",
"       <td>",
"        1,100,000",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"7\">",
"        Central America",
"       </td>",
"       <td>",
"        Belize&Delta;",
"       </td>",
"       <td>",
"        0.74",
"       </td>",
"       <td>",
"        2000",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Costa Rica&Delta;",
"       </td>",
"       <td>",
"        0.53",
"       </td>",
"       <td>",
"        23,000",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        El Salvador&Delta;",
"       </td>",
"       <td>",
"        3.37",
"       </td>",
"       <td>",
"        232,000",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Honduras&Delta;",
"       </td>",
"       <td>",
"        3.05",
"       </td>",
"       <td>",
"        220,000",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Guatemala&Delta;",
"       </td>",
"       <td>",
"        1.98",
"       </td>",
"       <td>",
"        250,000",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nicaragua&Delta;",
"       </td>",
"       <td>",
"        1.14",
"       </td>",
"       <td>",
"        58,600",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Panama&Delta;",
"       </td>",
"       <td>",
"        0.01",
"       </td>",
"       <td>",
"        21,000",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"13\">",
"        South America",
"       </td>",
"       <td>",
"        Argentina&loz;",
"       </td>",
"       <td>",
"        4.13",
"       </td>",
"       <td>",
"        1,600,000",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bolivia&loz;&sect;",
"       </td>",
"       <td>",
"        6.75",
"       </td>",
"       <td>",
"        620,000",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Brazil&loz;&sect;",
"       </td>",
"       <td>",
"        1.02",
"       </td>",
"       <td>",
"        1,900,000",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chile&loz;",
"       </td>",
"       <td>",
"        0.99",
"       </td>",
"       <td>",
"        160,200",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Colombia&sect;&yen;",
"       </td>",
"       <td>",
"        0.96",
"       </td>",
"       <td>",
"        436,000",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ecuador&sect;&yen;",
"       </td>",
"       <td>",
"        1.74",
"       </td>",
"       <td>",
"        230,000",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Guyana&sect;",
"       </td>",
"       <td>",
"        1.29",
"       </td>",
"       <td>",
"        18,000",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Suriname&sect;",
"       </td>",
"       <td>",
"        NDA",
"       </td>",
"       <td>",
"        NDA",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        French Guiana&sect;",
"       </td>",
"       <td>",
"        NDA",
"       </td>",
"       <td>",
"        NDA",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Paraguay&loz;",
"       </td>",
"       <td>",
"        2.54",
"       </td>",
"       <td>",
"        150,000",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Peru&sect;&yen;",
"       </td>",
"       <td>",
"        0.69",
"       </td>",
"       <td>",
"        192,000",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Uruguay&loz;",
"       </td>",
"       <td>",
"        0.66",
"       </td>",
"       <td>",
"        21,700",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Venezuela&sect;&yen;",
"       </td>",
"       <td>",
"        1.16",
"       </td>",
"       <td>",
"        310,000",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     NDA: no data available.",
"     <br>",
"      * Disease burden estimates based on references",
"      <sup>",
"       [1,2]",
"      </sup>",
"      .",
"      <br>",
"       <span class=\"bullet\">",
"        &bull;",
"       </span>",
"       The United States is not generally considered endemic, but established enzootic transmission cycles exist across the southern half of the country. Documented local transmission to humans is rare, but infected vectors and reservoir hosts are fairly frequent. Nevertheless, the vast majority of infected individuals living in the United States are immigrants who were infected in their country of origin.",
"       <br>",
"        &Delta; Member countries of Initiative of the Countries of Central America for Control of Vector-Borne and Transfusional Transmission and Medical Care for Chagas Disease (IPCA).",
"        <br>",
"         <span class=\"lozenge\">",
"          &loz;",
"         </span>",
"         Member countries of the Southern Cone Initiative to Control/Eliminate Chagas Disease (INCOSUR).",
"         <br>",
"          &sect; Member countries of Initiative of the Amazon Countries for Surveillance and Control of Chagas Disease (AMCHA).",
"          <br>",
"           &yen; Member countries of Initiative of the Andean Countries to Control Vectoral and Transfusional Transmission of Chagas Disease (IPA).",
"          </br>",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br>",
"      <ol>",
"       <li>",
"        Organizaci&oacute;n Panamericana de la Salud. Estimaci&oacute;n cuantitativa de la enfermedad de Chagas en las Americas. Organizaci&oacute;n Panamericana de la Salud, Montevideo, Uruguay 2006.",
"       </li>",
"       <li>",
"        Bern, C, Montgomery, SP. An estimate of the burden of Chagas disease in the United States. Clin Infect Dis 2009; 49:e52.",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_16_25869=[""].join("\n");
var outline_f25_16_25869=null;
var title_f25_16_25870="Contents: Hormone physiology";
var content_f25_16_25870=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?1/56/1934\">",
"       Endocrinology and Diabetes",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Hormone physiology",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Hormone physiology",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Adrenal hormones",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/46/28391\">",
"           Adrenal steroid biosynthesis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/20/2376\">",
"           Chapter 6C: Aldosterone",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/1/9240\">",
"           Metabolism of adrenal steroids",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Gastrointestinal hormones",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/33/16917\">",
"           Overview of gastrointestinal peptides in health and disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/51/35638\">",
"           Physiology of cholecystokinin",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/9/25751\">",
"           Physiology of gastrin",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/8/22660\">",
"           Synthesis, secretion, and regulation of gastrointestinal peptides",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         General",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/33/19988\">",
"           Chapter 6A: Mechanisms of hormone action",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/36/2631\">",
"           Chapter 6F: Hormonal regulation of calcium and phosphate balance",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/49/22293\">",
"           Peptide hormone signal transduction and regulation",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Hypothalamic-pituitary hormones",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/10/16552\">",
"           Chapter 6B: Antidiuretic hormone and water balance",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/30/25059\">",
"           Hypothalamic-pituitary axis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/46/13034\">",
"           Physiology and clinical use of melatonin",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/44/6857\">",
"           Physiology of corticotropin-releasing hormone",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/27/32181\">",
"           Physiology of gonadotropin-releasing hormone",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/1/43030\">",
"           Physiology of growth hormone",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/61/10200\">",
"           Thyroid hormone action",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/34/33320\">",
"           Thyroid hormone synthesis and physiology",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/47/40696\">",
"           Thyroid physiology and screening in preterm infants",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Mineral and bone hormones",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/33/42519\">",
"           Bone physiology and biochemical markers of bone turnover",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/15/9462\">",
"           Metabolism of vitamin D",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/5/34906\">",
"           Normal skeletal development and regulation of bone formation and resorption",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/56/36744\">",
"           Parathyroid hormone secretion and action",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Other",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/7/3192\">",
"           Physiology of insulin-like growth factor I",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/10/20650\">",
"           Regulation of erythropoiesis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Pancreatic hormones",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/57/28567\">",
"           Insulin resistance: Definition and clinical spectrum",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/46/41702\">",
"           Insulin secretion and pancreatic beta-cell function",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/60/29638\">",
"           Physiologic response to hypoglycemia in normal subjects and patients with diabetes mellitus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/23/6522\">",
"           Structure and function of the insulin receptor",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Renal hormones",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/25/13720\">",
"           Chapter 2B: Renin-angiotensin system",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/27/42422\">",
"           Chapter 6D: Natriuretic peptides",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/60/966\">",
"           Chapter 6E: Prostaglandins and the kidney",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/54/10083\">",
"           Chapter 6J: Erythropoietin",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/10/20650\">",
"           Regulation of erythropoiesis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Reproductive hormones",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/3/31800\">",
"           Male reproductive physiology",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/44/41672\">",
"           Molecular biology and physiology of estrogen action",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/16/41220\">",
"           Normal sexual differentiation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/2/27685\">",
"           Physiology of the normal menstrual cycle",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/8/44166\">",
"           Ultrasound evaluation of the normal menstrual cycle",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Thyroid hormones",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/53/856\">",
"           Euthyroid hyperthyroxinemia and hypothyroxinemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/61/10200\">",
"           Thyroid hormone action",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/34/33320\">",
"           Thyroid hormone synthesis and physiology",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/47/40696\">",
"           Thyroid physiology and screening in preterm infants",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-BAF379946F-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f25_16_25870=[""].join("\n");
var outline_f25_16_25870=null;
var title_f25_16_25871="Normal newborn larynx";
var content_f25_16_25871=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F73785&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F73785&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Normal newborn larynx",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 365px; height: 286px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Note the healthy appearance of the normal structures: epiglottis (E); glottis (G); aryepiglottic folds (AF); vocal folds (vf); and vestibular folds (VF).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Glenn C Isaacson, MD, FAAP, FACS.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_16_25871=[""].join("\n");
var outline_f25_16_25871=null;
